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Abstract 
Mutant forms of p53 with impaired DNA binding ability – termed mutp53 – promote cancer 
aggressiveness. As this occurs, in part, through mutp53’s ability to influence membrane 
trafficking pathways, we have investigated whether mutp53 influences extracellular vesicle 
(EV) production and/or function, using both cancer cell lines and mouse models of cancer.  
To understand whether mutp53 promotes the release of pro-invasive factors, we set up a co-
culture approach, using cancer isogenic cell lines differing in their p53 status. We found that 
poorly invasive H1299 cells lacking p53 (H1299-p53-/- cells) displayed increased 
invasiveness in 3D microenvironments when cultured in the same media as mutp53-
expressing H1299 cells. We then used differential centrifugation to collect EVs from H1299 
cells of differing p53 status (p53-/- or mutp53-EVs). We characterised these EV preparations 
using a range of techniques and found that mutp53 expression in cancer cells does not 
influence the number or size of EV released by these cells. Nevertheless, when used to pre-
treat H1299-p53-/- cells, mutp53-EVs promoted migration of recipient cells indicating that 
they were qualitatively different from p53-/--EVs. Further investigation determined that 
mutp53-EVs stimulate RCP- and DGKα-dependent recycling in recipient p53-/- cancer cells, 
and that inhibition of these pathways in recipient cells prevented their migratory response to 
mutp53-EVs.  
We then used quantitative proteomic approaches to characterise EVs from H1299 cells and 
found that mutp53 influences levels of EV-associated podocalyxin, a sialomucin with 
previous described roles in metastasis. Mutp53 suppressed podocalyxin levels in EVs by 
repressing cellular levels of podocalyxin, and we demonstrated that this likely occurs via 
inhibition of mutp53’s binding partner, p63. Furthermore, we showed that levels of EV-
associated podocalyxin must be within a certain range to influence the behaviour of recipient 
cancer cells, as manipulation of EV-associated podocalyxin impaired the ability of EVs in 
modulating migration and integrin recycling in recipient cancer cells. Although EV release 
in many cell types occurs via Rab27-dependent mechanisms, we found that loss of this Rab 
GTPase did not compromise the ability of mutp53-EVs to influence recipient cell behaviour. 
Instead, we found that another Rab GTPase, Rab35 is required for the production of 
phenotype-altering EVs, and it does so, not by influencing EV production, but by regulating 
EV-associated podocalyxin levels. In particular, we found that Rab35 associates with 
podocalyxin in mutp53-expressing cells which promotes podocalyxin sorting to the cell 
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surface, thereby reducing the level of podocalyxin in EVs to a range that allows non-cell 
autonomous communication to occur.  
Fibroblasts are known to be key to the acquisition of pro-invasive tumour 
microenvironments.  We therefore evaluated the effect of EVs on fibroblasts and found that 
mutp53-EV promote RCP- and DGKα-dependent integrin recycling and, in turn, increased 
migration of these cells. Integrins are key for the deposition of ECM, and we found that 
mutp53-EVs encouraged fibroblasts to deposit ECM with altered (more orthogonal) 
morphology and that this depended on DGKα-dependent integrin recycling.  We then found 
that cancer cells invade more efficiently in this “orthogonal” ECM, and this is likely owing 
to the reduced adhesiveness of this ECM.   
To investigate whether mutp53-expressing tumours influence ECM deposition in a non-cell 
autonomous fashion in vivo, we used quantitative second harmonic generation microscopy 
and evaluated the organisation of ECM in various organs in autochthonous models of 
pancreatic cancer. We found that KPC mice, which express mutp53 and develop highly 
metastatic tumours, display increased ECM orthogonality in the liver and lung prior to 
metastasis. Furthermore, we used xenograft transplantation models to demonstrate that 
subcutaneous tumours derived from mutp53-expressing H1299 cells also promote 
deposition of orthogonal ECM in the lung, and loss of podocalyxin or Rab35 in these 
tumours impaired their ability to do so. These data suggest that mutp53 expressing tumours 
promote ECM deposition in pre-metastatic niches and indicate the likelihood of this 
occurring via EVs and through the regulation of EV-associated podocalyxin levels.  
Taken together, these data provide evidence for a novel non-cell autonomous gain-of-
function of mutp53 that is mediated by EVs and involves modulation of integrin recycling 
in recipient cells. We propose that this mechanism might contribute to the aggressiveness of 
mutp53-expressing cancers, by affecting both tumour cell migration and ECM deposition by 
fibroblasts. Thus, we have discovered an intercellular/inter-organ communication pathway 
comprising a number of well-characterised components, which might inform for future 
therapies and may also act as novel biomarkers to indicate the presence of metastatic 
tumours. 
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 Introduction 
1.1 p53 as a tumour suppressor 
Evolution has shaped the appearance of mechanisms that maintain tissue homeostasis. The 
protein p53, encoded by the TP53 gene that is located in 17p13.1 chromosome, is arguably 
the most important hub for such mechanisms in humans (Levine and Oren, 2009). p53 is a 
transcription factor that is stabilised in times of stress. One example of this is when DNA 
damage arises from spontaneous mutagenesis or sustained oncogenic signalling (Kastan et 
al., 1991). The stabilisation of p53 allows it to recognise a specific DNA motif in the genome 
and to activate transcription of target genes (el-Deiry et al., 1992), thereby modulating 
cellular processes that preserve genomic integrity. Given the fact that cancer is enabled by 
the accumulation of genomic abnormalities (Hanahan and Weinberg, 2000), it is often 
characterised by the acquisition of mutations in TP53, leading to loss of tumour-suppressive 
functions (Olivier et al., 2010). 
 
 
Figure 1-1- p53 as a multifaceted tumour suppressor. 
The p53 transcription factor is stabilised and activated in response to cellular stresses, such as accumulation 
of DNA damage. The association of p53 with response elements in the genome allows transcription of target 
genes and subsequent induction of cellular processes. These include tumour-suppressive functions, such as 
the control of cell cycle arrest, replicative senescence and apoptosis. Additionally, other non-canonical 
functions of p53 have recently been identified, such as the control of autophagy, antioxidation and cellular 
metabolism. 
 
Chapter 1 18 
The best characterised cellular processes regulated by p53, often referred to as its canonical 
roles, are the induction of cell cycle arrest, apoptosis and senescence (Di Micco et al., 2006; 
Jimenez et al., 2000; Kastan et al., 1991). Additionally, several non-canonical roles for p53 
have emerged over the years, likely reflecting the broad range of target genes regulated by 
p53. These include, but are not limited to, modulation of autophagy, cellular metabolism and 
antioxidant responses (Bensaad et al., 2006; Crighton et al., 2006; Sablina et al., 2005). 
Although the mechanism by which one of these responses is selected is not completely clear, 
the outcome of p53 stabilisation seems to be fine-tuned according to the cell type, 
microenvironmental cues, and the type and extent of stress (Kastenhuber and Lowe, 2017). 
In response to spontaneous mutagenesis, p53 stabilisation is often associated with induction 
of cell cycle arrest, with concomitant activation of pathways that promote DNA repair. When 
the damage is beyond repair, as is the case for sustained oncogenic signalling, p53 seems to 
favour senescence or apoptosis. Either way, p53 activation in response to DNA damage 
ultimately protects genomic integrity, ensuring that DNA abnormalities are not carried over 
to daughter cells, thus suppressing tumourigenesis. 
1.2 p53 domains and mutations 
p53 has a modular protein domain organisation, characteristic of transcription factors (TFs). 
The N-terminus contains two acidic, tandem transactivation domains (TADs), TAD1 and 
TAD2, spanning amino acid residues 1-40 and 40-60 respectively. These domains are 
independently capable of mediating the start of transcription at target sites by recruiting 
histone-modifying enzymes, co-activators and members of the transcription machinery 
(Sullivan et al., 2018). There is a proline-rich domain (PRD) adjacent to these, spanning 
residues 60-95, with a structural but essential role in p53-mediated responses (Toledo et al., 
2007; Walker and Levine, 1996). These are followed by a core region, within residues 100-
300, comprising the evolutionary conserved DNA-binding domain (DBD), which is 
responsible for specific binding to DNA response elements (Bargonetti et al., 1993, 1991; 
Kern et al., 1991). Adjacent to this an oligomerisation domain (OD), ranging from residues 
325-356, allows formation of p53 tetramers; the conformation that is required for p53-
mediated responses (Clore et al., 1995). Finally, p53 contains a basic, lysine-rich C-terminal 
domain (CTD), between residues 369-393, which binds DNA in a non-specific manner to 
promote p53’s DNA sliding and homing to response elements (Terakawa et al., 2012).  
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Figure 1-2- p53 is a modular transcription factor and most of the mutations in p53 occur in the DNA-
binding domain. 
p53 is a multidomain transcription factor. The transactivation domains 1 and 2 (TA1 and TA2) are responsible 
for starting transcription at target genes via recruitment of transcriptional machinery. The proline-rich domain 
(PRD) is thought to have a structural role. The DNA-binding domain dictates the association of p53 with DNA 
response elements in a sequence-specific manner. The oligomerisation domain (OD) drives formation of p53 
tetramers. The C-terminal domain (CTD) binds DNA in a non-specific manner and allows p53 homing to 
response elements. Even though mutations in every p53 domain have been identified in humans, single amino 
acid substitutions within the DNA-binding domain are the most prevalent. The arginine located at 175 and 273 
are mutated at such frequency in human cancers that they are referred to as mutational hotspots.  
TP53 is the most frequently mutated gene in human cancers. Germline mutations in p53 are 
known to cause Li-Fraumeni syndrome (LFS), a hereditary predisposition to cancer in a 
variety of organs, such as breast, pancreas, lung and brain (Malkin 1990). While p53 can be 
lost by deletion, around 40% of all cancers acquire single amino acid substitutions within 
the p53 DBD. Within this domain, 6 residues are mutated so frequently that they are referred 
to as “mutational hotspots” (Olivier et al., 2010). Mutations in the DBD often give rise to 
full length proteins, termed mutant p53 (mutp53), which fail to activate p53-mediated 
transcription by either being unable to engage DNA (contact mutants), or by acquiring 
conformational changes that impair recognition of p53 response elements (conformational 
mutants). Examples of mutational hotpots from these 2 categories are R273H and R175H, 
respectively. Furthermore, around 60% of human cancers with mutations in one TP53 allele 
display loss-of-heterozygosity, where the remaining functional allele is lost (Baker et al., 
1990; Olivier et al., 2010), reinforcing the selective pressure for p53 loss in tumour 
progression. 
1.3 Stabilisation of mutp53 in cancer 
Although the observation that mutp53s are expressed at high levels in tumour cells 
(Rodrigues et al., 1990) led to the assumption that mutp53 is inherently stable, this has been 
proven not to be the case. For instance, healthy tissue in mutp53 knock-in mice display low 
levels of mutp53 expression (Lang et al., 2004; Olive et al., 2004), indicative of the 
requirements of secondary events to stabilise the protein during tumourigenesis. As for 
p53wt, levels of mutp53 in the cell are regulated by the ubiquitin ligase MDM2, through 
binding to the N-terminus of mutp53, leading to its polyubiquitylation and proteasomal 
degradation (Terzian et al., 2008). Accordingly, stimuli that are supposed to stabilise p53wt, 
such as DNA damage resulting from oncogenic signalling, lead to post-translational 
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modification (PTM) of mutp53 and weaken its association with MDM2, preventing its 
degradation (Frum et al., 2016). Although accumulation of p53wt would result in drastic 
cytotoxicity, mutp53 is tolerated because it fails to activate tumour suppressive mechanisms. 
Also, MDM2 is a p53wt target and as such, mutp53 fails to activate its transcription, 
disrupting a negative feedback loop that would otherwise contribute to keeping the levels of 
mutp53 in check (Midgley and Lane, 1997).  
Mutp53 stabilisation depends on its interaction with members of the heat-shock family of 
chaperones, in particular HSP90. Binding of HSP90 to a mutp53-MDM2 complex protects 
mutp53 from polyubiquitination, thereby contributing to its accumulation (Peng et al., 2001). 
Although HSP90 can interact with p53wt in a transient manner, its association with mutp53 
in cancer cells is stable and a number of pathways were shown to contribute to this. For 
instance, HSP90 levels are increased upon oxidative stress, due to activation of the TF HSF1 
(Ahn, 2003). Additionally, geranylgeranylation of RhoA via the mevalonate pathway (MVP) 
can sustain HSP90-dependent mutp53 stabilisation (Ingallina et al., 2018). As HSF1, RhoA 
and MVP are often hyper-activated during tumourigenesis, their effect on mutp53 
stabilisation is likely to be relevant and might explain the high levels at which mutp53 
accumulate in cancer cells. Furthermore, these pathways were previously shown to be 
upregulated by mutp53, thus raising the possibility for a feedback loop allowing mutp53 to, 
once stabilised, sustain its own expression (Freed-Pastor et al., 2012; Li et al., 2014; Timpson 
et al., 2011b).    
 
 
Figure 1-3- HSP90 stabilises mutp53 by preventing its association with MDM2 and its consequent 
proteasomal degradation.  
Expression of mutp53 in cells is influenced by MDM2, an ubiquitin-ligase that tags mutp53 for proteasomal 
degradation. Mutp53 polyubiquitination and degradation is opposed by its association with heat-shock 
chaperones (e.g. HSP90). Levels of HSP90 and its ability to associate with mutp53 depend on HSF1 and the 
MVP-RhoA axis respectively.  
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1.4 Mechanisms of mutp53’s action 
Expression of mutp53 is associated with poor prognosis in a variety of cancer types (Freed-
Pastor and Prives, 2012). Primarily, this is likely to be the result of loss of p53wt function in 
mutant forms of the protein, due to the key role for the DBD in p53-mediated tumour 
suppression. Nonetheless, this is not the only mechanism through which mutp53s act. In 
situations where the functional allele of p53 is not lost, mutp53 may form tetrameric 
complexes with p53wt, keeping the functional protein away from its response element and, 
therefore, inhibiting its function via a dominant-negative mechanism (Willis et al., 2004). 
Finally, mutp53 can also acquire functions distinct from the wild-type protein, thereby 
modulating cellular responses in gain-of-function mechanisms. 
The mechanisms by which mutp53s exert gain-of-function phenotype mostly involve their 
stable interaction with varied cellular partners, and modulation of their functions. The 
majority of mutant p53 binding partners are TFs. However, many reports have identified 
other types of mutp53-binding partners, and not surprisingly most of these reside in the 
nucleus. Although there is some evidence that mutp53 may directly bind to DNA in a rather 
specific manner (Göhler et al., 2005), this hypothesis remains to be further investigated. 
Importantly, these mechanisms are not mutually exclusive and require cellular accumulation 
of mutp53. 
Mutp53 can physically associate with a number of TFs to transactivate their target genes. 
This function is consistent with the intact TADs of mutp53, leading to the recruitment of 
transcription activators p300 to the RE of these genes and transcription initiation (Valenti et 
al., 2011). Many prominent TFs interact with mutp53 in this manner, including NF-Y, YAP, 
SREBP-2, Sp1 and VDR (Di Agostino et al., 2016, 2006; Freed-Pastor et al., 2012; 
Sorrentino et al., 2014; Stambolsky et al., 2010; Tocci et al., 2019; Vogiatzi et al., 2016). 
mutp53 can also interact with other TFs of the p53-family, such as p63 and p73. As opposed 
to the role of mutp53 in transactivating response elements of other TFs, the association of 
mutp53 with members of its own family mostly leads to transcriptional repression of their 
target genes, likely by forming tetrameric forms with these and preventing their homing to 
their specific response elements (Strano et al., 2002). 
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Figure 1-4- Mechanisms of mutp53’s GOF. 
In addition to dominant negative regulation of p53-wild-type proteins, mutp53 may acquire novel functions 
through a set of mechanisms. These include: (A) interaction of mutp53 with certain transcription factors (TFs) 
and the transactivation of their target genes; (B) oligomerisation of mutp53 with members of the p53 family 
p63 and p73, thereby preventing their homing to response elements and inhibiting their transactivating 
activities; (C) association of mutp53 with non-transcription factors and modulation of their cellular activity.  
1.5 mutp53 gain-of-function in cancer 
The high accumulation of mutant forms of p53 in cancer cells (Rodrigues et al., 1990), as 
well as the ability of these to promote tumourigenesis when over-expressed in a p53-null 
background (Wolf et al., 1984), led to p53 being initially classified as an oncogene. This was 
proven to be wrong a decade later, with seminal work from Bradley lab reporting that p53 
knock-out mice are prone to tumourigenesis (Donehower et al., 1992). However, those early 
observations were likely to be the first hints of gain-of-function (GOF) for mutp53 in cancer; 
a postulate that was experimentally confirmed by the development of p53 knock-in mice. In 
comparison to mice lacking p53, animals engineered to express p53R172H or p53R270H (which 
are equivalent to the human hotspot mutants p53R175H and p53R273H respectively) display a 
more diverse tumour spectrum and, perhaps more importantly, more metastatic tumours 
(Lang et al., 2004; Olive et al., 2004). Consistently, LFS patients that carry mutp53 alleles 
present a prognosis poorer than patients with p53 loss, indicating the likelihood of mutp53 
GOF to be manifest in humans (Malkin et al., 1990). Even though the phenotypes resulting 
from mutp53 expression are diverse and reflect the cellular context in which these mutants 
occur (Freed-Pastor and Prives, 2012), mutp53 may influence multiple, if not all, stages of 
carcinogenesis. 
1.5.1 Genomic instability and tumour growth 
Carcinogenesis occurs through accumulation of deleterious mutations. Genomic instability 
is key for this to occur, as the rate of spontaneous mutagenesis for a normal cell is low 
(Hanahan and Weinberg, 2000). In contrast to the key role of p53 as the “guardian of the 
genome”, mutp53 can interfere with and impair genome integrity processes. This is 
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consistent with studies highlighting chromosomal rearrangements and genomic 
abnormalities as a result of mutp53 expression (Mackay et al., 2018). The best characterised 
mechanism through which this occurs involves modulation of ataxia-telangiectasia mutated 
(ATM), a DDR transducer that is activated in response to DNA double-stranded breaks. This 
is achieved by binding of mutp53 to the nuclease Mre11, preventing this protein from 
forming a complex required for ATM activation and G2-M checkpoint. Through this 
mechanism, mutp53 may increase the rate of intrachromosomal translocations in the cell, 
driving genomic instability (Song et al., 2007). Speculatively, such phenotype is likely to be 
selected for during the early phases of tumour progression and may allow mutp53 to 
contribute to a higher mutational load, therefore driving carcinogenesis. 
 
 
Figure 1-5- mutp53 promotes genomic instability, tumour growth and drug resistance. 
(A) mutp53 drives genomic instability by increasing the rate of intrachromosomal translocations in cells. A 
way for this to occur is through mutp53’s association with Mre11 and inhibition of ATM activation in response 
to DNA double-stranded breaks (DSBs). (B) mutp53 promotes tumour growth by driving expression of cell 
cycle and pro-survival genes, through forming complexes with transcription factors (e.g. NF-Y and VDR) in 
their DNA response elements. (C) mutp53 may drive detoxification and tumour growth by upregulating the 
proteasome machinery, through associating with the NRF2 transcription factor at response elements of 
proteasome genes.  
 
Tumour growth is characterised by modulation of cell cycle progression and/or apoptosis. 
Mutp53s may promote tumour growth by associating with a number of TFs and 
transactivating target genes involved in these programs. For example, mutp53 can form a 
stable complex with Yap and NF-Y at RE of genes encoding for the cell cycle stimulators 
cyclin A, cyclin B and CDK1, thereby sustaining proliferation by potently upregulating these 
genes (Di Agostino et al., 2016). Similarly, mutp53 may bind to VDR and promote 
transcriptional activation of several pro-survival genes (Stambolsky et al., 2010). 
Furthermore, mutp53 can associate with the TF NRF2 at the RE of genes encoding for 
members of the proteasome machinery, leading to increased proteasomal degradation of 
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several tumour suppressors, in turn sustaining tumour cell proliferation and resistance to 
proteasomal inhibitors (Walerych et al., 2016). As chemotherapeutic drugs are known to 
cause proteolytic stress, mutp53-mediated upregulation of proteasome might allow cancer 
cells to cope better in such conditions, likely contributing to the clear correlations between 
mutp53 expression, drug resistance and tumour relapse after therapy in a variety of cancer 
types (Mantovani et al., 2019). 
1.5.2 Tumour metabolism 
Metabolic rewiring is often observed in cancer (Dang, 2012) and mutp53 was previously 
shown to play roles in these processes. One frequent metabolic adaptation of tumour cells is 
their ability to uptake large amounts of glucose and use it for aerobic glycolysis (known as 
the Warburg effect). Mutp53 can sustain this process firstly by stimulating glucose uptake 
through translocation of the glucose transporter GLUT1 to the plasma membrane, via 
activation of RhoA and Rock (Zhang et al., 2013), and secondly by directly inducing aerobic 
glycolysis, through association and inhibition of AMPK (Zhou et al., 2014).  
 
Figure 1-6- mutp53 deregulates aerobic glycolysis and lipid metabolism. 
Tumour growth occurs through rewiring of cellular metabolism and mutp53 influences this. (A) Tumours often 
use aerobic glycolysis to produce cellular ATP, coupled with release of lactate to the extracellular milieu – the 
Warburg effect. mutp53 drives this phenotype via activation of RhoA-ROCK-dependent recycling of the 
glucose transporter GLUT1 from endosomes to the plasma membrane, thereby sustaining the uptake of glucose 
in cells. mutp53 may also promote the expression of several glycolytic enzymes by associating with and 
inhibiting the function of the energy sensor, AMPK. (B) Many tumours display rewiring of lipid metabolism. 
The association of mutp53 with SREBP2, a major inducer of fatty acid and cholesterol biosynthesis, drives 
expression of mevalonate pathway (MVP) enzymes. Downstream of this, the MVP sustains 
geranylgeranylation of RhoA, which in turn drives the translocation of YAP to the nucleus and HSP90-
mediated mutp53 stabilisation, thus reinforcing a positive feedback loop.  
Many tumours are characterised by rewiring of lipid metabolism (Munir et al., 2019). The 
interaction of mutp53 with SREBP2, which is a major inducer of fatty acids and cholesterol 
biosynthesis, led to transcriptional activation of the MVP (Freed-Pastor et al., 2012). 
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Downstream of mutp53, the MVP drives geranylgeranylation and activation of RhoA, which 
in turn promotes the translocation of YAP/TAZ to the nucleus and subsequent oncogenic 
signalling (Sorrentino et al., 2014). As geranylgeranylation of RhoA leads to mutp53 
stabilisation (Ingallina et al., 2018), lipid rewiring by mutp53 contributes to mutp53 
accumulation, thus likely driving gain-of-function mechanisms.  
1.5.3 Tumour cell invasion 
The best elucidated mechanism through which mutp53s promote cancer aggressiveness 
involves its stable association with, and inhibition of, p53-family members p63 and p73.  In 
fact, mice with loss of p63 recapitulate the highly metastatic phenotype reported for mutp53 
knock-in mice (Su et al., 2010), and depletion of p63 or p73 in p53-null cancer cell 
phenocopied invasiveness of cells expressing mutp53 (Muller et al., 2009; Weissmueller et 
al., 2014). 
Mutp53-mediated inhibition of p63/p73 functions can promote tumour cell invasion by 
deregulating their target genes. Mutp53-dependent inhibition of p63/p73 functions in tumour 
cells suppressed expression of SHARP1, cyclin G2 and DICER, and/or stimulated 
expression of PDGFR2. As it has been reported that the rescuing of the levels of these 
proteins reduced invasiveness in mutp53-expressing cells (Adorno et al., 2009; Muller et al., 
2014; Weissmueller et al., 2014), it is likely that modulation of these p63/p73 targets 
contributes to mutp53-mediated invasiveness. In particular, the loss of DICER in p63-
knockout mice impairs miRNA processing and potentiates metastasis formation in vivo (Su 
et al., 2010), so it is likely that mutp53 promotes invasion, at least in part, by deregulating 
miRNA levels in cells. 
The mutp53-p63 axis can also promote tumour cell invasion by modulating endocytic 
recycling of receptors. In particular, inhibition of p63 function by mutp53 stimulates 
recycling of α5β1 integrin from recycling endosomes to the plasma membrane, by promoting 
its association with the Rab11 effector Rab-coupling protein (RCP) (Muller et al., 2009). 
Through its N-terminus, RCP can associate with a number of RTKs, including EGFR and 
cMET (Caswell et al., 2008; Muller et al., 2013, 2009). Thus, via RCP, mutp53 stimulates 
the coordinated recycling of adhesion and growth factor receptors. 
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Figure 1-7- mutp53 promotes cancer cell invasion by inhibiting p63 function and stimulating receptor 
recycling. 
Inhibition of p63 function by mutp53 stimulates the association of Rab-coupling protein (RCP) with α5β1 
integrin and receptor tyrosine kinases EGFR and cMET.  This promotes their recycling to the plasma membrane 
and activation of the Akt/PI3K and MAP kinase (MAPK) pathways. Activation of Akt drives phosphorylation 
and recruitment of Rac1GAP to the plasma membrane at the front of migrating cells, leading to local activation 
of RhoA. In turn, RhoA activates the formin FHOD3, mediating actin polymerisation to drive formation of 
invasive protrusions. In parallel, through activation of MAPKs and Akt respectively, mutp53 upregulates and 
activates myosin X, a motor protein that associates with α5β1 integrin and mediates its translocation to the tips 
of filopodia. This way, mutp53 modulates tumour cell-ECM adhesions and invasion. 
Consistent with the trafficking of RTK influencing their signalling, mutp53 stimulation of 
EGFR and cMET recycling was shown to activate the Akt/PI3K and MAP kinase (MAPK)  
pathways respectively (Muller et al., 2013, 2009). Activation of Akt drives phosphorylation 
and recruitment of Rac1GAP to the plasma membrane at the front of migrating cells, leading 
to local activation of RhoA (Jacquemet et al., 2013; Timpson et al., 2011b). In turn, RhoA 
activates formin FHOD3, mediating actin polymerisation to drive formation of filopodial 
spike-based protrusions (Paul et al., 2015). In parallel, through activation of MAPKs and 
Akt respectively, mutp53 upregulates and activates myosin X, a motor protein that associates 
with b1 integrin (Arjonen et al., 2014). Together with the enhanced surface levels of α5β1 
integrin resulting from RCP-mediated recycling, myosin X drives translocation of α5β1 
integrin to the tips of filopodia, where it can associate with components of the extracellular 
matrix (ECM), thereby allowing mutp53 to induce the formation of tumour cell-ECM 
adhesion and invasion (Arjonen et al., 2014). Additionally, mutp53 was recently shown to 
drive invasion by upregulating ENTPD5, a uridine 5′-diphosphatase (UDPase) that resides 
in the endoplasmic reticulum (ER) and controls folding of N-glycosylated proteins (Vogiatzi 
Recycling 
endosome 
Chapter 1 27 
et al., 2016). As integrins and RTKs are often highly N-glycosylated, is it interesting to 
speculate whether this mechanism might contribute to the quality-control of proteins, thus 
sustaining the presence of a recycling pool of glycosylated receptors. 
Although other pathways have been reported to cooperate with mutp53 to drive the 
acquisition of aggressive phenotypes, it seems that many do so, at least in part, by affecting 
mutp53-p63 binding. For example, Pin1, TopBP1 and SMAD2, which were shown to 
promote mutp53-mediated cancer cell invasion, can associate with mutp53 and form 
complexes with p63, stimulating such inhibition (Adorno et al., 2009; Girardini et al., 2011; 
Liu et al., 2011). This, again, reinforces the idea that phenotypes resulting from mutp53 
expression are context dependent, and are potentially affected by the levels of multiple 
mutp53-binding partners in cells. 
1.6 Tumour microenvironment 
Tumour cells reside within a complex tumour microenvironment (TME) consisting of 
numerous cell types and the ECM. Reciprocal interactions between TME components, 
including tumour, immune, endothelial, and lymphatic cells, and cancer-associated 
fibroblasts (CAFs) and their deposited ECM, influence tumour growth and progression into 
invasive disease. Thus, metastasis formation depends on both autonomous and non-cell 
autonomous mechanisms.  
Perhaps the first obstacle for tumour growth is the immune system. Anti-tumour immunity 
is largely mediated by resident CD8+ cytotoxic T lymphocytes (CTL) and natural killer (NK) 
cells, which have the ability to bind to antigens at the tumour cell surface and promote its 
elimination (Binnewies et al., 2018). Thus, in order to grow, tumours may have to avoid 
immune surveillance. A common mechanism for avoidance of anti-tumour immunity is 
cancer-induced inflammation, often characterised by recruitment of immune-suppressive 
bone marrow-derived cells (BMDCs). Many cell types with immune-suppressive function 
are often present within the TME, including regulatory T-lymphocytes (Treg), immature 
monocytes, tumour-associated macrophages, neutrophils and dendritic cells, all of which 
may counterbalance T cell function and subsequent anti-tumour immunity (Vinay et al., 
2015). 
Tumour cells can be highly metabolically active and require nutrients and oxygen from the 
bloodstream to survive and proliferate. Interactions within the TME may influence 
Chapter 1 28 
endothelial cell behaviour and stimulate the vascularisation of tumours, supporting tumour 
growth (Hillen and Griffioen, 2007). Importantly, tumours may enter the vasculature to 
disseminate to other organs, making vascularisation of tumours a possible contributor to 
metastasis. 
 
Figure 1-8- The components of the tumour microenvironment.  
Tumour cells reside within a complex tumour microenvironment (TME), consisting of various cell types and 
ECM. The interactions between TME components, including tumour, immune, endothelial, and lymphatic 
cells, and CAFs and their deposited ECM, are thought to influence the way tumours grow and progress into 
metastatic disease. Abbreviation are as follows: CTL – cytotoxic T-lymphocyte; Treg – regulatory T-
lymphocyte; NK – natural killer cell; TAM – tumour-associated macrophage; CAF - carcinoma-associated 
fibroblast.  
In order to reach the vasculature, tumour cells must cross physical barriers posed by the 
ECM, such as the basement membrane outlining the epithelium and vasculature, and the 
rich, desmoplastic stroma that separates them. Tumour cell dissemination depends on the 
intrinsic invasiveness of tumour cells, as well as the existence of an invasion-permissive 
stroma (Levental et al., 2009). CAFs in the stroma have a major role in allowing this to 
occur. Furthermore, CAFs can perform a set of behaviour that may influence other TME 
components, contributing to the formation of a tumour-permissive microenvironment.  
1.6.1 Cancer-associated fibroblasts 
CAFs are an abundant cell type in the TME. Although the origin of CAFs is complex and 
continues to be somewhat controversial, the main source for CAFs is thought to be via 
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activation of tissue-resident fibroblasts by microenvironmental signals (LeBleu and Kalluri, 
2018). This process shares features with fibroblast activation during tissue healing 
responses. However, fibroblast activation in cancer is a persistent phenomenon, because 
many factors that stimulate this are within the tumour secretome. Indeed, many proteins in 
the tumour secretome, such as TGFβ, PDGF, LIF and OSM, have been shown to promote 
fibroblast activation and are also known to contribute to wound healing (Albrengues et al., 
2014; Midgley et al., 2013; Rajkumar et al., 2006; Scaffidi et al., 2002).  
 
Figure 1-9- Fibroblast activation in cancer. 
CAFs are an abundant cell type in the TME and may derive from the activation of tissue-resident fibroblasts 
by factors within the tumour secretome (e.g. TGFβ, PDGF, LIF and OSM). Activation of CAFs is often 
accompanied by upregulation of PDGFR1, FSP1, FAP, and/or aSMA. While resident fibroblasts are often kept 
in a quiescent, inactive state during homeostasis, CAFs are proliferative, contractile cells that produce a 
complex secretome and actively deposit and remodel the ECM. 
The lack of bona fide markers for distinguishing CAFs from other fibroblasts is consistent 
with the observation that CAFs in the TME are heterogenous (Bu et al., 2019; Neuzillet et 
al., 2019). Nonetheless, activation of CAFs is often accompanied by upregulation of 
PDGFR1, FAP, and/or aSMA (Anderberg et al., 2009; Rønnov-Jessen et al., 1995; 
Teichgräber et al., 2015). Furthermore, while resident fibroblasts are kept in a quiescent, 
inactive state during homeostasis, CAFs are proliferative, contractile cells that produce a 
secretome containing copious amounts of ECM components (LeBleu and Kalluri, 2018).  
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1.6.2 ECM components 
The desmoplastic stroma is characterised by aberrant deposition of ECM. The ECM 
components which constitute the bulk of the CAF secretome are the fibrillar proteins 
collagen I and fibronectin (De Boeck et al., 2013).  
1.6.2.1 Collagen I 
The collagen family of proteins comprises 28 members. A hallmark of all collagens is their 
triple-helix, formed by homo- or heterotrimers of collagen polypeptides. This structure is 
supported by the core collagenous domain which comprises the repeating motif, Gly-X-Y. 
Some collagens can also be modified in the extracellular space to be assembled into fibrils 
– termed fibrillar collagens. Collagen I is the most abundant fibrillar collagen in most healthy 
tissues, as well as in desmoplastic TME (Mouw et al., 2014).  
The product of transcription and translation of collagen genes are the collagen α-chains. 
These are precursor molecules with large N- and C-terminal regions – named N- and C-
propeptide respectively, and a central collagenous domain.  In the ER, many residues in the 
newly-synthesised α-chains are hydroxylated and glycosylated (KellokumpuS et al., n.d.; 
Schegg et al., 2009). Such PTMs stabilise the triple-helix, which starts at the C-propeptide 
domains via nucleation and specific chain recognition (Bourhis et al., 2012). Additionally, 
the Gly-X-Y motif in the collagenous domain gives further stability to the triple-helix, with 
glycine being small enough to be accommodated in a packed structure that enforces steric 
constrains on every third amino acid (Brodsky and Persikov, 2005). Procollagen is then 
trafficked to the Golgi apparatus, where it can be further modified and secreted to the 
extracellular milieu. 
Following or during secretion of procollagen, the propeptides are cleaved by collagen-
specific metalloproteases, giving raise to mature collagen that can self-assemble and grow 
unilaterally into microfibrils (Orgel et al., 2006). Multiple microfibrils can merge and grow 
both longitudinally and axially, leading to formation of mature fibrils. Importantly, fibril 
maturation is regulated by the incorporation of collagen-binding proteins in the assembling 
structure, including other collagens and small leucine-rich repeat proteoglycans (SLRPs) 
that modulate fibril stability (Holmes et al., 2001; Zhang et al., 2006). Finally, extracellular 
lysyl-oxidases (LOX), transglutaminases and other cross-linking enzymes catalyse the 
introduction of covalent cross-links into the supramolecular structure, between and within 
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collagen fibrils. This last step in collagen fibrillogenesis leads to the formation of mature 
fibres, capable of enduring tensile force (Grenard et al., 2001; Herchenhan et al., 2015). 
 
Figure 1-10- Biogenesis of fibrillar collagen. 
The product of collagen genes are the collagen α-chains. These are precursor molecules with large N- and C-
terminal regions – named the N- and C-propeptides respectively, and a central collagenous domain.  In the 
endoplasmic reticulum (ER), many residues in the α-chains are hydroxylated and glycosylated. Such post-
translational modifications ( PTMs) stabilise the triple-helix, which starts forming at the C-propeptide domains 
via nucleation and specific chain recognition. Procollagen is then trafficked to the Golgi apparatus, where it 
can be further modified and then secreted to the extracellular milieu. Following, or during, secretion of 
procollagen, the propeptides are cleaved by N- and C-procollagen proteinases (NP and CP), giving raise to 
mature collagen that can self-assemble and grow unilaterally into microfibrils.  Multiple microfibrils can merge 
and grow, leading to formation of mature fibrils. Fibril maturation is regulated by the incorporation of collagen-
binding proteins in the assembling structure, including fibril associated collagens with interrupted triple helices 
(FACIT) and small leucine-rich repeat proteoglycans (SLRPs) Finally, cross-linking enzymes (e.g. lysyl-
oxidase (LOX)) catalyse the introduction of covalent cross-links into the supramolecular structure, between 
and within collagen fibrils.  
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1.6.2.2 Fibronectin 
The fibril-forming protein fibronectin is an obligate component of the ECM in mammals. 
Fibronectin is a dimeric modular glycoprotein, composed of type I, II and III repeating units 
that are organised into domains for interaction with several ECM components, including 
collagen I and other fibronectin molecules, as well as cell adhesion receptors (i.e. integrins) 
(Schwarzbauer and DeSimone, 2011). This way, fibronectin fibrillogenesis influences ECM 
maintenance and the behaviour of cells which inhabit it. Additionally, the fibronectin mRNA 
is subject to alternative splicing which may yield at least 20 different isoforms of the protein 
in humans (Schwarzbauer and DeSimone, 2011). 
 
Figure 1-11- Fibronectin domains and fibrillogenesis. 
(A) Fibronectin is a modular glycoprotein, composed of type I, II and III repeating units that are organised into 
domains for interaction with several ECM components, including collagen I and other fibronectin molecules, 
as well as cell adhesion receptors (i.e. integrins). Fibronectin exists as a dimer, consisting of two fibronectin 
molecules linked by a pair of disulphide bonds at their C-terminus (red lines). Additionally, the fibronectin 
mRNA is subject to alternative splicing which may yield at least 20 different isoforms of the protein in humans. 
Domains required for fibronectin fibrillogenesis are in red. Domains under the control of alternative splicing 
are in brown. (B) Upon fibronectin secretion, its binding to α5β1 or αvβ3 integrins leads to integrin activation 
and clustering, which promotes fibrillogenesis in multiple ways. Firstly, it contributes to local accumulation of 
fibronectin molecules. Secondly, integrins can transmit forces onto the fibronectin dimer and expose residues 
that are critical for binding to other fibronectin molecules, changing its conformation to one that favours 
fibrillogenesis. These forces are generated by actomyosin cables and transmitted to integrins via adhesion 
complexes. Finally, integrins can be translocated along actomyosin cables, stimulating fibrillogenesis by 
pulling on bound fibronectin.  
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Upon secretion of the fibronectin dimer, its fibrillogenesis is initiated by integrin binding to 
the RGD sequence and adjacent synergy site (Schwarzbauer and DeSimone, 2011). Binding 
of α5β1 (but also αvβ3) integrins to fibronectin leads to integrin activation and receptor 
clustering (Roca-Cusachs et al., 2009), which promotes fibrillogenesis in multiple ways. 
Firstly, it contributes to accumulation of fibronectin molecules in the same vicinity. 
Secondly, integrins can transmit forces onto the fibronectin dimer and expose residues that 
are critical for binding to other fibronectin molecules, changing its conformation to one that 
favours fibrillogenesis (Klotzsch et al., 2009). These forces are generated by actomyosin 
cables and transmitted to integrins via adhesion complexes. Finally, integrins can be 
translocated along actomyosin cables, stimulating fibrillogenesis by pulling onto bound 
fibronectin (Clark, 2005). 
Nascent fibronectin fibrils are formed through end-to-end association of dimers, via the N-
terminal residues that become exposed following the exertion of tension by integrin 
engagement and the cell’s contractile machinery. As the matrix matures, small fibrils can 
then establish lateral associations, leading to longitudinal and axial growth. During growth, 
the matrix is irreversibly converted into a deoxycholate-insoluble form, via strong, 
noncovalent protein-protein interactions (Schwarzbauer and DeSimone, 2011). 
1.6.2.3 CAFs are ‘masters of ECM remodelling’ 
The ability of CAFs to deposit substantial levels of fibrillar ECM is owing to a combination 
of phenotypes that result from their activation. These include the secretion of copious 
amounts of ECM proteins and proteins involved in ECM remodelling (e.g. MMPs and FAP) 
and cross-linking (e.g. LOX and LH2), as well as their ability to contract. Their increased 
contractility is particularly relevant, as it allows CAFs to generate forces during 
fibrillogenesis and to align those newly-formed fibres in a direction parallel to the 
actomyosin cytoskeleton (Barbazán and Matic Vignjevic, 2019).  
The contractile phenotype of CAFs is the result of the organisation of α-smooth muscle actin 
(α-SMA) in actomyosin cables and this depends on the activity of the RhoA-ROCK axis 
(Sanz-Moreno et al., 2011), as well as the translocation and activation of YAP into the 
nucleus (Calvo et al., 2013). These pathways are often hyperactivated in CAFs, thereby 
allowing CAFs to contract and deposit ECM. Furthermore, the increased stromal stiffness 
that results from ECM deposition and cross-linking is in itself a stimulus for RhoA and YAP 
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signalling (Handorf et al., 2015), highlighting a positive feedback-loop that ensures 
prolonged fibroblast activation and desmoplasia. 
 
Figure 1-12- Mechanisms by which CAFs deposit/remodel ECM. 
The ability of CAFs to deposit substantial levels of fibrillar ECM is owing to a combination of phenotypes that 
result from their activation. These include the secretion of copious amounts of ECM proteins and proteins 
involved in ECM remodelling (e.g. MMPs and FAP) and cross-linking (e.g. LOX and LH2), as well as their 
ability to contract and apply forces to ECM molecules via integrin-mediated adhesions. The contractile 
phenotype of CAFs is the result of the organisation of α-SMA into actomyosin cables, and this depends on the 
activity of the RhoA-ROCK axis and YAP. These pathways are often hyperactivated in CAFs, thereby allowing 
efficient CAF contraction and ECM deposition. 
1.6.3 CAFs and cancer 
Although a few reports have suggested that certain CAFs may inhibit carcinogenesis 
(Özdemir et al., 2014), most studies showed that CAFs stimulate tumour growth and 
progression. The mechanisms that CAFs use to impact on tumour progression are diverse, 
and are associated with the CAF secretome, as well as their ability to generate forces and 
deposit ECM. 
The secretome of CAFs may affect multiple cell types in the TME, including tumour cells 
and those of the vasculature and immune system. Indeed, CAF-derived vascular endothelial 
derived growth factor (VEGF) may stimulate endothelial cells to establish new capillaries, 
allowing oxygenation of tumours and their growth, and indirectly stimulating immune cell 
infiltration (Tang et al., 2016). Also, within the CAF secretome, TGFβ, IL-6 and CCL5, to 
name a few, may modulate the inflammatory state of tumours, often in ways that are 
permissive to their grow (Cho et al., 2019; Poggi et al., 2014). Furthermore, the CAF 
secretome may also comprise molecules that directly affect tumour cell behaviour. For 
example, previous studies indicate that certain growth factors in the CAF secretome, such as 
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HGF and PDGF, can stimulate tumour cell growth and invasion (Ding et al., 2018; Neri et 
al., 2017). 
 
Figure 1-13- CAFs and tumour progression. 
The mechanisms that CAFs use to impact on tumour progression are diverse, and are associated with the CAF 
secretome, as well as their ability to generate forces and deposit ECM. (A) The secretome of CAFs may affect 
multiple cell types in the TME. Growth factors secreted from CAFs may stimulate endothelial cells to establish 
new capillaries, allowing oxygenation of tumours and their growth. Cytokines within the CAF secretome may 
modulate the inflammatory state of tumours, often in ways that are permissive to their growth. The CAF 
secretome may also comprise molecules that directly affect the behaviour of tumour cells, such as their 
proliferation and invasion. (B) CAFs may use their contractile phenotype to modify physical barriers for the 
dissemination of tumour cells, like basement membranes (BM). This involves pulling and softening of the 
basement membrane, allowing the formation of gaps that tumour cells may use to invade through. (C) CAFs 
may form heterotypic adhesions with tumour cells and use their contractility to pull on fibres, thereby dragging 
tumour cells along the ECM and facilitating tumour invasion. (D) The progression of tumours is influenced by 
desmoplasia. Initial tumour growth is accompanied by activation of fibroblasts, resulting in the deposition of 
ECM fibres in a direction parallel to the tumour edge. During tumour progression, further ECM is deposited 
and linearised, contributing to the stiffening of TME. Finally, in areas of tumour cell invasion, ECM fibres 
organise perpendicularly to the tumour edge. Tumour cells may follow such tracks, pulling on linearised fibres 
to migrate towards the stroma. 
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In parallel to the generation of a secretome, CAFs may use their contractile phenotype to 
modify physical barriers for the dissemination of tumour cells, like basement membranes. 
This can occur in an MMP-independent manner and involves the pulling and softening of 
the basement membrane, allowing the formation of gaps that tumour cells may use to invade 
through (Glentis et al., 2017). Additionally, CAFs may form heterotypic adhesions with 
tumour cells and use their contractility to pull onto fibres, thereby dragging tumour cells 
along the ECM and facilitating tumour invasion (Labernadie et al., 2017). 
The progression of tumours is influenced by the desmoplastic stroma. In mouse and humans, 
initial tumour growth is accompanied by activation of fibroblasts, resulting in the deposition 
of ECM fibres in a direction parallel to the tumour edge (Conklin et al., 2011; Levental et 
al., 2009). During tumour progression, further ECM is deposited and linearised, contributing 
to the stiffening of TME. Finally, in areas of tumour cell invasion, ECM fibres organise 
perpendicularly to the tumour edge (Conklin et al. 2011; Levental et al. 2009). 
Hypothetically, in vivo, tumour cells may follow such tracks, pulling onto linearised fibres 
to migrate towards the stroma. 
1.7 The pre-metastatic niche 
Since the proposal of the ‘seed and soil’ hypothesis by Paget in 1889 it has been thought that 
certain organs are more receptive to the seeding of metastases than other.  Moreover, it is 
now thought that primary tumours release factors which increase the receptivity of certain 
organs to metastasis – a so-called ‘pre-metastatic niche’ (PMN).  Indeed, tumour-derived 
factors can influence processes that allow this to occur, including vascular leakiness and the 
recruitment of immune-suppressive cells to create a tumour-permissive microenvironment 
(Peinado et al., 2017). Resident fibroblasts in these sites have also been shown to be 
influenced by signals from the primary tumour in a way that alters ECM dynamics to 
stimulate PMN formation (Erler et al., 2009).  
The first solid piece of evidence supporting the existence of PMNs was provided through 
transplantation experiments in mice. These researchers observed that the injection of a Lewis 
lung carcinoma cell line, which would normally only colonise the lung, together with media 
conditioned by melanoma cells, led to metastasis in organs associated with melanoma 
dissemination, such as the kidney, spleen and intestine (Kaplan et al., 2005). In addition to 
this observation which moots the existence of PMNs, it also suggests that metastasis 
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formation is not a random process. Instead, the organs in which tumour cells colonise and 
outgrow are pre-determined by tumour-derived factors, supporting the concept of 
organotropism in metastasis.    
Following this seminal study, multiple tumour-specific mechanisms that contribute to 
priming of the PMN have been identified. It seems that these effects are a combination of 
various tumour-derived factors, many of which have similar roles in the modulation of the 
TME. For example, tumour-derived VEGF-A may promote vascular leakiness in both the 
TME and the PMN (Kaplan et al., 2005; Tang et al., 2016). Cytokines and chemokines such 
as TGFβ and CCL2, which can be secreted by cells in the TME to stablish an immune-
suppressive phenotype, may also modulate the immune composition of the PMN (Qian et 
al., 2011; Yan et al., 2015). Furthermore, proteins involved in remodelling and cross-linking 
of the stromal ECM, such as MMPs and LOX respectively, may also mediate metastasis 
formation by affecting ECM properties in the PMN (Erler et al., 2009; Kaplan et al., 2005).  
Another tumour-derived factor that has been extensively associated with the PMN is 
extracellular vesicles. EVs have been shown to influence many of the aspects that mediate 
PMN priming, likely reflecting their ability to serve as information carriers in long-distance 
communication (Wortzel et al., 2019). Importantly, there is also evidence that they are 
determinants of organotropic metastasis (Hoshino et al., 2015). 
1.8 Extracellular vesicles 
From bacteria to humans, membrane vesicle release is a conserved process (Margolis and 
Sadovsky, 2019). Apart from secretory vesicles that are released by specialised cells, 
including those containing hormone and neurotransmitter cargoes, all cells can release 
membrane-bounded vesicles, which have been termed EVs. As they can carry a variety of 
cargoes, EVs can be used by cells as means of intercellular communication. This is observed 
in both tissue homeostasis and cancer. Cancer, however, hijacks many cellular processes and 
it can do so via regulation of EV release, including cargo sorting (Rajagopal and Harikumar, 
2018). Thus, not only are EVs being considered as cancer biomarkers, increasing evidence 
suggests that they effect the behaviour of recipient cells. EVs can influence phenotypes in 
the TME (Li and Nabet, 2019) and, owing to their capacity in transmitting signalling in a 
long-range manner, it also influences the PMN (Costa-Silva et al., 2015; Hoshino et al., 
2015; Peinado et al., 2012), as will be discussed later in this chapter.  
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1.8.1 EV classes 
Despite EVs being highly heterogenous, they can largely be classified into 2 categories - 
microvesicles and exosomes – according to their origin. Microvesicles are vesicles derived 
from the outward budding and fission of the plasma membrane. In contrast, exosomes have 
an endosomal origin. They are intraluminal vesicles (ILVs) that form by the inward 
membrane budding of maturating multivesicular endosomes (MVE) which are subsequently 
released to the extracellular milieu by fusion of MVEs with the plasma membrane. Although 
exosomes are often small, ranging from 50-150 nm in diameter, microvesicles can display a 
broader range of sizes, from 100 to 1000 nm, which renders the evaluation of EV dimensions 
insufficient for distinguishing between exosomes and microvesicles (Margolis and 
Sadovsky, 2019).  
 
Figure 1-14- EV classes. 
EVs are membrane-bound structures released by cells that may encapsulate a variety of cargoes, such as 
proteins, lipids and nucleic acids, thereby functioning as means for intercellular communication. Despite EVs 
being highly heterogeneous, they can largely be classified into 2 categories - microvesicles and exosomes – 
according to their origin. Microvesicles are vesicles derived from the outward budding and fission of the plasma 
membrane. In contrast, exosomes are intraluminal vesicles (ILVs) that form by the inward membrane budding 
of maturating multivesicular endosomes (MVE), which are subsequently released to the extracellular milieu 
by fusion of MVEs with the plasma membrane. Although exosomes are often small, ranging from 50-150 nm 
in diameter, microvesicles can display a broader range of sizes, from 100 to 1000 nm, which renders the 
evaluation of EV dimensions insufficient for distinguishing between these classes. 
EV composition is likely to be cell type-specific. Both microvesicles and exosomes can 
encapsulate a multitude of cargoes, including nucleic acids, proteins and lipids. Although 
the sorting of nucleic acids to EVs is not well understood, microvesicles and exosomes may 
indeed carry DNA and different types of RNA, including mRNA, microRNAs and other 
non-coding RNAs, and these are thought to affect the transcriptome of recipient cells 
(Gusachenko et al., 2013). The lipid composition of EVs is now beginning to emerge, and 
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exosomes and microvesicles are thought to be enriched for particular lipid species which 
respectively reflect their endosomal or plasma membrane origin, and there is some evidence 
that EV-lipids may modulate recipient cell signalling (Garcia et al., 2019; Skotland et al., 
2017). Finally, EVs can carry a multitude of protein cargoes with many different molecular 
functions, thereby having the potential to influence recipient cell post-transcriptionally 
(Yang et al., 2017).   
Owing to their heterogeneity, a large number of protein cargoes of EVs have been identified. 
Despite microvesicles and exosomes originating from different cellular compartments, many 
of their protein cargoes overlap, which may reflect common elements to the intracellular 
mechanisms and sorting machineries that drive their biogenesis (Mathieu et al., 2019). EVs 
often include membrane organisers of the tetraspanin family, with CD63 as an exosome-
specific tetraspannin -  according to studies employing the most precise methods for 
exosome purification, whereas CD9 and CD81 are present in both exosomes and 
microvesicles (Zhang et al., 2018). EV cargoes can also include components of the ESCRT 
machinery and members of the Rab family of GTPases which, as will be discussed below, 
have an important role in EV biogenesis and transport respectively. Both exosomes and 
microvesicles can contain cell adhesion receptors, such as integrins (Zhang et al., 2018), and 
some microvesicles have even been shown to be associated with ECM components such as 
fibronectin (Chanda et al., 2019). Microvesicles are also likely to be enriched for cytosolic 
material, as well as cytoskeletal proteins, such as actin and tubulin (Zhang et al., 2018). 
1.8.2 EV production 
EV biogenesis starts with clustering of lipids and membrane-associated proteins in specific 
microdomains of the plasma membrane, for microvesicles, or of the limiting membrane of 
MVE for exosomes. These microdomains are also likely to participate in the recruitment of 
soluble cargoes, such as cytosolic proteins and nucleic acids. Then, membrane 
rearrangements promote membrane budding and fission at the cell surface for EV release, or 
at the limiting membrane of MVE for ILV formation (Yáñez-Mó et al., 2015). 
1.8.2.1 Exosome production 
Biogenesis 
The biogenesis of exosomes is fairly well understood and largely depends on the endosomal 
sorting complexes required for transport (ESCRT) machinery. (Colombo et al., 2013). 
Subunits of the ESCRT machinery act sequentially to modulate membrane shape and 
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scission. ESCRT-0 and ESCRT-1 subunits cluster ubiquitinated transmembrane cargoes on 
microdomains of the limiting MVE membrane. Together with ESCRT-2, they recruit 
ESCRT-3 to the assembly to execute budding and fission of the microdomain, leading to 
ILV formation (Colombo et al., 2013; Wollert and Hurley, 2010).  This canonical pathway 
for exosome biogenesis can be influenced by syntenin. Through binding to the cytosolic 
domain of syndecan-1, syntenin can recruit the ESCRT-accessory protein Alix, which in 
turn bridge syntenin-associated cargoes to VPS32, a member of the ESCRT-3 subunit 
(Baietti et al., 2012). 
 
Figure 1-15- Biogenesis of exosomes. 
The biogenesis of exosomes mostly occurs through endosomal sorting complexes required for transport 
(ESCRT)-mediated membrane remodelling and scission. ESCRT-0 and ESCRT-1 subunits cluster 
ubiquitinated transmembrane cargoes on microdomains of the limiting MVE membrane. Together with 
ESCRT-2, they recruit ESCRT-3 to the assembly to execute budding and fission of the microdomain, leading 
to ILV formation. The Syndecan-binding protein, syntenin, may also promote ILV biogenesis, by recruiting 
the ESCRT-accessory protein, Alix, which in turn bridges syntenin-associated cargoes to VPS32, a member of 
the ESCRT-3 subunit. The synthesis of ceramide in the limiting membrane of MVE, catalysed by neutral type 
II sphingomyelinases, was previously shown to promote membrane budding and ILV biogenesis. Proteins of 
the tetraspanin (tetrasp.) family may also mediate ILV biogenesis, likely by having a structure that induces 
membrane curvature and contributing to the formation of budding microdomains. 
Despite the importance of the ESCRT machinery for ILV formation, other pathways have 
also shown to influence exosome biogenesis. This is the case for the synthesis of ceramide 
in the limiting membrane of MVE, catalysed by neutral type II sphingomyelinases, which 
was previously shown to promote membrane budding and ILV biogenesis (Trajkovic et al., 
2008). Proteins of the tetraspanin family may also mediate ILV biogenesis, likely by having 
a structure that induces membrane curvature (Zimmerman et al., 2016), thus contributing to 
the formation of budding microdomains. In support of this, loss of CD9 and CD81 was 
previously shown to modulate the levels of various cargoes in exosomes, and other studies 
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demonstrated that loss of CD63 has an impact on both cargo sorting and exosome release in 
various cell types (Margolis and Sadovsky, 2019). Additionally, chaperones such as HSP70 
and HSP90 might regulate EV biogenesis, by modulating sorting of cytosolic proteins to 
budding microdomains of the MVE limiting membrane (Lancaster and Febbraio, 2005; 
Lauwers et al., 2018).   
Avoiding degradation 
As MVEs are classically fated for lysosomal degradation, mechanisms that prevent this 
outcome are likely in place in MVEs destined for secretion. This is in line with previous 
studies showing that the inhibition of endosome acidification is a trigger for EV release, 
presumably by re-routing MVE to the plasma membrane (Villarroya-Beltri et al., 2016). 
While this aspect of exosome biogenesis is still a mystery, an attractive hypothesis in the 
field is that ESCRT-dependent mechanisms of cargo sorting lead to MVEs that can follow 
either route, while ESCRT-independent cargo sorting is exclusive for those that will produce 
exosomes (van Niel et al., 2018).  Consistent with this hypothesis, syntenin function seems 
to be restricted to MVEs that result in exosomes. Furthermore, overexpression of 
tetraspanin-6, which recruits and physically interacts with syntenin in MVE, impairs 
lysosomal function whilst upregulating exosome release (Guix et al., 2017). This is also 
supported by observations that the level of ubiquitination of certain cargoes, which might 
influence their affinity to ESCRT-0 and -1 complexes, dictated whether they were degraded 
or released in exosomes (Buschow et al., 2009).  
The endosomal and autophagy pathways can also converge, due to fusion of MVEs with the 
autophagosome. There are many reports in which modulation of autophagy has been shown 
to influence EV release. For example, caveolin has an inhibitory role on autophagosome 
formation, whereas modulation of caveolin function by prion protein (PrP) potentiates EV 
release (Dias et al., 2016). Thus, exosome production is likely to be influenced by levels of 
autophagy in cells.  
Transport 
Once matured, the transport of MVEs towards the lysosome for degradation, or the plasma 
membrane for exosome release, occurs through engagement of MVEs with microtubules and 
associated motor proteins. As membrane trafficking events, these processes are regulated by 
members of the Rab family of small GTPases. Trafficking of MVE to the lysosome is 
mediated by Rab7 and its associated effectors, and this is mediated through retrograde 
transport on microtubules (Guerra and Bucci, 2016). In contrast, targeting to the plasma 
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membrane for exosome release is mediated by Rab27a and Rab27b and their effector 
proteins synaptogmin-like protein 4 and exophilin 5 respectively. Rab27b acts on the 
antegrade transport of MVB and both Rab27s mediate the docking of MVE to the plasma 
membrane (Ostrowski et al., 2010).  
 
 
Figure 1-16- Transport of MVE and exosome release. 
The transport of MVEs towards the lysosome for degradation, or the plasma membrane for exosome release, 
occurs through engagement of MVEs with microtubules and associated motor proteins. As membrane 
trafficking events, these processes are regulated by members of the Rab family of small GTPases. Trafficking 
of MVEs to the lysosome is mediated by Rab7 and occurs through retrograde transport on microtubules. For 
exosome release, anterograde transport of MVEs to the plasma membrane and their subsequent docking at this 
site is largely mediated by Rab27a and Rab27b and, to a lesser extent, Rab11 and Rab35. The final step in 
exosome production is the fusion of the limiting MVE membrane with the plasma membrane, leading to 
exosome release. This process is mediated by the SNARE machinery and is likely to also involve 
rearrangements in the actin cytoskeleton.  
Although several studies have demonstrated that Rab27a and Rab27b are required for 
exosome production, the GTPases are not ubiquitously expressed, which may indicate that 
other GTPases mediate MVE trafficking to the plasma membrane. Indeed, while their 
mechanisms of actions are not clear, other Rab family members, such as Rab35 and Rab11, 
have previously been shown to mediate transport and docking of MVE to the plasma 
membrane in some cell types (Hsu et al., 2010; Koles et al., 2012; Messenger et al., 2018). 
Release 
The final step in exosome production is the fusion of the limiting MVE membrane with the 
plasma membrane, with concomitant exosome release. As a membrane fusion event, this 
process is mediated by SNARE and synaptotagmin family members, and actin. A SNARE 
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complex known to be involved in the exocytosis of conventional lysosomes includes 
VAMP7, syntaxin7 and synaptotagmin7, and exosome release in some cell lines has been 
shown to be dependent on these proteins (Fader et al., 2009). However, some studies have 
provided evidence for exosome release being independent of these proteins in other cell 
types (Proux-Gillardeaux et al., 2007), which is a reason to believe that other SNARE 
proteins might participate in this fusion event. The SNARE protein SNAP23, for example, 
has been shown to mediate exosome release in a number of human tumour cell lines (Wei et 
al., 2017). In humans and C. elegans, exosome release can be modulated by the SNARE 
proteins syntaxin-1 and syntaxin-5 respectively (Hyenne et al., 2015; Koles and Budnik, 
2012). Thus, this aspect of exosome release is complex, and different SNARE and SNARE-
associated proteins execute this process depending on the cell type and biologic context.  
1.8.2.2 Microvesicle production 
Biogenesis 
The machinery responsible for microvesicle biogenesis has only recently started to be 
revealed. Microvesicle biogenesis seems to comprise rearrangements of lipid and protein 
elements within the plasma membrane, as well as modulation of local Ca2+ levels 
(Minciacchi et al., 2015). Ca2+ within those domains activates Ca2+- dependent enzymatic 
machineries, including aminophospholipid translocases and scramblases that drive 
translocation of phosphatidylserine and phosphatidylethanolamine from the inner to the 
outer leaflet of the plasma membrane (Al-Nedawi et al., 2008). Such phospholipid 
translocation may lead to bending of the membrane and subsequent association with the 
actomyosin cytoskeleton, leading to membrane budding and microvesicle biogenesis (Al-
Nedawi et al., 2008). Accordingly, the actomyosin regulators RhoA and ROCK have been 
shown to stimulate microvesicle biogenesis in tumour cells (Li et al., 2012). Furthermore, 
cholesterol is often abundant in microvesicles, and there is some evidence that it might 
promote microvesicle biogenesis, by inducing lipid raft formation (Pollet et al., 2018).  
Release 
Upon formation, the release of microvesicles is completed by their fission from the plasma 
membrane. This step is also likely to involve  the actomyosin cytoskeleton, as modulation 
of the actin regulators Arf6, Arf1 and cdc42 have been shown to influence the fission of 
microvesicles from the plasma membrane (Antonyak et al., 2012; Muralidharan-Chari et al., 
2009; Schlienger et al., 2014). Additionally, some of the factors that mediate exosome 
biogenesis have also been shown to modulate fission of microvesicles. For instance, a rise 
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in levels of ceramide, mediated by acidic sphingomyelinases, can promote membrane 
bending and microvesicle release from glial cells (Bianco et al., 2009). Likewise, the 
ESCRT-I complex members TSG101 and ESCRT-III associated protein VPS4 have been 
reported to be required for the release of certain EVs (Nabhan et al., 2012), and the MVE-
to-plasma membrane trafficking regulators Rab27a and Rab27b have been shown to mediate 
shedding of EVs from the plasma membrane (van Niel et al., 2018). Thus, modulation of 
these pathways is likely to affect the biogenesis and/or release of both microvesicles and 
exosomes. 
 
 
Figure 1-17- Microvesicle production. 
EV biogenesis starts with clustering of lipids and membrane-associated proteins in specific microdomains of 
the plasma membrane, as well as modulation of local Ca2+ levels. Ca2+ within those domains activates 
aminophospholipid translocases and scramblases that drive translocation of phosphatidylserine and 
phosphatidylethanolamine from the inner to the outer leaflet of the plasma membrane, leading to membrane 
bending and subsequent association with the actomyosin cytoskeleton, in a RhoA-ROCK-dependent manner. 
The release of microvesicles is completed by their fission from the plasma membrane. This step is also likely 
to require engagement with the actomyosin cytoskeleton, as modulation of the actin regulators Arf6, Arf1 and 
cdc42 were shown to influence the fission of microvesicles from the plasma membrane. In certain cell types, 
a rise in levels of ceramide, mediated by acidic sphingomyelinases, can promote membrane bending and 
microvesicle release. Likewise, the ESCRT-I complex members, TSG101 and ESCRT-III associated protein 
VPS4 have been reported to be required for the release of certain microvesicles.  
1.8.3 EVs and recipient cells 
Once in the extracellular milieu, EVs may come into contact with recipient cells. The 
intercellular communication mediated by EVs is likely to require their docking with the 
plasma membrane of recipient cells. An important aspect to consider is that EVs may dock 
to the plasma membrane of other cells, as well as of the cell that released them. This way, 
EVs can modulate both paracrine and autocrine signalling (Matsumoto et al., 2017). The 
docking of EVs to recipient cells seems to occur through interaction between molecules at 
the EV surface with those on the cell surface. There is evidence for some degree of 
specificity to the docking of EVs with recipient cells, and a number of factors have been 
shown to mediate, and to define the specificity of, these interactions. 
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The best understood mechanisms for EV docking involve interactions with integrins on the 
EV surface. EV-associated integrins can bind to adhesion molecules on recipient cells, such 
as intercellular adhesion molecules (ICAMs), thereby favouring their docking (Morelli, 
2004). As will be discussed later in this chapter, experiments in mice have demonstrated that 
different integrin heterodimers on EVs can modulate their accumulation in specific organs, 
further reinforcing the hypothesis that EV-associated adhesion molecules play a role in the 
binding and recognition of EVs by recipient cells (Hoshino et al., 2015). Additionally, the 
interaction of integrins on both EV and recipient cell membrane with fibronectin in the ECM 
may also mediate this process, with ECM favouring their docking by retaining EVs in close 
proximity to the cell (Purushothaman et al., 2016). Furthermore, EV-associated 
tetraspannins have also been shown to mediate docking and uptake of EVs to recipient cells 
(Nazarenko et al., 2010), possibly by interacting with integrins in tetraspannin-enriched 
microdomains.  
Docking of EVs to recipient cells is also likely to depend on their lipid composition. In this 
context, the level of phosphatidylserine in EVs can determine the amount of specific lipid-
binding proteins in EVs, including galectin 5, a lectin that can induce EV docking to 
macrophages (Barres et al., 2010). As galectins have been identified in EVs from cancer cell 
lines (Klibi et al., 2009), it is interesting to speculate whether these mechanisms are in place 
for uptake of EVs released by cancer cells.  
Upon docking to recipient cells, EVs may transmit information by acting at the cell surface, 
without transferring their content. This mechanism is particularly relevant for immune-cell 
modulation, as EVs may contain major histocompatibility complex peptides that can bind to 
T-cell receptors on the surface of T-lymphocytes (Admyre et al., 2003; Testa et al., 2010). 
For EVs that transfer their content to cells, this can occur via EV fusion with the plasma 
membrane, through a mechanism that is largely unknown, or via EV internalisation. 
For EVs that are internalised, several well-described pathways were shown to facilitate this, 
including clathrin-dependent endocytosis (i.e. receptor-mediated endocytosis), endocytosis 
mediated by caveolae and lipid rafts, micropinocytosis and even phagocytosis by cells such 
as macrophages and monocytes. Although the factors that dictate which internalisation 
pathway is used remain elusive, studies suggest that EV size and composition might play a 
role in this (van Niel et al., 2018). Furthermore, perhaps more pertinent for the context of 
this work, EV uptake in certain fibroblasts was previously shown to occur through clathrin-
dependent endocytosis and to be influenced by the formation of filopodia, which stimulated 
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the movement of single EVs toward sites of the plasma membrane where endocytosis occurs 
(Heusermann et al., 2016)  
Internalised EVs may then follow an endocytic pathway and reach MVE in recipient cells. 
Once in the MVE, they may be degraded by fusion of this compartment with lysosomes, 
transported to the plasma membrane for re-release or, in some cases, these ILV have been 
suggested to fuse with the MVE’s limiting membrane (termed ‘back-fusion’) and release 
their content in the cytoplasm (Tian et al., 2014). The latter is particularly significant for the 
intercellular delivery of nucleic acids or cytosolic components, if they are to modulate 
responses in recipient cells. However, the mechanisms controlling back-fusion have not yet 
been elucidated. 
1.8.4 EVs as cancer biomarkers 
There is substantial interest in exploiting EVs as cancer biomarkers. This is based on the fact 
that tumour-derived EVs can be purified from body fluids, such as blood and urine, and the 
premise that EV cargoes may reflect the composition of the donor cell.  
Among the first studies that explored the utility of EVs as tumour biomarkers was the 
comparison of the composition of glioblastoma-EVs with those of their normal counterparts. 
These researchers demonstrated that EVs in the serum of glioblastoma patients contained 
glioblastoma-associated RNA and proteins (Skog et al., 2008). Subsequently, several reports 
validated these observations in multiple cancer types, by showing that EVs encapsulate 
cargoes that reflect the cell of origin (Kloecker et al., 2008; Soldevilla et al., 2014). 
Furthermore, other studies suggested that EV composition might be informative of patient 
prognosis in a variety of cancer types, including pancreatic and non-small cell lung cancer 
(Vader et al., 2014). Therefore, the correlation between EV and cell composition might be 
valuable for the detection and monitoring of tumours. 
Early detection of cancer greatly impacts the chances for successful therapy. This is 
especially important for many deadly types of cancer, such as pancreatic adenocarcinoma, 
which are often ‘silent’ and may form metastasis before the patient develops symptoms. In 
this context, there is some evidence indicating that tumour-derived EVs may be detected in 
the blood stream of tumour-bearing mice prior to the tumour being fully formed (Sharma et 
al., 2017). However, markers that enable cancer-specific EVs to be discriminated from their 
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normal counterparts are still lacking which has, so far, precluded the use of EVs as early 
detection markers for cancer. 
1.8.5 Tumour-EVs and the tumour microenvironment 
As mediators of intercellular communication, it is likely that EVs from different cell types 
contribute to the many interactions that occur in the TME, thereby potentially shaping the 
way tumours grow and progress. There are, indeed, many reports in the literature that are 
consistent with this hypothesis. Bellow, we focus on a few examples regarding tumour-EVs.  
Increasing evidence suggests that tumour-EVs may influence the behaviour of other tumour 
cells. For example, certain tumour-EVs have previously been shown to carry oncogenic 
proteins, such as EGFRvIII, to generate a transformed phenotype in recipient cells(Al-
Nedawi et al., 2008). Similarly, a few studies have shown that EVs released from aggressive 
tumour cell lines can induce migratory phenotypes in recipient cells in vitro, and a study 
using a co-transplantation mouse model has confirmed that this type of communication can 
also occur in vivo (Rahman et al., 2016; Zomer et al., 2015). However, in the context of 
tumour-EV-induced migration, the mechanisms by which EVs may stimulate such 
phenotypes are not yet clear. 
Tumour-EVs may also affect the behaviour of non-tumour cells in the TME, such as 
endothelial cells. EVs released from tumour cells overexpressing EGFR, for example, have 
previously been shown to transfer the receptor to recipient endothelial cells, leading to 
VEGF upregulation and angiogenesis (Al-Nedawi et al., 2009).  
Tumour cell-EVs may also directly interact with immune cells to stimulate the formation of 
a tumour-permissive microenvironment. Numerous reports have demonstrated that EVs 
released by tumour cells can modulate the polarisation of macrophages to a tumour-
permissive state (Cooks et al., 2018; Sun et al., 2019). Additionally, a recent study has 
demonstrated that EVs from metastatic melanoma may carry PD-L1 on their surface, directly 
suppressing the activity of CD8+ T cells (Chen et al., 2018) 
There is also evidence for fibroblasts being affected by tumour-EVs. For instance, tumour-
EVs may stimulate activation of fibroblasts into CAFs by transferring activating factors, 
such as TGF-b and certain miRNAs (Baroni et al., 2016; Ringuette Goulet et al., 2018).  
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1.8.6 Tumour-EVs and the pre-metastatic niche 
Over the last few years, it has become clear that EVs are key players in orchestrating the 
formation of PMNs. As previously mentioned, an early event in the formation of the PMN 
is acquisition of vascular leakiness. Indeed, previous reports showed that injection of tumour 
cell-EVs in mice is sufficient to induce vascular leakiness in PMNs (Hoshino et al., 2015; 
Peinado et al., 2012). Several in vitro studies have demonstrated that tumour-EVs may 
disrupt endothelial cell junctions, and this often involves transfer of certain EV cargoes, such 
as VEGFA and specific miRNAs (Di Modica et al., 2017; Treps et al., 2017).  
 
Figure 1-18- The priming of pre-metastatic niches occurs in a multistep process. 
Primary tumours release factors that prime the receptivity of certain organs to metastasis – a so-called ‘pre-
metastatic niche’ (PMN).  Given that tumour-EVs may travel the circulation and affect the behaviour of cells 
in distant organs, they have been implicated in the establishment of PMNs. An early event in the formation of 
PMNs is acquisition of vascular leakiness and evidence suggest that EVs may lead to this by transferring certain 
growth factors and miRNAs that disrupt endothelial cell junctions. Another event in the PMN is the “education” 
of resident fibroblasts and modulation of ECM deposition and/or remodelling. Tumour EVs may also modulate 
the behaviour of resident fibroblasts in the PMN, as well as the characteristics of the ECM deposited by these 
cells. Finally, formation of the PMN involves recruitment of immune cells and establishment of an immune-
suppressive microenvironment, and tumour-cell EVs have been shown to stimulate this by promoting the 
infiltration of bone marrow-derived cells (BMDCs), in part through modulating ECM deposition in distant 
organs.  
Formation of the PMN involves recruitment of immune cells and establishment of an 
immune-suppressive microenvironment, and tumour-cell EVs may modulate this process. 
When injected into mice, EVs from highly metastatic tumour cells have been shown to 
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stimulate recruitment of BMDCs to both the lung and the liver PMNs, possibly leading to 
impairment of anti-tumour immunity (Costa-Silva et al., 2015; Hoshino et al., 2015; Peinado 
et al., 2012). Additionally, tumour EVs have been shown to mediate expression of TLR3 in 
the lung epithelium, which led to recruitment of neutrophils to the lung and PMN formation 
(Liu et al., 2016). Conversely, EVs released from poorly metastatic tumour cells promoted 
the recruitment of tumour-reactive macrophages, leading to reduced metastasis (Plebanek et 
al., 2017)  Thus, it seems that EVs from multiple cancer types can modulate immune 
responses in the PMN, and that the ability of EVs to promote immune suppression may 
depend on the metastatic capacity of the donor cell. 
A common event in the PMN is the “education” of resident cells, such as fibroblasts, and 
modulation of ECM deposition and/or remodelling. Tumour EVs may also modulate the 
behaviour of resident fibroblasts in the PMN, as well as the characteristics of ECM deposited 
by these cells. For instance, injection of tumour cell-EVs in mice induced fibronectin 
deposition in both the liver and lung PMN. In the liver, pancreatic cancer EVs that are 
positive for migration inhibitory factor (MIF) stimulated TGF-b  secretion by Kupffer cells, 
leading to fibronectin deposition by neighbouring stellate cells (Costa-Silva et al., 2015). In 
the lung, breast cancer EVs promoted fibroblast activation and fibronectin deposition 
(Hoshino et al., 2015). Importantly, immune-suppressive BMDCs were found in association 
with these fibronectin-rich regions, indicating that ECM deposition and/or remodelling may 
contribute to the priming of PMNs (Costa-Silva et al., 2015; Hoshino et al., 2015). 
Finally, there is also evidence that EVs play a key role in the organotropism of metastasis. 
As previously discussed in this chapter, adhesion molecules at the EV surface, such as 
integrins, may be involved in specific docking of EVs to recipient cells. Consistently, the 
expression of different integrin heterodimers at the surface of EVs has been shown to dictate 
to which organs they are targeted. In particular, a6b4 and a6b1 integrins were enriched in 
EVs that accumulated in the lung, while avb5 integrin was upregulated in EVs that end up 
in the liver. The pattern of internalisation of these EVs mirrored the organotropism of the 
donor cells, indicating that EV-associated integrins play a role in organotropic metastasis, 
by determining where in the body the PMN is formed (Hoshino et al., 2015). 
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1.9 PhD objectives 
The investigation of mechanisms that drive carcinogenesis has contributed immensely to the 
improvement of survival in cancer patients. Still, for many cancer types the prognosis is poor 
and the main cause of cancer-related death is metastasis. In addition to cell-autonomous 
phenomena, such as the ability of cancer cells to invade the ECM, metastasis is known to be 
driven by non-cell autonomous mechanisms. Of the several diffusible factors that cancer 
cells release, EVs can drive many of the processes that contribute to metastasis formation. 
Not only are EVs able to transmit information between different cell types in the TME, they 
have the capacity to travel bloodstream as carriers of information between distant sites, and 
sometimes affect processes such as ECM remodelling and immune composition, thereby 
being involved in the priming of metastatic niches. Thus, deciphering how EVs contribute 
to metastasis might lead to improvement in therapy and might inform for biomarkers of 
metastatic disease.  
In addition to playing a clear role in bypassing mechanisms of tumour suppression, many 
oncogenes (including mutp53s) also contribute to metastasis formation. Of the many 
mutp53-binding partners, its association with p63 is particularly relevant in the acquisition 
of invasive traits and this is, in part, achieved through deregulation of membrane trafficking 
processes. EVs are classically known to depend on membrane trafficking processes for their 
production, and this might be indicative of a possible role for mutp53 in influencing EV 
production and/or function. The objective of this thesis is therefore to investigate whether 
expression of mutp53 in cancer cells influences EV release, composition and function, with 
a particular interest in understanding whether EVs from mutp53-expressing cells influence 
non-cell autonomous processes and/or inter-organ communication in a way that might 
promote metastasis. 
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 Materials and methods 
2.1 Materials 
2.1.1 Reagents 
Reagent Supplier 
0.45 µm filter Gilson 
2 % gelatin Sigma 
27-gauge needle Becton Dickinson 
4.8 µm silica microsphere Bang Labs 
96 well PCR plate Bio-Rad 
Acetonitrile Sigma 
AFM probe Nanoworld 
Agarose Melford Laboratories 
All blue protein standard Bio-Rad 
Ampicillin Sigma 
Apo-transferrin Sigma 
Ascorbic acid Sigma 
ATP Sigma 
BSA First Link 
BsmBI enzyme NEB 
CaCl2 Sigma 
Cell lifter Corning 
Citric acid Sigma 
Dialysed FBS Life Technologies 
DMEM Thermo Fisher 
DNA dilution buffer NEB 
DNaseI Roche 
DTT Melford Laboratories 
Dynabeads (anti-mouse) Life Technologies 
Dynabeads (streptavidin) Life Technologies 
EDTA Sigma 
EGF Life Technologies 
EGTA Sigma 
F12 ham medium Sigma 
FBS PAA 
Filtered FBS Thermo Fisher 
Formic acid Sigma 
Formvar carbon coated EM grids Polysciences 
Glucose Sigma 
Glutamine Life Technologies 
Glutaraldehyde Sigma 
Glycine Sigma 
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Heavy arginine (10) Cambridge Isotope Labs 
Heavy lysine (8) Cambridge Isotope Labs 
HEPES Life Technologies 
Hydrocortisone Sigma 
Hydrogen peroxide Sigma 
IAA Sigma 
Igepal CA-630 Fluka 
Insulin ActRApid Life Technologies 
Iodoacetamide Sigma 
KCl Sigma 
Lipofectamine RNAiMAX Thermo Fisher 
Low melting point agarose Sigma 
M199 medium Sigma 
Medium arginine (6) Cambridge Isotope Labs 
Medium lysine (4) Cambridge Isotope Labs 
MEM vitamins Life Technologies 
MesNa Fluka 
Methyl cellulose Sigma 
Milk powder Marvel 
Na2CO3 Thermo Fisher 
Na2HPO4 Sigma 
Na3VO4 Thermo Fisher 
NaCl Thermo Fisher 
NaF Sigma 
NEBuffer 3.1 NEB 
NH4OH Sigma 
Nunc MaxiSorp plates Thermo Fisher 
NuPage MOPS running buffer Life Technologies 
NuPAGE pre-cast gel (4-12 %) Life Technologies 
NuPage sample buffer Life Technologies 
NuPage transfer buffer Merck 
Ortho-phenylenediamine Sigma 
Ortho-phosphorylethanolamine Sigma 
PBS Thermo Fisher 
PBS with calcium and magnesium Sigma 
Penicillin/streptomycin Life Technologies 
Pentobarbital Sigma 
PerfeCTa SYBR green master mix Quantabio 
PFA EMS 
Polybrene Sigma 
Primaquine Sigma 
Puromycin Sigma 
PVDF membrane Merck 
S.O.C medium Thermo Fisher 
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SDS Thermo Fisher 
SILAC DMEM Lonza 
Stbl3 competent cells Thermo Fisher 
Streptavidin-HRP GE Healthcare 
Sucrose Sigma 
Sulfo-NHS-SS-biotin Thermo Fisher 
T4 DNA ligase NEB 
T4 DNA ligation buffer NEB 
T4 polynucleotide kinase NEB 
T4 polynucleotide kinase reaction buffer NEB 
Thinwall Polypropylene Tube (38.5 mL) Beckman 
Tissue culture dishes (10 and 15 cm2) BD Biosciences 
Tissue culture plate (6 well) Corning 
Tri-iodotyronine Sigma 
Tris HCl Melford Laboratories 
Triton-X100 Sigma 
Trypsin Life Technologies 
Tween-20 Sigma 
Uranyl oxalate Thermo Fisher 
Urea Sigma 
Vectashield (soft set with DAPI) Vector Labs 
Table 2-1- Reagents and suppliers. 
 
2.1.2 Solutions 
Solution Components 
1% SDS lysis buffer 1% SDS (v/v), 50 mM Tris-HCl pH7.0, 0.1 M DTT 
2x HBS 274 mM NaCl, 10 mM KCl, 1.4 mM Na2HPO4, 15 mM glucose, 42 mM HEPES, pH6.8 
Antibody coating buffer  0.05 M Na2CO3, pH9.6 
CDM extraction buffer 10 mM NH4OH, 0.5 % Triton-X100 (v/v) in PBS with calcium and magnesium 
ELISA developing 
buffer 
0.56 mg/mL ortho-phenylenediamine, 25.4 mM Na2HPO4, 12.3 
mM citric acid, pH5.4 with 0.003% H2O2  
LB Broth 85mM NaCl, 1% bacto-trypton (w/v), 0.5% yeast extract (w/v) 
Non-denaturing lysis 
buffer  
50 mM Tris-HCl pH7.0, 150 mM NaCl, 10 mM NaF, 1 mM 
Na3VO4, 5 mM EDTA, 5 mM EGTA, 1.5 % Triton-X100 (v/v), 
0.75 % Igepal CA-630 (v/v) 
PBS-T  PBS, 0.1 % Tween-20 (v/v) 
TBS-T  10 mM Tris-HCl pH7.4, 150 mM NaCl, 0.1 % Tween-20 (v/v) 
Table 2-2- Solutions and their components. 
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2.1.3 Kits 
Kit Supplier 
Amaxa Nucleofector Kit V Lonza 
QIAquick Gel Extraction Kit QIAGEN 
QIAshredder columns QIAGEN 
Reverse Transcription system Promega 
RNAeasy spin columns  QIAGEN 
Table 2-3- Kits and suppliers. 
 
2.1.4 Primers 
Primer Product, supplier, catalogue number/sequence 
GAPDH QuantiTect, QIAGEN, QT00273322 
LKO.1 forward  5’-GACTATCATATGCTTACCGT-3’ 
Podocalyxin QuantiTect, QIAGEN, QT00005138 
Table 2-4- Primers. 
 
2.1.5 siRNA 
Target Product, supplier, catalogue number/sequence 
DGKα ON-TARGET, Dharmacon, L-006711-00-0020 
α3 Integrin  ON-TARGET, Dharmacon, L-004571-00-0010 
p53 5’-GACUCCAGUGGUAAUCUACUU-3’ 
p63 5’-UGAACAGCAUGAACAAGCUTT-3’ 
Podocalyxin ON-TARGET, Dharmacon, L-010617-00-0020 
Rab27a ON-TARGET, Dharmacon, L-004667-00-0010 
Rab27b ON-TARGET, Dharmacon, L-004228-00-0010 
Rab35 ON-TARGET, Dharmacon, L-009781-00-0020 
Rab35 ON-TARGET, Dharmacon, J-009781-05-0010 
RCP ON-TARGET, Dharmacon, L-015968-00-0020 
Table 2-5- siRNAs. 
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2.1.6 Plasmids 
Plasmid Supplier 
GFP-Rab35 Addgene 
lentiCRISPR vector Addgene 
podocalyxin-GFP Echard lab 
podocalyxinV486A/Y500A-GFP Echard lab 
psPAX2 packaging plasmid Addgene 
VSV-G plasmid Addgene 
Table 2-6- Plasmids and suppliers. 
 
2.1.7 Antibodies 
Antibody Species Application and dilution Supplier 
Actin Rabbit WB - 1:3000 Sigma 
Alexa-fluor 488 anti-mouse Goat IF - 1:400 Life Technologies 
Alexa-fluor 555 anti-mouse Goat IF - 1:400 Life Technologies 
CD63 Mouse WB - 1:1000; IF - 1:200; IEM - 1:200 Pelicluster 
CD9 Rabbit WB - 1:10000 Abcam 
cMET Goat ELISA - 5 µg/mL R&D Systems 
DGK⍺ Rabbit WB - 1:500 Protein Tech 
Fibronectin Mouse IF - 1:100 BD Pharmingen 
GFP Rabbit WB - 1:1000 Abcam 
HSPA8 Rabbit WB - 1:1000 Cell Signalling 
α3 Integrin Rabbit WB - 1:1000 Abcam 
β1 Integrin Mouse WB - 1:2000 BD Pharmingen 
α5 Integrin Mouse ELISA - 5 µg/mL BD Pharmingen 
IRDye 680CW anti-mouse Donkey WB - 1:20000 LI-COR 
IRDye 680CW anti-rabbit Donkey WB - 1:20000 LI-COR 
IRDye 800CW anti-mouse Goat WB - 1:20000 LI-COR 
IRDye 800CW anti-rabbit Goat WB - 1:20000 LI-COR 
mouse IgG Rabbit IEM - 1:200 Pierce 
p21 Rabbit WB - 1:1000 Cell Signalling 
p53 Mouse WB - 1:10000 In-house antibody 
p63 Rabbit WB - 1:1000 Abcam 
Paxillin Mouse IF - 1:100 BD Pharmingen 
PODXL Rabbit WB - 1:1000 Abcam 
Rab27 Mouse WB - 1:1000 Abcam 
RCP  Rabbit WB - 1:1000 in-house 
Tnf Receptor  Mouse ELISA - 5 µg/mL BD Pharmingen 
TSG101  Mouse WB - 1:1000 GeneTex 
Table 2-7- Antibodies. 
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2.2 Methods 
2.2.1 Mouse models of cancer 
2.2.1.1 Autochthonous mouse model 
KP172C (Pdx1-Cre, KrasG12D/+, p53R172H/+), KP270C (Pdx1-Cre, KrasG12D/+, p53R270H/+), KPflC 
(Pdx1-Cre, KrasG12D/+, p53fl/+) and KC (Pdx1-Cre, KrasG12D/+) mice of mixed FVB/Bl6 
background are as previously described (Hingorani et al., 2005; Morton et al., 2010).  At 
approximately 12 weeks of age, when metastases were not apparent, mice were culled and 
liver and lung ECM was visualised ex vivo, as described in 2.2.1.3 (bellow). Tumour growth 
was assessed by gross pathology and confirmed by histology. All animal experiments were 
performed under UK Home Office licence and approved by the University of Glasgow 
Animal Welfare and Ethical Review Board.  
2.2.1.2 Xenograft mouse model  
For xenograft experiments, 1×106 H1299 cells were subcutaneously injected into 8-week-
female CD1 nude mice. Subcutaneous tumours were measured by callipers three times a 
week until they reached a size endpoint of 8 mm in diameter. Mice were culled once tumours 
reached the defined size endpoint and lung ECM was visualised ex vivo, as described in 
2.2.1.3. All xenografts experiments were performed under UK Home Office licence and 
approved by the University of Glasgow Animal Welfare and Ethical Review Board. 
2.2.1.3 Second harmonic generation microscopy of lung and liver  
Mice were sacrificed by intraperitoneal injection of pentobarbital and lungs were inflated 
with 2% low melting point agarose and visualised by second harmonic generation (SHG) 
microscopy. Briefly, a small incision was performed in the trachea and liquid agarose was 
injected with a blunted syringe needle. Mice were then left on ice for 10 minutes to allow 
agarose to solidify in lungs. Lungs were dissected and sliced using a vibratome for 
downstream analysis (Campden Instruments 5100mz). Fresh lung slices were imaged using 
a Trimscope multiphoton microscope (Lavision) to visualise fibrillar collagen in the lung 
parenchyma by SHG microscopy. For the visualisation of perivascular/peribronchial areas, 
lung slices were fixed in 4% PFA and imaged using an LSM 880 NLO multiphoton 
microscope (Zeiss). 
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For the animals in which liver ECM was examined, we dissected the liver and imaged 
fibrillar collagen in the liver capsule by SHG microscopy, using a Trimscope multiphoton 
microscope (Lavision). 
2.2.2 Cell culture 
2.2.2.1 Cancer cell lines 
H1299 (p53−/− and p53R273H /R175H) and MDA-MB-231 cells (ATCC) were cultured in 
Dulbecco’s modified Eagle medium supplemented with 10% foetal bovine serum (FBS), 1 
mM L-glutamine, 100 µg/mL streptomycin and 100 U/mL penicillin, here referred to as 
complete media, and incubated at 37oC in 10% CO2.  Cells were passaged by washing with 
PBS, followed by a 3-minute incubation in 0.25 % trypsin to detach cells from plates, with 
trypsin being quenched using complete media. Cell lines were routinely tested for 
mycoplasma contamination. 
2.2.2.2 Immortalised cell lines 
Telomerase-immortalised human dermal fibroblasts (TIFs, in house, Beatson Institute) and 
HEK 293T cells (ATCC) were cultured in complete media and incubated at 37oC in 10% 
CO2. Cells were passaged by washing with PBS followed by a 3-minute incubation in 0.25% 
trypsin to detach cells from plates. The trypsin was quenched using complete media. Cell 
lines were routinely tested for mycoplasma contamination. 
2.2.2.3 Patient-derived cell lines (PDCLs) 
The three PDCLs were previously generated by the Biankin lab (Bailey et al., 2016). They 
were cultured in M199/F12 HAM medium supplemented with 7.5% filtered FBS, 15 mM 
HEPES, 2 mM L-glutamine, 20 ng/mL EGF, 40 ng/mL hydrocortisone, 5 ng/mL apo-
Transferrin, 0.2 IU/mL Insulin ActRApid, 0.06% glucose, 0.5 pg/mL Tri-iodotyronine, 1x 
MEM vitamins and 2 g/mL Ortho-phosphoryl ethanolamine and were incubated at 37oC in 
5% CO2. Cells were passaged by washing with PBS followed by a 3-minute incubation in 
0.25 % trypsin to detach cells from plates. The trypsin was quenched using the culture media 
described above. Experiments using these cell lines were done in collaboration with Peter 
Bailey and Giuseppina Caligiuri, Beatson Institute. 
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2.2.2.4 Transient transfection 
H1299 cells were transfected with 2 μg of expression constructs containing podocalyxin-
GFP, podocalyxinV486A/Y500A-GFP (kindly gifted from the Echard lab, Institute Pasteur, Paris, 
France) or GFP, using the AMAXA system with Solution V and X-001 nucleofection 
protocol, as per manufacturer’s instructions.  
H1299 cells were transfected with siRNA targeting RCP, DGKα, PODXL, Rab35, Rab27a, 
Rab27b, ITGA3, or non-targeting siRNA, at a concentration of 5 nM, using the AMAXA 
system with Solution V and X-001 nucleofection protocol, as per manufacturer’s 
instructions.  
PDCLs were transfected with siRNA targeting p53 or a non-targeting siRNA, at a 
concentration of 5 nM, using lipofectamine RNAiMAX, according to the manufacturer’s 
instructions.  
One nucleofection reaction was conducted per 80% confluent 15cm2 cell culture dish and 
transfected cells were seeded in new 15 cm2 dishes for downstream experiments. Details of 
siRNAs and plasmids used are in Tables 2-5 and 2-6 respectively. 
2.2.2.5 CRISPR 
The guide RNA (gRNA) sequences used were 5’-GTAGCGAACGTGTCCGGCGT-3’ as 
non-targeting control, 5’-TTGTCAACGTCAAGCGGTGG-3’ against Rab35, and 5’-
GTGAGGTTCAGGACGAGCTG-3’ against podocalyxin. These sequences were cloned 
into lentiCRISPR vector, previously established by the Zhang lab (Shalem et al., 2014). For 
this, 5 μg of lentiCRISPR vector were digested with 20 units of BsmBI enzyme in buffer 3.1 
in a volume of 50 μL, for 2 hours at 37°C. The digested plasmid was then run on agarose gel 
and purified using QIAquick Gel Extraction Kit as per the manufacturer’s instructions. 1 μg 
of each pair of gRNA oligos was then phosphorylated and annealed with 1mM ATP and 5 
units of T4 polynucleotide kinase, in T4 polynucleotide kinase reaction buffer, for 30 
minutes at 37°C, followed by a step of 5 minutes at 95°C and a ramp down to 25°C 
(5°C/minute). The phosphorylated and annealed sgRNAs were then diluted at 1:200 in 
ddH2O. Finally, we performed a ligation reaction between 1 μL of phosphorylated and 
annealed sgRNA and 50 ng of digested lentiCRISPR vector, using 1 μL of T4 DNA ligase 
in DNA dilution buffer, DNA ligation buffer. As a negative control, we set up a ligation 
reaction with the digested lentiCRISPR vector in the absence of gRNA oligos. 
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For the propagation of these constructs, we transformed stbl3 competent cells. Briefly, 1 μL 
ligation reaction was added to a vial of competent cells. After gently mixing, cells were 
incubated on ice for 30 minutes, heat-shocked for 45 seconds at 42°C and returned to ice for 
2 minutes. 250 μL of S.O.C medium was added to each vial, which were then cultured at 
37°C, for 1 hour in a shaking incubator. 100 μL of each transformation was spread onto 
ampicillin-containing agar plates and incubated overnight at 37°C. From each 
transformation plate, several colonies were picked and grown overnight in ampicillin-
containing LB broth, at 37°C in a shaking incubator. Pellets were maxiprepped and 
sequenced using the LKO.1 forward primer, by the Molecular Technology Service, CR-UK 
Beatson Institute, Glasgow. Workbench software was used to analyse the sequences and to 
confirm that the constructs contained the desired guide sequences. 
For the production of lentivirus encoding Cas9 and the respective gRNAs, HEK 293T cells 
were used as a packing cell line and were transfected as follows. 10 μg lentiCRISPR plasmid, 
7.5 μg psPAX2 packaging plasmid and 4 μg VSV-G plasmid, were incubated with 120 mM 
of CaCl2 in HBS buffer, for 30 minutes at 37°C. This mixture was then added to the media 
of HEK 293T cells (50% confluent 10 cm2 dish) and left overnight at 37°C. The following 
day, culture media was replenished with fresh media.  
48 hours after transfection, the supernatant from HEK 293T cells was replaced with fresh 
media and passed through a 0.45 μm filter. Subsequently, the supernatant was supplemented 
with 4 μg/mL Polybrene and added onto a 10 cm2 dish of 50% confluent target H1299-
p53R273H cells. 24 hours later, the new supernatant from HEK 293T cells was passed through 
a 0.45 μm filter, supplemented with 4 μg/mL Polybrene and used to transduce target cells as 
above. After 24 hours of culture, the virus-containing media was removed and replenished 
with media containing puromycin 2.5 μg/mL, which was replenished every 2 days for a 
period of 2 weeks. The loss of podocalyxin or Rab35 in target cells was confirmed using 
western blotting and cryofreezing was conducted for long term storage of CRISPR cell lines. 
These cells lines were established with Louise Mitchell, CRUK Beatson Institute. 
2.2.2.6 Condition media (CM) assays 
H1299 p53-/- and p53R273H cells were seeded at a density of 1x106 cells per 15 cm2 culture 
dish and grown to 90 % confluency over 72 hours. CM was then collected and subjected to 
differential centrifugation at 300 g for 10 minutes, 2000 g for 10 minutes and 10,000 g for 
30 minutes to remove live cells, dead cells and cell debris respectively. The supernatant was 
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collected and used to treat recipient H1299 p53-/- cells for 72 hours. Recipient cells were 
than reseeded in 6 well plates and cultured for 24 hours, upon reaching confluency and being 
ready to use in cell migration experiments. 
2.2.2.7 Cell-derived matrix (CDM) generation 
Telomerase-immortalised human dermal fibroblasts (TIFs) were cultured in the presence of 
purified exosomes for 72 hours. To produce de-cellularised CDM, 0.2% gelatine-coated 
tissue cultureware was cross-linked with 1% glutaraldehyde for 30 minutes, quenched in 1 
M glycine for 20 minutes, and equilibrated in DMEM containing 10% FBS. EV-treated TIFs 
were detached with trypsin and re-plated at near confluence (~2 × 104 cells/cm2) and grown 
for 8 days in complete media supplemented with 50 µg/mL ascorbic acid. Matrices were 
denuded of living cells by incubation with CDM extraction buffer, and DNA residue was 
removed by incubation with DNaseI. CDMs were stored at 4oC or used immediately in 
further experiments. 
2.2.2.8 Collagen organotypic assay 
Collagen plugs were generated from rat tail derived collagen 1 and pre-conditioned with 
fibroblasts (TIFs).  Cells were seeded in DMEM supplemented with 10% FBS and allowed 
to contract the plug for 2 days. 4 × 104 H1299 cells were then plated on top of these plugs 
and cultured for 2 days. Plugs were then transferred to a metal grid and cultured with full 
DMEM for 1 week. For the co-culture experiment with H1299 p53-/- and H1299 p53R273H 
cells, plugs containing each of the cell lines were bathed in the same culture media, allowing 
diffusible factors to operate. Plugs were then fixed in 4% paraformaldehyde before paraffin 
embedding. 4 µm sections were then cut and stained using haematoxylin and eosin. The 
distance between the cells and the top of the plug was measured for each cell in the field of 
views that were acquired using a brightfield microscope.  
For plugs that were used to assess collagen organisation, they were visualised by SHG 
microscopy after the contraction phase, in the absence of tumour cells, using a Trimscope 
multiphoton microscope (Lavision). 
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2.2.3 Extracellular vesicle (EV) preparations 
2.2.3.1 EV collection 
EV-free media was prepared by ultracentrifugation at 100,000g for 16 hours at 4oC and 
collection of the supernatant. Cells were then cultured in complete media for 24 hours and 
cultured for 48 hours in EV-free media. CM was collected and centrifuged to remove live 
cells (300g), dead cells (2000g) and finally to remove cell debris and larger lipid membrane 
fragments (10,000g). EVs were then pelleted in thinwall polypropylene tubes by a spin at 
100,000g, using an ultracentrifuge (Beckman coulter) with a SW32 rotor. The pellet was 
washed in PBS before a final centrifugation at 100,000 g, after which EVs were resuspended 
in 200µl of PBS and used on the same day, or stored at 4oC until the next day. All 
centrifugation steps were performed at 4oC. 
When incubating recipient cells (H1299 or TIFs) with EVs, we routinely added these to the 
medium at a concentration of approx. 1 × 109 particles/ml and culture cell in EV-containing 
medium for 72 hours. Cells were then washed in PBS, reseeded and used for further 
experiments. 
2.2.3.2 Sucrose density gradient 
For sucrose density gradient centrifugation, EV pellets were mixed with 1 mL of a 2.5 M 
solution of sucrose at the bottom of a 12 mL centrifugation tube. EVs were overlaid with 11 
layers of sucrose decreasing in concentration (from 2 to 0.4 M sucrose using 20 nM HEPES 
as diluent). The gradient was centrifuged at 200,000 g overnight using a SW40 rotor. EVs 
were collected from each gradient fraction by a final centrifugation in PBS at 100,000 g. 
Pellets were resuspended in 50 ul PBS. 
2.2.3.3 Nanoparticle tracking analysis 
Nanoparticle tracking analysis was carried out using the NanoSight LM10 instrument 
(Malvern) according to the manufacturer’s instructions. EVs collected by ultracentrifugation 
(200 µL final volume) were diluted 1:30 in filtered PBS before being introduced into the 
instrument for measurement.  
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2.2.3.4 Transmission electron microscopy 
EVs were collected and fixed in 2 % paraformaldehyde. Subsequently, 5 μl of fixed EVs 
were adsorbed onto Formvar carbon coated EM grids overnight at 4°C. Grids were washed 
with 100 μl PBS and treated with 1 % glutaraldehyde for 5 min. This was followed by eight 
washes with distilled water. EVs were visualised by negative staining, grids were incubated 
with uranyl oxalate for 5 minutes and subsequently methyl cellulose-UA for 10 minutes at 
4°C. Air dried grids were imaged on the transmission electron microscope FEI Tecnai T20 
running at 200 kV using Olympus Soft Imaging System software. 
For immunogold staining of CD63, adsorbed EVs were subject to four blocking washes with 
PBS/50 mM glycine after initial adsorption onto grids. A second blocking step was then 
carried out using PBS/5 % BSA for 10 minutes. EVs were then exposed to CD63 primary 
antibody or mouse IgG1 isotype control antibody and incubated in 1% BSA for 30 minutes. 
Grids were washed in 0.1 % BSA in PBS six times, 5 minutes each. Grids were then 
incubated with anti-mouse 10 nm protein A-gold conjugate secondary antibodies for 30 
minutes following eight PBS washes. From here onwards, fixation and negative staining 
protocol was performed as described in the paragraph above. Acquired Images were 
analysed using ImageJ to determine EV size. Experiment conducted by Margaret Mullin and 
Nikki Heath, at the University of Glasgow and the Beatson Institute.  
2.2.4 Migration assays  
2.2.4.1 Scratch-wound assay 
Cells were seeded in 6 well plates at a density of 4x105 cells/well and cultured for 24 hours 
until reaching around 90% confluency. At that time, a scratch-wound was performed using 
a p200 tip. Cells were washed with culture media and fed with fresh media. Cell plates were 
introduced into a 5% CO2 chamber and imaged every 10 minutes for 16 hours using a Nikon 
time-lapse Z6011, CoolSNAP HQ camera (photometrics) and metamorph software 
(molecular devices). Cell tracking was performed using imageJ and parameters of migration 
calculated using Chemotaxis plugin. 
2.2.4.2 Random migration 
Fibroblasts were seeded in 6 well plates at a density of 5x104 cells/well and cultured for 24 
hours. Cell plates were introduced in a 5% CO2 chamber and imaged every 10 minutes for 
16 hours using a Nikon time-lapse Z6011, CoolSNAP HQ camera (photometrics) and 
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metamorph software (molecular devices). Cell tracking was performed using imageJ and 
parameters of migration calculated using Chemotaxis plugin. 
2.2.4.3 Migration on CDM 
MDAMB231 cells were seeded onto de-cellularised CDM at a density of 8x104 cells/well in 
a 6-well plate. Cells were allowed to attach for 4 hours and then the plate was introduced in 
a 5% CO2 chamber and imaged every 10 minutes for 16 hours using a Nikon time-lapse 
Z6011, CoolSNAP HQ camera (photometrics) and metamorph software (molecular 
devices). Cell tracking was performed using imageJ and parameters of migration calculated 
using Chemotaxis plugin. 
2.2.5 Quantitative reverse transcription PCR  
2.2.5.1 RNA extraction 
H1299 cells were seeded in 6 well plates and cultured for 24 hours until cells had reached 
around 70% confluency. Cells were washed twice with ice-cold PBS and put on ice before 
RNA extraction using RNAeasy spin columns according to manufacturer’s instructions. The 
concentration and quality of RNA extracted was quantified using the nanodrop system. 
2.2.5.2 cDNA synthesis 
cDNA was synthesised using Promega Reverse Transcription system following 
manufacturer’s instructions. Samples were subjected to the following cycle protocol: 
annealing 25 °C for 5 minutes, extension 42 °C for 60 minutes and inactivation 70 °C for 5 
minutes. The resulting cDNA was stored at – 20°C until further use. 
2.2.5.3 Quantitative PCR 
1 μl of synthesised cDNA in 7 μl H20 was analysed in a quantitative PCR (qPCR) reaction 
using 10 μl PerfeCTa SYBR green master mix and 2 μl QuantiTect primers for podocalyxin 
or GAPDH (housekeeping gene), according to manufacturer’s instructions. Samples were 
loaded into a Biorad 96 well plate in triplicates. Quantitative PCR was run on the Biorad 
C1000 thermal cycler. DNA was denatured at 95 °C for 5 minutes. This was then followed 
for 40 cycles of denaturation at 95 °C for 30 seconds, annealing at 60 °C for 30 seconds and 
extension at 72 °C for 30 seconds. A final step of extension was performed for 5 minutes at 
72 °C. Data was analysed using Biorad software using Ct cycle values. Levels of 
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podocalyxin expression were compared between cell lines using the ΔΔCt method and 
GAPDH as a sample control.  
2.2.6 SILAC proteomics 
H1299 cells (p53-/- or p53R273H) were cultured in Single Isotope Labelling by Amino acids in 
Culture (SILAC) DMEM with 10% dialysed FBS, 1 mM L-glutamine, 100 μg/ml 
streptomycin, 100 U/ml penicillin and 1:1000 amino acid isotopes (heavy: lysine8, arginine10 
or medium: lysine4, arginine6). p53-/- cells were labelled with heavy amino acid isotopes and 
p53R273H cells were labelled with medium amino acid isotopes. Once amino acid isotopes 
were fully incorporated, p53-/- and p53R273H cells were seeded for EV collection. After 
collection of the conditioned medium, both conditions were merged prior to processing to 
minimize technical errors. The final EV pellet was re-suspended in 6M urea for mass 
spectrometry analysis. During mass spectrometry analysis, proteins detected in EV from 
H1299-p53-/- and H1299-R273H could be distinguished from one another in the sample due to 
the different amino acid isotope labelling. 
EV proteins were reduced (10 mM dithiothreitol), alkylated (55 mM iodoacetamide) and 
digested (Lys C and trypsin). Peptides were cleaned using stage tips and re-dissolved in 5 % 
acetonitrile/0.25 % formic acid. Protein samples were then applied on the Orbitrap Elite (LC-
MS). Data was searched and quantified against Swissprot (Human) database using 
MaxQuant software. Mass spectrometry experiments were performed in collaboration with 
Sara Zanivan, David Sumpton and Nikki Heath, from The CRUK Beatson Institute. Dataset 
in appendix I. 
2.2.7 Western blotting 
Cell culture media was removed from cells, which were then washed in ice-cold PBS and 
lysed on ice in 50 mM tris/1 % SDS lysis buffer. Cells were scraped and homogenised using 
Qia-shredder columns. Cell lysate was then mixed in NuPage sample buffer and boiled for 
5 minutes at 95 °C.  
To resolve proteins by electrophoresis, samples were loaded into a NuPage pre-cast gel (4-
12 %) alongside a protein ladder. Gels were ran using NuPage MOPS running buffer at 150 
V for 2 hours. Proteins were then transferred from the gel onto methanol activated PVDF 
membrane in NuPage transfer buffer at 120 V for 90 minutes. The membrane was blocked 
using 5 % Milk or 3 % BSA in TBS-T for one hour at room temperature under agitation. 
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Primary antibodies were then applied to the membrane in 1 % milk/BSA in TBS-T overnight 
at 4 °C under agitation. 
Membranes were washed 3 times with TBS-T, every 10 minutes, before secondary Licor 
infra-red fluorescent antibodies of the appropriate species were applied for 30 minutes, at 
room temperature. Three more TBS-T washes were carried out and the membrane was 
transferred to distilled water before the Licor Odyssey system was used to expose the blots 
and visualise protein bands. 
2.2.8 Immunoprecipitation 
H1299 cells were transfected with GFP-Rab35, podocalyxin-GFP or 
podocalyxinV486A/Y500A-GFP as in 2.2.2.4, cultured for 48 hours and lysed in non-
denaturing lysis buffer. Lysates were passed through a 27-gauge needle three times before 
being clarified by centrifugation at 10,000 x g for 10 minutes at 4 °C. Magnetic beads 
conjugated to sheep anti-mouse IgG were bound to anti-GFP antibody. Conjugated beads 
were then incubated with lysates for 2 hours at 4 °C whilst being subjected to constant 
rotation. The beads were then washed in lysis buffer and immunoprecipitated proteins were 
eluted at 95oC for 10 minutes in NuPage sample buffer. Proteins were resolved by SDS-
PAGE and analysed by Western blotting.  
2.2.9 Surface biotinylating assay 
H1299 cells were labelled with the membrane-impermeable reagent sulfo-NHS-SS-biotin 
(0.2 mg/mL in PBS) on ice for 30 minutes. Cells were then washed with ice-cold PBS and 
lysed in non-denaturing lysis buffer. Lysates were passed through a 27-gauge needle three 
times before being clarified by centrifugation at 10,000 x g for 10 minutes at 4 °C. 
Biotinylated proteins were than precipitated using streptavidin-conjugated beads. The levels 
of podocalyxin associated to the labelled (surface) and input (total) fractions were assessed 
by western blotting.  
2.2.10 Internalisation assay 
Recipient H1299-p53−/− cells were cultured in the presence of purified EVs for 72 h. 
Following this, cells were trypsinised and washed to remove EVs, re-plated and grown for 
48 h to achieve a confluence of 80–90%. Cells were incubated in serum-free DMEM, 
transferred to ice, washed twice in ice-cold PBS and surface-labelled at 4oC with 0.2 mg/mL 
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sulfo-NHS-SS-biotin (Pierce) in PBS for 30 min. Cells were washed with ice-cold PBS, 
replenished with serum-free medium with the recycling inhibitor primaquine (0.6 mM), and 
shifted to 37oC for the stated times to allow internalisation of tracer. After washing cells with 
ice-cold PBS, the biotin remaining at the surface was reduced for 1 hour in 20 mM MesNa, 
and quenched in 20 mM IAA for 10 minutes, at 4 °C. Cells were then washed using ice-cold 
PBS and lysed in non-denaturing lysis buffer. Lysates were passed through a 27-gauge 
needle three times before being clarified by centrifugation at 10,000 x g for 10 minutes at 
4°C. 
Internalised/biotinylated α5β1, cMET and TfnR were then quantified by capture-ELISA as 
follows. In the previous day, Maxisorp plates were coated with antibodies recognising 
human α5 integrin, cMET or TfnR in antibody coating buffer, and incubated overnight at 
4°C. Plates were then washed with PBS-T and blocked with 5% BSA in PBS-T, for 1 hour 
at room temperature. Following another wash in PBS-T, the antibody-coated plates were 
incubated with cell lysates, overnight at 4°C. Plates were washed again in PBS-T and 
incubated with streptavidin-HRP in 0.1% BSA PBS-T, for 1 hour at 4°C. A final wash in 
PBS-T was performed and plates were incubated with ELISA developing reagent, for 10-15 
minutes at room temperature. The reaction was stopped with 8 M sulfuric acid and 
absorbance at 490 nm was determined. We determined the level of internalisation of each 
receptor (i.e. protected from MesNa reduction and therefore biotinylated) as a percentage of 
the total surface biotinylated pool of the approapriate receptor. 
2.2.11 Recycling assay 
Recipient cells were cultured in the presence of purified EVs for 72 h. Following this, cells 
were trypsinised and washed to remove EVs, re-plated and grown for 48 h to achieve a 
confluence of 80–90% prior to conducting receptor recycling assays. H1299-p53−/− cells 
were incubated in serum-free media, transferred to ice, washed twice in cold PBS and 
surface-labelled at 4oC with 0.2 mg/mL sulfo-NHS-SS-biotin in PBS for 30 minutes. Cells 
were transferred to serum-free DMEM for 30 minutes at 37 °C to allow internalisation of 
tracer. Cells were returned to ice, washed with ice-cold PBS and biotin was removed from 
proteins remaining at the cell surface by performing a reduction with 20 mM MesNa at 4 °C 
for 1 hour.  
The internalised fraction was then chased from the cells by returning them to 37 °C in serum-
free DMEM. At the indicated times, cells were returned to ice and biotin removed from 
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recycled proteins by a second reduction with 20 mM MesNa for 1 hour, followed by 10 
minutes of quenching with 20 mM IAA, at 4 °C. The DGK inhibitor (R59022) or DMSO 
control were added as the receptor internalised and were maintained during the subsequent 
recycling period.  
Biotinylated α5β1, cMET and TfnR were then determined by capture-ELISA as in 2.12. The 
% of recycling was calculated by subtracting the absorbance obtained upon the second 
reduction with MesNa from the absorbance of the internal pool (obtained upon the first 
reduction with MesNa), followed by dividing this value by the absorbance of the internal 
pool. 
2.2.12 Immunofluorescence  
Cells or decellularized CDMs were fixed in 4 % paraformaldehyde in PBS for 8 minutes and 
permeabilised with 0.2 % triton-X100 in PBS for 10 minutes. Cells were washed twice with 
PBS and blocked using 1 % BSA in PBS. 
The primary antibody was applied to cells in 1 % BSA/PBS for 1 hour. After 3 washes in 
PBS, the Alexa-conjugated secondary antibodies were incubated for 45 minutes in 1% BSA 
in PBS. After 3 washes with PBS, soft set Vectashield with DAPI was used to mount 
samples. Samples were then visualised by confocal microscopy using Olympus Fluoview 
FV1000.  
2.2.13 GLCM analysis of ECM organisation 
Using image sets generated by second harmonic and immunofluorescence imaging, the 
structure and organisation of the ECM was analysed by applying grey level co-occurrence 
matrix (GLCM) analysis, a second-order statistical method. Briefly, the intensity of each 
pixel containing collagen signal is compared to the neighbouring pixels (up to 100 pixels 
away, corresponding to 100 μm) and a 2D histogram of intensity occurrences compiled, from 
which statistical parameters of the intensity distribution are calculated such as correlation, 
homogeneity, contrast and entropy. This has the advantage of removing bias introduced by 
varying total amounts of signal, changes in the image acquisition and/or signal strength as 
compared to direct measurements from the raw image data. A bi-exponential model is 
applied to the correlation decay data and the fit parameters are used to calculate a weighted 
mean decay distance that serves as a parameterisation metric between sample conditions. 
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2.2.14 Atomic force microscopy 
The mechanical properties of the cell-derived matrix were carried out with an Atomic Force 
Microscope Nanowizard II (JPK Instruments) mounted on an inverted optical microscope 
(Zeiss Observe) with a cell heater attachment. Force indentation measurements were carried 
out using an AFM probe attached with a 4.8 µm silica microsphere. Thermal calibrations 
were performed to determine the spring constant of each cantilever before use. Force 
spectroscopy measurements were performed on 50 randomised locations on each sample by 
applying a 3 nN force indentation. The Hertzian spherical model was applied to the approach 
force–distance curves to deduce the elastic modulus of the ECM using an in-house algorithm 
written in R.  
The adhesive properties of the ECM were estimated through analysing the energy required 
to remove the probe from the matrix, which is the total areas of adhesion peaks in the 
retraction force–distance curves (JPK data analysis software). These experiments were 
performed in collaboration with Huabing Yin and Laura Charlton, University of Glasgow. 
2.2.15 Statistics 
Statistical analysis was performed on all relevant experiments. To compare two data-sets 
unpaired t-tests were performed if the data were normally distributed, or a Mann-Whitney 
test if the data were not normally distributed. To compare more than two data sets, ANOVA 
tests were used if the data were normally distributed, and a Kruskal-Wallis test if the data 
were not normally distributed. Statistical significance is annotated within the figures and the 
associated p-values are indicated in each figure legend, with p<0.05 considered as 
significant. 
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 A novel non-cell autonomous gain-of-
function of mutp53 
(This chapter features work relating to Novo et al. (2018) – Appendix II). 
 
 
3.1 Introduction 
Wild-type p53 function is often lost in human cancers. This is frequently driven by point 
mutations in ‘hotspot’ residues within the DNA binding domain of p53 that lead to the 
expression of full-length mutants with abrogated wild-type p53 function (Petitjean et al., 
2007). Mutp53s are not, however, phenotypically silent, as they can interact with cellular 
proteins and/or directly with DNA to drive transcriptional and non-transcriptional changes 
in the cells which express them (Freed-Pastor et al., 2012; Jordan et al., 2008; Strano et al., 
2002). This, along with the fact that mutp53s are often stable in human cancers, gives rise to 
an aberrantly expressed oncogene that influences a multitude of signalling pathways. As a 
consequence, mutp53-expressing cancers often display gain-of-function (GOF) phenotypes 
that render them more aggressive than the ones driven solely by p53 loss (Lang et al., 2004; 
Morton et al., 2010; Olive et al., 2004). This occurs, in part, through a cell autonomous 
mechanism in which mutp53s, by interacting with p63 and blocking its functions, activates 
integrin recycling in cancer cells to promote invasive migration (Muller et al., 2014, 2009).  
Nonetheless, tumour progression does not depend solely on cell autonomous mechanisms. 
Tumours are often composed by multiple clonal populations of cancer cells within a complex 
microenvironment, allowing intercellular communication to occur through diffusible factors. 
Among these diffusible factors are EVs. In addition to cancer cell-derived EVs being 
considered to be potential cancer biomarkers, it is now clear that they can modulate 
responses in non-tumour cells to influence multiple aspects of tumour progression, including 
modulation of anti-tumour immunity (Wolfers et al., 2001), reprogramming of 
microenvironments to foster tumour progression (Baglio et al., 2017; Cooks et al., 2018; 
Webber et al., 2015), and priming of metastatic niches (Costa-Silva et al., 2015; Peinado et 
al., 2012; Zhang et al., 2017). Moreover, a few studies have now indicated that EVs can 
mediate communication between different cancer cells, allowing for transfer of migratory 
and invasive traits (O’Brien et al., 2013; Rahman et al., 2016; Tang et al., 2018). However, 
despite studies outlining how certain oncogenic proteins and microRNAs might be 
transferred between cells through EVs, the molecular mechanisms that mediate the non-cell 
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autonomous effects of EVs in tumour progression, as well as the role of oncogenic pathways 
in the release of metastasis-promoting EVs, remain elusive.  
In this chapter, we sought to identify non-cell autonomous mechanisms of cancer 
aggressiveness, by taking advantage of a well characterised cell autonomous GOF of 
mutp53s, i.e. their ability to promote cancer cell migration and invasion. In particular, we 
explored whether mutp53-expressing cancer cells can transfer aggressive traits to other cells 
through the release of EVs. Furthermore, we evaluated the effect of mutp53’s expression on 
the release of EVs and their physical properties. Subsequently, we explored whether 
mutp53s control EV composition and, if so, whether composition imbues EVs with the 
ability to transfer phenotypic traits. Finally, we describe a signalling pathway that allows 
recipient cells to respond to EVs. 
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3.2 Results 
3.2.1 mutp53 promotes release of pro-invasive factors 
‘Organotypic’ plugs of native type I collagen in which the ECM has been conditioned for 
several days by human fibroblasts provide an excellent model for assessing cancer cell 
invasiveness in complex microenvironments (Figure 3-1 A) (Timpson et al., 2011a). When 
plated onto organotypic plugs, pre-conditioned by telomerase-immortalised human 
fibroblasts (TIFs), H1299 non-small cell lung carcinoma cells (which do not express p53 -
H1299-p53-/-) were poorly invasive, with most cells residing in the upper portion of the plug 
10 days after seeding. By contrast, isogenic H1299 cells expressing p53R273H, a mutant form 
of p53 described to have GOF, invaded extensively into organotypic plugs (Figure 3-1 B). 
This is consistent with the well-established cell autonomous role of mutp53s in driving 
cancer cell invasion (Muller et al., 2014, 2009; Timpson et al., 2011b). 
 
 
 
(A) Schematic with protocol of organotypic invasion assay. (B) Organotypic plugs were generated allowing 
collagen to polymerise in the presence of telomerase-immortalised human dermal fibroblasts (TIFs). TIF-
containing plugs were conditioned for 2 days to allow TIFs to deposit and remodel the ECM. Plugs were 
overlaid with H1299-p53−/− (left panel), or H1299-p53R273H (middle panel) cells and placed onto grids in 
independent culture dishes containing medium. In the right panel, plugs which were overlaid with H1299-
p53−/− were placed onto grids in the same culture dish as those overlaid with H1299-p53R273H cells, thus 
allowing the possibility of exchange of factors between plugs. Tumour cells were allowed to invade for 10 
days, followed by fixation and H&E staining. The distance between each tumour cell and the top of the plug 
was determined and plotted in C. Bars are mean ± SEM, n= 8 plugs; *** p <0.001 Mann–Whitney test. 
Figure 3-1- mutp53 promotes release of diffusible factors to foster tumour cell invasion in an 
organotypic microenvironment. 
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Pro-invasive oncogenic pathways can also operate in a non-cell autonomous fashion via 
diffusible factors. To test whether mutp53 promotes release of pro-invasive factors, we 
placed organotypic plugs containing H1299-p53R273H cells in the same Petri dish as plugs 
with H1299-p53-/- cells. When cultured in this way, H1299-p53-/- cells displayed invasive 
behaviour that was indistinguishable from H1299-p53R273H cells (Figure 3-1 B, C). These 
data indicate that mutp53’s invasive gain-of-function may be transferred to other cells via 
diffusible factors.  
3.2.2 mutp53 promotes release of EV-associated, pro-migratory 
factors 
In addition to their increased invasiveness, mutp53-expressing cells migrate faster and more 
erratically on 2D substrates than their p53-null counterparts (Muller et al., 2014, 2009). 
Indeed, persistence and forward migration index (FMI) of H1299 cells migrating into 
scratch-wounds was suppressed by expression of mutp53 (Figure 3-2A - C). To represent 
these changes graphically, we calculated the differences between the persistence and FMI of 
mutp53-expressing and p53 null cells—these we term the ΔPersistence and ΔFMI—and 
plotted them as x and y coordinates, respectively (Figure 3-2D). 
 
 
Figure 3-2- mutp53 supresses the forward migration index and persistence of H1299 cells.  
Confluent monolayers of H1299-p53-/- or H1299-p53R273H cells were wounded with a pipette tip and their 
migration into these scratch-wounds was monitored by time-lapse microscopy followed by cell tracking. 
Representative tracks are displayed in (a). Bar, 100 μm. The speed (B), persistence and forward migration 
index (FMI) (C) of migration into scratch-wounds was determined using cell tracking software. The differences 
between the migratory persistence and FMI (the Δ Persistence & Δ FMI respectively) of H1299-p53R273H and 
H1299-p53-/- cells were calculated and are represented graphically in (D). Values are mean ± SEM; *** 
p<0.001 Mann-Whitney test. Experiment conducted by Nikki Heath, the Beatson Institute. 
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We then used this approach to investigate whether mutp53’s migratory gain-of-function can 
be transferred to other cells via diffusible factors. We pre-treated recipient H1299-p53-/- cells 
with media conditioned by donor H1299-p53-/- cells (p53-/--CM) or H1299-p53R273H cells 
(p53R273H-CM) and evaluated their migration into scratch-wounds. Recipient cells pre-
treated with p53-/--CM migrated indistinguishably from untreated H1299-p53-/- (Figure 3-3 
A). By contrast, p53R273H-CM suppressed the migratory persistence and FMI of H1299-p53-
/- recipient cells to a similar extent as mutp53 expression did in cancer cells (Figure 3-3A), 
indicating that mutp53’s migratory gain-of-function can be transferred to recipient cells via 
diffusible factors. 
Expression of mutp53 in cancer cells modulates membrane trafficking. This, together with 
previous reports of non-cell autonomous mechanisms of cancer aggressiveness being 
mediated by cancer cell-derived EVs, led us to investigate the requirement of EVs for 
transfer of mutp53’s migratory phenotype. Indeed, depletion of EVs by centrifugation 
completely opposed the ability of p53R273H-CM to suppress the migratory persistence and 
FMI of recipient H1299-p53-/- cells into scratch-wounds (Figure 3-3 B). These data suggest 
that the diffusible factor(s) responsible for transfer of mutp53’s migratory gain-of-function 
are associated with EVs.  
 
 
Figure 3-3- Media conditioned by mutp53-expressing tumour cells promotes cell migration in p53-/- cells. 
(A) Conditioned medium (CM) was collected from H1299-p53-/- and H1299-p53R273H ‘donor’ cells and then 
placed onto H1299-p53-/- ‘recipient’ cells for 72 hr. Recipient cells were then replated, grown to confluence 
and wounded, and the Δ Persistence and Δ FMI of migration into scratch-wounds determined as for (Figure 3-
2D). Values are mean ± SEM; ***yellow versus green and ***red versus blue in (B) is p<0.001, Mann-
Whitney test. (B) CM was collected from H1299-p53-/- and H1299-p53R273H ‘donor’ cells, depleted of EVs by 
centrifugation at 100,000 g for 70 min, and then placed onto H1299-p53-/- ‘recipient’ cells for 72 hr. Recipient 
cells were then replated, grown to confluence and wounded, and the Δ Persistence and Δ FMI of migration into 
scratch-wounds determined as for (Figure 3-2D). Values are mean ± SEM; ***yellow versus green in (A) is 
p<0.001, Mann-Whitney test. Experiment conducted by Nikki Heath, the Beatson Institute. 
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3.2.3 mutp53 does not influence EV production 
Following the observation that depleting EVs from p53R273H-CM abolished the transfer of 
migratory characteristics, we sought to determine whether mutp53 influences EV production 
and/or release. To do this, we collected EVs by differential centrifugation of p53-/-- or 
p53R273H-CM (Figure 3-4 A) and compared these EV preparations using Nanoparticle 
tracking analysis (NTA) (Figure 3-4 B) and Transmission Electron Microscopy (TEM) 
(Figure 3-4 C). These showed that neither number nor size of EVs was significantly different 
between p53-/-- and p53R273H-EV, with the average diameter of EVs detected by NTA and 
TEM being approximately 150 and 200 nm respectively. Notably, both analyses revealed 
that over 50% of EVs in both preparations were smaller than 200 nm in diameter, which is 
consistent with the size that is canonically attributed to exosomes. 
 
Figure 3-4- mutp53 does not influence the number nor size of EVs released by tumour cells. 
(A) Schematic with protocol for collection of EVs. Conditioned medium was collected and centrifuged to 
remove live cells (300g), dead cells (2000g) and finally to remove cell debris and larger lipid membrane 
fragments (10,000g). EVs were then pelleted at a 100,000g. The pellet was washed in PBS before a final 
pelleting centrifugation at 100,000 g, after which EVs were re-suspended in PBS. (B) EVs were purified from 
H1299-p53-/- and H1299- p53R273H-CM using differential centrifugation and the particle concentration and 
average particle diameter of this material were determined using Nanosight particle tracking. In (C), the 
average diameter of EVs in those preparations was determined using transmission electron microscopy (TEM). 
Values are mean ± SEM.  
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We then used western blotting to evaluate the expression of a panel of EV markers in our 
preparations. This revealed that p53-/-- and p53R273H-EV express similar levels of EV 
markers, including the tetraspannin CD63, which is strongly enriched in late endosomes and 
exosomes (Escola et al., 1998) (Figure 3-5 A). Accordingly, immunogold EM indicated that 
the majority of EVs from H1299 cells were CD63 positive and this was not altered by their 
p53 status (Figure 3-5 B). Taken together, these data indicate that mutp53 expression in 
cancer cells does not influence EV number or size, nor the levels of EV markers in EV 
preparations, thus suggesting that mutp53 does not regulate EV production per se.  
  
Figure 3-5- mutp53 does not influence expression of EV markers in EVs released by tumour cells. 
(A) EVs from H1299-p53-/- and H1299- p53R273H were purified by differential centrifugation and analysed by 
western blotting for the presence of established EV markers. (B) EVs from H1299-p53-/- and H1299- 
p53R273H were purified by differential centrifugation, fixed, adsorbed onto nitrocellulose-coated Formvar 
grids, negatively stained and labelled with anti-CD63 conjugated to 10 nm gold particles before visualisation 
by TEM. Bar 200 nm.  
3.2.4 mutp53-EVs influence recipient cell migration 
Despite the similarities found between EVs released by p53-/-- and mutp53-expressing cells, 
we examined whether EVs are sufficient to mediate intercellular transfer of mutp53’s 
migratory gain-of-function. To this end, we pre-incubated recipient H1299-p53-/- cells with 
EVs collected from donor H1299 cells expressing either of two mutp53s, p53R273H or 
p53R175H (p53R273H- or p53R175H-EV respectively, and referred to as mutp53-EVs), and from 
p53 null H1299 cells (p53−/−-EV) and evaluated their migration into scratch-wounds (Figure 
3-6 A). Strikingly, p53R273H- and p53R175H-EV evoked a phenotype associated with mutant 
p53’s migratory gain-of-function (i.e. suppression of migratory persistence and FMI and 
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increased migration speed) in recipient cells, whereas p53-/--EV were ineffective in this 
regard (Figure 3-6 B). This indicates that mutp53’s migratory gain-of-function can be 
transferred to recipient cells through EVs.  
 
 
Figure 3-6- mutp53-EVs induce migration in p53-/- tumour cells. 
(A) Schematic with protocol for assessing the effect of EVs on cell migration. (B) H1299-p53-/-, H1299-
p53R273H or H1299-p53R175H ‘recipient’ cells were pre-treated with EVs collected from H1299-p53-/-, H1299-
p53R273H or H1299-p53R175H donor cells, or were left untreated as indicated. Cells were then re-plated and the 
speed, Δ Persistence and Δ FMI of migration into scratch-wounds determined as for (Figure 3-2D). Values are 
mean ± SEM; n > 195 cells from three individual experiments; *** in the right panel, and ***yellow vs green 
and *** purple vs green in the left panel are p<0.001, Mann–Whitney. (C) EVs from donor H1299-p53-/-, or 
H1299-p53R273H were adjusted to the indicated concentrations and then incubated with recipient H1299-p53-/- 
cells for 72 hr. Recipient cells were re-plated and grown to confluence for 24hr. Cells were wounded with a 
pipette tip and their speed of migration was determined using time lapse microscopy and cell tracking. Values 
are mean ± SEM. *** are p<0.001, Mann–Whitney. n > 100 cells from 3 individual experiments. 
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We then performed titration experiments to determine the minimal concentration of 
p53R273H-EV required for modulating migration in recipient H1299-p53-/- cells, which was 
2x107 EV/mL (Figure 3-6 C). Thus, the concentration of EV which accumulate in the 
medium bathing mutant p53-expressing cells over 72 hours (approximately 1x109 EV/mL) 
is 100-fold more than is required to generate a migratory phenotype in recipient cells.  
Mutations in the DNA-binding domain of p53, such as p53R273H and p53R175H, are known to 
lead to loss of tumour-suppressive functions. However, some reports have suggested that 
mutp53s may retain and/or exaggerate other aspects of p53wt function (Como and Prives, 
1998; Jordan et al., 2008). This raised the possibility that not only mutp53, but also p53wt 
expression in donor cells, could drive migration in recipient cells. Thus, we used a tetON-
inducible system to express p53wt in H1299 cells (Figure 3-7 A). EVs released by H1299 
cells induced to express p53wt (p53wt-EV) did not affect FMI, directionality nor speed of 
recipient H1299-p53-/- cells into scratch-wounds (Figure 3-7 B), indicating that mutp53’s 
ability to drive transfer of migratory characteristics is, indeed, a gain-of-function. 
 
 
Figure 3-7- p53wt does not drive production of phenotype-altering EVs.  
(A) H1299-p53tetON cells were incubated in the presence or absence of doxycycline and induction of wild-
type p53 was confirmed by western blotting. (B) EVs from these cells were incubated with recipient H1299-
p53−/− cells, the cells re-plated and the speed, ΔPersistence and ΔFMI of migration into scratch-wounds 
determined as for (Figure 3-2D). Values are mean ± SEM; n > 110 cells; *** are p < 0.001, Mann-Whitney. 
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3.2.5 mutp53-EVs promote receptor recycling in recipient cells 
Integrin internalisation and recycling are crucial for cell migration. Accordingly, previous 
studies showed that expression of mutp53s with pro-migratory gain-of-functions in cancer 
cells stimulate recycling of α5β1 integrin and RTKs (Muller et al., 2014, 2009; Rainero et 
al., 2012). Thus, we assessed the rates of internalisation and recycling of a number of 
receptors in recipient H1299-p53-/- cells which had been pre-treated with different EV 
preparations. Recipient cells pre-incubated with p53-/-- or p53R273H-EV displayed similar 
rates of internalisation for a5b1, cMET and TfnR (Figure 3-8 A). However, the rates at 
which the internalised fraction of these receptors returned to the plasma membrane were 
strongly increased in recipient cells which had been pre-incubated with p53R175H- or 
p53R273H-EV, whilst pre-incubation with p53-/--EV was ineffective in this regard (Figure 3-
8 B). These data show that EVs released by mutp53-expressing cells enhance receptor 
recycling, but not internalisation, in recipient cells.  
 
Figure 3-8- mutp53-EVs promote receptor recycling (but not internalisation) in p53-/- cells. 
(A) H1299-p53-/- recipient cells were pre-treated for 72 hours with EVs collected from H1299-p53-/- or H1299-
p53R273H donor cells. Cells were reseeded and culture for a further 72 hours. Internalisation of α5β1integrin, 
cMET and TfnR was determined in the presence of 0.6mM primaquine. Values are mean ± SEM; n=2. (B) 
H1299-p53-/- recipient cells were pre-treated for 72 hours with EVs collected from H1299-p53-/-, H1299-
p53R273H or H1299-p53R175H donor cells, or were left untreated. Cells were reseeded and culture for a further 
72 hours. Recycling of integrin α5β1, cMET and TfnR was determined. Values are mean ± SEM; n=3; 
***yellow versus green and ***purple versuss green in the left panel are p<0.001, ANOVA.  
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In cancer cells, mutp53-mediated receptor recycling occurs through an RCP and DGKα-
dependent pathway (Muller et al., 2009; Rainero et al., 2012). We, therefore, assessed 
whether EV-mediated receptor recycling in recipient cells was dependent on DGKα. We pre-
incubated recipient H1299-p53-/- cells with p53R273H-EV and measured their rates of 
recycling for a5b1 and cMET in the presence of R59022, an inhibitor of DGKa. DGKa 
inhibition in recipient cells opposed the ability of p53R273H-EV to enhance receptor recycling 
(Figure 3-9), indicating that EVs released by mutp53-expressing activate DGKa-dependent 
recycling of receptors in recipient cells. 
 
 
Figure 3-9- mutp53-EV-mediated receptor recycling in p53-/- cells depends on DGKa function.   
H1299-p53−/− recipient cells were pre-treated for 72 hours with EVs collected from H1299-p53−/− or H1299-
p53R273H. Recipient cells were then trypsinised and re-plated. Seventy-two hours following re-plating, recycling 
of integrin α5β1, cMET and TfnR was determined in the presence of R59022 (10 μM) or DMSO control as 
indicated. Values are mean ± SEM, n=3; ***green versus black are p<0.001, ANOVA. 
3.2.6 Recipient cells require RCP and DGKa-dependent signalling 
to respond to mutp53-EVs 
The migratory and invasive behaviour of mutp53-expressing cells depends on RCP- and 
DGKa-mediated α5β1 integrin recycling.  Thus, we sought to test whether the transfer of 
mutp53’s migratory phenotype depends on such a pathway. Addition of R59022 to, or 
knock-down of RCP in, recipient cells (Figure 3-10 A) completely abolished the ability of 
p53R273H-EV to influence cell migration into scratch-wounds (Figure 3-10 B), strongly 
indicating that EVs released by mutp53-expressing cells evoke migratory characteristics in 
recipient cells by upregulating RCP- and DGKa-dependent recycling. 
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(A) Validation of the knockdown of RCP in recipient H1299-p53−/− cells by western blotting with an antibody 
recognising RCP, and tubulin as loading control. (B) H1299-p53−/− cells recipient cells were pre-treated with 
EVs derived from H1299-p53R273H donor cells. Recipient cells were then transfected with siRNAs targeting 
RCP (siRCP) or a non-targeting control (siNT), and the characteristics (ΔPersistence, ΔFMI and speed) of their 
migration into scratch-wounds was determined in the presence and absence of a DGK inhibitor (R59022; 10 
μM) or DMSO control. Values are mean ± SEM; n > 273 cells; *** in right panel, and ***green versus black 
and ***purple versus yellow are p < 0.001, Mann-Whitney test. 
3.2.7 Podocalyxin is a mutp53-regulated EV cargo 
We proposed that altered EV composition might be responsible for intercellular transfer of 
mutp53’s migratory gain-of-function. Thus, we used SILAC-based proteomics to compare 
the proteome of EVs released by H1299-p53R273H and H1299-p53-/- cells which had been 
previously labelled with light and heavy SILAC amino acids respectively (Figure 3-11 A). 
Of the 428 proteins that were unambiguously identified, only 4 of these differed significantly 
between p53R273H- and p53-/--EVs. Podocalyxin, a sialomucin associated with cancer 
aggressiveness (Wang et al., 2017), was significantly reduced in p53R273H-EV (Figure 3-11 
B), and the ability of mutp53s to supress EV-associated podocalyxin was confirmed by 
western blotting (Figure 3-11 C). Together, these data indicate that the quantity of 
podocalyxin in EVs is suppressed by mutp53.  
Figure 3-10- Migration mediated by mutp53-EVs depends on RCP and DGKa functions in p53-/- cells. 
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Figure 3-11- mutp53 controls EV-associated podocalyxin levels. 
(A) Schematic of the protocol for analysis of EV-associated proteome by SILAC-MS. (B) H1299-p53−/− and 
H1299-p53R273H cells were SILAC-labelled with heavy and light amino acids respectively. Conditioned media 
were collected from labelled cells, EVs purified from these using differential centrifugation, and their proteome 
analysed by mass spectrometry. Scatter plot indicates the SILAC ratio H1299-p53R273H/H1299-p53−/− (Log2 
scale) of each protein identified in the EV proteome. Proteins to the left and right of the red dotted lines are 
significantly down and up-regulated respectively in EVs from H1299-p53R273H cells (Significance B statistic 
test, false discovery rate of 5%, Perseus software). These data are extracted from the table presented in 
Appendix 1. Arrow highlights podocalyxin. (C) EVs from H1299-p53−/−, H1299-p53R273H, and H1299-
p53R175H cells were analysed by western blotting with an antibody recognising podocalyxin. CD63 was used 
as sample control. 
Although differential centrifugation-based methods are the most commonly used for EV 
purification from cell culture media, these approaches may yield non-EV components, such 
as large protein aggregates. To further establish whether podocalyxin is integrally associated 
with EVs (and not present as a protein aggregate or other contaminant), we performed 
sucrose density gradients of p53-/-- and p53R273H-EV preparations, collected fractions with 
increasing density from these gradients, and evaluated the quantity of podocalyxin and the 
EV marker CD63 in these fractions by western blotting (Figure 3-12 A). Podocalyxin 
precisely co-migrated with CD63 at a density of 1.1 – 1.15 g/mL (consistent with the 
established density of exosomes (Gupta et al., 2018)), indicating that it is integrally 
associated with EV (Figure 3-12 B). Furthermore, the fact that CD63 is considered to be an 
exosomal marker indicates the likelihood of podocalyxin being associated with exosomes. 
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Importantly, podocalyxin levels in CD63-positive fractions were decreased in p53R273H-EV 
by comparison with p53-/--EV, emphasizing the role of mutp53 in suppressing EV-associated 
podocalyxin levels.  
 
 
Figure 3-12- EV-associated podocalyxin co-sediments with the EV marker CD63 in sucrose density 
gradients (SDGs) 
(A) Schematic with SDG protocol. (B) EVs were collected by differential centrifugation of media conditioned 
by H1299-p53−/− and H1299-p53R273H cells and characterised using sucrose density gradient centrifugation 
followed by western blotting for PODXL and the EV marker, CD63. 
3.2.8 mutp53 suppresses podocalyxin expression in cancer cells 
Our observation that podocalyxin was suppressed in EVs released by mutp53-expressing 
cells led us to investigate whether mutp53s regulate podocalyxin expression at the cellular 
level. To this end, we assessed podocalyxin levels in lysates from H1299 cells with different 
p53 status. qPCR and western blotting analyses showed respectively that podocalyxin 
mRNA and protein levels in cancer cells were suppressed by expression of mutp53s (Figure 
3-13 A, B). By contrast, induction of p53wt did not affect podocalyxin levels in H1299 cells 
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(Figure 3-13 C), suggesting that the ability to regulate podocalyxin expression is a gain-of-
function for mutp53s. 
  
Figure 3-13- mutp53-p63 axis control cellular podocalyxin levels.  
(A) H1299-p53−/−, H1299-p53R273H and H1299-p53R175H cells were lysed and assayed for the levels of mRNA 
encoding podocalyxin using qPCR. Values are mean ± SEM, n = 3; *** is p < 0.001 unpaired t-test (B) H1299-
p53−/−, H1299-p53R273H and H1299-p53R175H cells were lysed and assayed for the levels of podocalyxin protein 
by western blotting with an antibody recognising podocalyxin. Actin was used as load control. n=3 (C) H1299-
p53tetON cells were incubated in the presence or absence of doxycycline and cellular levels of wild-type p53 
and podocalyxin were determined by western blotting using antibodies specific for these proteins. Actin was 
used as loading control. n=3 (D) H1299-p53-/- cells were transfected with siRNAs targeting p63 (sip63) or a 
non-targeting control (siNT). 48 hr following transfection, the levels of podocalyxin and p63 were determined 
by Western blotting. Actin was used as loading control. n=2 
We and others have previously shown that mutant p53s exert migratory GOF by associating 
with and inhibiting p63 (Muller et al., 2014, 2009). Therefore, we knocked-down p63 in 
H1299-p53-/- cells and found that this suppressed cellular podocalyxin levels to a similar 
extent as did expression of mutp53s (Figure 3-13 D). This suggests that podocalyxin 
expression is under the control of p63 and mutp53 likely suppresses podocalyxin levels in 
cells by interfering with p63 function. 
3.2.9 Podocalyxin levels in EVs dictate the intercellular transfer 
of mutp53’s GOF phenotype 
To investigate whether suppression of EV-associated podocalyxin underpins the transfer of 
mutant p53’s GOF phenotypes, we increased podocalyxin levels in p53R273H-EV by 
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expressing podocalyxin-GFP in H1299-p53R273H (Figure 3-14 A). This did not influence the 
quantity nor size of p53R273H-EV (Figure 3-15 A, B). Nonetheless, we assessed the ability of 
these EVs to affect migration of recipient cells. Over-expression of podocalyxin-GFP in 
H1299-p53R273H cells significantly impaired the ability of p53R273H-EV to affect the FMI, 
directionality, and migration speed of recipient H1299-p53-/- cells into scratch-wounds 
(Figure 3-16 B). Likewise, EVs purified from podocalyxin-GFP overexpressing H1299-p53-
/- cells were ineffective in driving a5b1 and cMET recycling in recipient cells (Figure 3-17). 
 
(A) H1299-p53R273H cells were transfected with podocalyxin-GFP or GFP. Conditioned media was collected 
from these cells and EVs purified from these using differential centrifugation. The levels of podocalyxin- GFP 
(green) and GFP (red) in these cells and the EVs from them were determined by western blotting. Tubulin and 
CD63 were used as loading controls for the cell extracts and EV preparations respectively. (B) H1299 cells 
were transfected with siRNA targeting podocalyxin, integrin or a non- targeting control (NT). 72 hr following 
transfection, cells were lysed and the levels of the indicated proteins determined by immunoblotting with 
tubulin as a loading control. 
Figure 3-14- Manipulation of levels of EV-associated cargoes. 
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H1299-p53R273H cells were transfected with siRNAs targeting podocalyxin (siPodocalyxin), a non-targeting 
control (siNT), GFP or podocalyxin-GFP. EVs were collected from these cells by differential centrifugation 
and Nanosight particle tracking used to determine their particle concentration (A) and size distribution (B). 
Values are mean ± SEM. n=3. 
In many reports, it is the presence (not the absence) of podocalyxin and other sialomucins 
which has been linked to cancer progression (Snyder et al., 2015). Thus, we were interested 
in determining the consequences of reducing podocalyxin levels in H1299 cells to levels 
below those effected by expression of mutp53. To this end, we collected EVs from H1299-
p53R273H cells in which podocalyxin had been knocked-down (Figure 3-14 B). Even though 
the quantity or size of p53R273H-EV was not affected by loss of podocalyxin (Figure 3-15 A, 
B), the ability of these EVs to modulate migratory characteristics (Figure 3-16 B) and 
receptor recycling (Figure 3-17) in H1299-p53-/- cells was abolished. By contrast, knock-
down of α3β1 integrin (Figure 3-14 B), the most abundant EV cargo, which was similarly 
expressed in p53R273H- and p53-/--EVs, did not oppose the ability of p53R273H-EV to drive 
migration of recipient cells (Figure 3-16 A). 
Taken together, these data indicate that podocalyxin is required for EV to influence receptor 
recycling and migration in recipient cells, and that mutp53s maintain the levels of EV-
associated podocalyxin within a range that allows this to occur. 
Figure 3-15- Manipulation of EV-associated podocalyxin levels do not influence EV production. 
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(A) H1299-p53R273H donor cells were transfected with siRNAs targeting α3 integrin (siITGA3) or a non-
targeting control (siNT). EVs were collected from these donor cells by differential centrifugation and incubated 
with H1299-p53-/- recipient cells for 72 hr. Recipient cells were re-plated and characteristics of their migration 
into scratch-wounds determined as for Figure 3-2D n>100 cells. (B) Donor H1299-p53R273H cells were 
transfected with GFP, or podocalyxin-GFP, siRNAs targeting podocalyxin (siPodocalyxin) or non-targeting 
control (siNT). EV collected from these cells were used to treat H1299-p53−/− recipient cells for 72 hours before 
the cells were re-plated and migratory characteristics of these cells into scratch-wounds were determined as for 
Figure 3-2D. Values are mean ± SEM. n > 317 cells; ***green versus black, and ***purple versus yellow are 
p < 0.001, Mann–Whitney test. In the right panel, *** is p < 0.001 and * is p < 0.05, Mann–Whitney.  
 
 
Figure 3-16- Manipulation of EV-associated podocalyxin impairs the ability of mutp53-EVs to influence 
migration of p53-/- cells. 
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Donor H1299-p53R273H cells were transfected with GFP, or podocalyxin-GFP, siRNAs targeting podocalyxin 
(siPodocalyxin) or non-targeting control (siNT). EVs collected from these cells were used to treat H1299-
p53−/− recipient cells for 72 hours before the cells were re-plated and recycling rates of α5β1 and cMET were 
determined. Values are mean ± SEM; n=3; ***green versus black, and ***purple versus yellow are p < 0.001, 
Mann–Whitney test.  
3.2.10 Rab35 interacts with podocalyxin to drive its sorting to the 
plasma membrane 
In polarised epithelial cells, podocalyxin binds to the small GTPase Rab35 and this 
association controls podocalyxin trafficking to the plasma membrane (Klinkert et al., 2016). 
This led us to investigate whether podocalyxin interacts with Rab35 in cancer cells. We 
transfected H1299 cells (p53-/- or p53R273H) with GFP-Rab35 and assessed its co-
immunoprecipitation with podocalyxin using western blotting (Figure 3-18). Rab35 and 
podocalyxin co-immunoprecipitated to an extent that is commensurate with the expression 
levels of podocalyxin in p53−/− and mutp53-expressing cells, indicating that podocalyxin and 
Rab35 interact in cancer cells. 
 
 
Figure 3-18- Podocalyxin co-immunoprecipitates with Rab35. 
H1299 (p53−/− or p53R273H) cells were transfected with GFP-Rab35 or mock transfected (no plasmid). GFP-
tagged proteins were immunoprecipitated using an antibody recognising GFP conjugated to magnetic beads. 
Rab35 and podocalyxin were detected in the lysates (total) and immunoprecipitates (GFP-IP) using western 
blotting; n=3 
Figure 3-17- Manipulation of EV-associated podocalyxin impairs the ability of mutp53-EVs to influence 
receptor recycling in p53-/- cells.   
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Rab35 has previously been shown to drive sorting of podocalyxin to the plasma membrane 
(Klinkert et al., 2016; Mrozowska and Fukuda, 2016). Thus, we used cell surface 
biotinylation followed by streptavidin pulldown and western blotting approaches to 
investigate whether Rab35 controls levels of plasma membrane-exposed podocalyxin in 
mutp53-expressing cancer cells (Figure 3-19 A, B). Whilst knockdown of Rab35 in H1299-
p53R273H cells (using SMARTPool siRNAs, an individual siRNA oligo or CRISPR gene 
editing) did not significantly affect the total levels of cellular podocalyxin, it drastically 
reduced podocalyxin expression at the cell surface, indicating that Rab35 drives podocalyxin 
sorting to the plasma membrane in mutp53-expressing cells. 
 
 
Figure 3-19- Rab35 promotes podocalyxin sorting to the cell surface. 
(A) H1299-p53R273H cells were transfected with siRNAs targeting Rab35 (SMARTPool (Rab35-sp) or an 
individual siRNA (Rab35#1)) or a non-targeting control (NT). Cell surface proteins were labelled with NHS-
Biotin at 4 °C and precipitated using streptavidin beads. Labelled (surface) and total (input) podocalyxin were 
then visualised by western blotting with actin as sample control. n=3.   (B) H1299 cells in which Rab35 had 
been disrupted by CRISPR or non-targeting control (NT) were used. Cells were then treated with sulfo-NHS-
Biotin at 40C to label proteins exposed at the plasma membrane. Labelled cells were lysed, and labelled proteins 
precipitated using streptavidin beads. Podocalyxin levels in labelled surface (surface) and total (input) then 
visualised by western blotting with antibodies recognising podocalyxin. Actin was used as loading control. n=2 
(C) H1299-p53R273H cells were transfected with GFP-podocalyxin in combination with SMARTPool siRNAs 
targeting Rab35 (Rab35-sp) or a non-targeting control (NT). Cells were then treated with sulfo-NHS-Biotin at 
4oC to label proteins exposed at the plasma membrane. Labelled cells were lysed, and GFP-PODXL 
immunoprecipitated using magnetic beads coupled to an antibody recognising GFP (GFP- IP). Biotinylated 
GFP-podocalyxin was then visualised by western blotting with labelled streptavidin. Actin was used as loading 
control. 
To further investigate the role of Rab35 in podocalyxin trafficking, we knocked-down Rab35 
in H1299-p53R273H cells expressing podocalyxin-GFP and used immunofluorescence to 
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assess its colocalisation with the late endosomal/MVE marker, CD63 (Figure 3-20 A). 
Rab35 knockdown led to increased colocalisation between podocalyxin and CD63, 
suggesting that, upon Rab35 loss, podocalyxin accumulates in CD63-positive compartments.  
 
 
Figure 3-20- Rab35 loss in mutp53-expressing cells leads to accumulation of podocalyxin in CD63-
positive organelles and in EVs. 
(A) H1299-p53R273H cells were transfected with siRab35-sp, siRab35#1, or siNT. Cells were fixed and 
podocalyxin (green) and CD63 (red) were visualised by immunofluorescence. Bar, 15 μm. ImageJ was used to 
quantify co localised pixels as determined by the Costes method. Values are mean ± SEM. n > 16 cells. *** is 
p < 0.001, Mann–Whitney. (B) H1299-p53R273H cells were transfected with siRNAs targeting Rab35 (Rab35-
sp or Rab35#1), Rab27a/Rab27b (Rab27) or a non-targeting control (NT) ± GFP-podocalyxin. EVs were 
purified by differential centrifugation. Western blotting was used to determine EV levels of podocalyxin and 
GFP-Podocalyxin with CD63 as sample control. n=3 
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3.2.11 Loss of podocalyxin-Rab35 interaction drives accumulation 
of podocalyxin in CD63-positive compartments 
Mutation of residues in the juxtamembrane region of the cytoplasmic tail of podocalyxin   
which have previously been found to be important for podocalyxin-Rab35 association 
(Val496 and Tyr500), were shown to reduce co-immunoprecipitation and co-localisation 
between the two proteins (Klinkert et al., 2016) (Figure 3-21 A). Indeed, mutation of 
podocalyxin’s Val496 and Tyr500 to alanine reduced both co-immunoprecipitation between 
Rab35 and GFP-podocalyxin in H1299-p53R273H cells (Figure 3-21 B). Thus, we evaluated 
the colocalisation between podocalyxinV486A/Y500A-GFP and CD63 in H1299-p53R273H cells 
(Figure 3-22 A). This showed that podocalyxinV486A/Y500A colocalised more efficiently with 
CD63 than podocalyxinwt. These data indicate that the loss of podocalyxin-Rab35 
association is sufficient to oppose its delivery to the plasma membrane and thus drive 
podocalyxin accumulation in CD63-positive compartments.  
 
Figure 3-21 - PodocalyxinV486A/Y500A does not co-immunoprecipitate with Rab35. 
(A) Schematic with comparison between the amino acid sequences of podocalyxinwt and 
PodocalyxinV486A/Y500A. (B) H1299-p53R273H cells were transfected with GFP, GFP-podocalyxin or GFP-
podocalyxinV486A/Y500A. GFP-tagged proteins were immunoprecipitated using an antibody recognising GFP 
conjugated to magnetic beads. GFP-podocalyxin and Rab35 was detected in the lysates (total) and 
immunoprecipitates (GFP-IP) using western blotting; n=3 
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Figure 3-22- PodocalyxinV486A/Y500A accumulates in CD63-positive organelles and in EVs. 
(A) H1299-p53R273H cells were transfected with GFP-PODXL or GFP-PODXLV486A/Y500A. Cells were 
fixed and podocalyxin (green) and CD63 (red) were visualised by immunofluorescence. Bar, 15 μm. ImageJ 
was used to quantify co localised pixels as determined by the Costes method. Values are mean ± SEM. n > 16 
cells. *** is p < 0.001, Mann–Whitney. (B) H1299-p53R273H cells were transfected with GFP-podocalyxin or 
GFP-podocalyxinV486A/Y500A. EVs were collected by differential centrifugation. Western blotting was used to 
determine EV-associated GFP-podocalyxin levels with CD63 as a sample control. 
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3.2.12 Loss of podocalyxin-Rab35 interaction leads to 
accumulation of podocalyxin in EVs 
As we had demonstrated that Rab35 functions to (in particular via its ability to bind to 
podocalyxin) regulate podocalyxin trafficking, we were interested in evaluating the effect of 
Rab35 loss on the levels of EV-associated podocalyxin. To do this, we knocked down Rab35 
in H1299-p53R273H and collected EVs from these cells. NTA analysis showed that Rab35 
loss did not affect EV number nor size (Figure 3-23 A). However, knockdown of Rab35 
resulted in increased levels of podocalyxin associated with EVs (Figure 3-20 B). We then 
took advantage of the mutant of podocalyxin with impaired ability to bind to Rab35 to 
examine whether podocalyxin-Rab35 association regulates the levels of EV-associated 
podocalyxin.  For this, we collected EVs from H1299-p53R273H cells which had been 
transfected with podocalyxin-GFP or podocalyxinV486A/Y500A -GFP and compared the levels 
of these proteins associated with EVs. GFP-podocalyxinV486A/Y500A was sorted more 
efficiently to EVs than GFP-podocalyxinwt (Figure 3-22B). These data indicate that Rab35 
regulates podocalyxin levels in EVs and that this is likely to depend on its association with 
podocalyxin. 
Because Rab27 is known to play a role in MVB dynamics and exosome release (Ostrowski 
et al., 2010), we also knocked down this Rab GTPase to determine whether this influences 
the sorting of podocalyxin to EVs.  Surprisingly, combined knockdown of Rab27a and b, 
did not affect EV-associated podocalyxin levels (Figure 3-20 B) nor the number and size of 
EVs (Figure 3-23 A) released from H1299-p53R273H cells. Together, these data suggest that 
Rab35 controls the levels of podocalyxin associated with EVs, but it does not regulate the 
number nor size of EVs released by H1299-p53R273H cells. Furthermore, these data indicate 
that Rab27s do not regulate EV release from H1299 cells nor podocalyxin sorting into EVs. 
3.2.13 Loss of Rab35 impairs ability of EVs to mediate 
intercellular transfer of mutp53’s migratory GOF 
As loss of Rab35 led to increased levels of EV-associated podocalyxin, we reasoned that 
Rab35 function in mutp53-expressing cells may be required for the production of phenotype-
altering EVs. Consistently, knockdown of Rab35 opposed the ability of H1299- p53R273H to 
release EVs capable of influencing the migration of recipient H1299-/- cells (Figure 3-23 B).  
By contrast, knock-down of Rab27a and b in donor cells, which did not influence 
podocalyxin sorting to EVs, did not oppose the ability of EVs released by H1299-p53R273H 
cells to influence the migratory behaviour of recipient cells (Figure 3-23 B).  Together, these 
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data suggest that Rab35 (but not Rab27) function is required for the production of EVs 
capable of transferring mutp53’s migratory gain-of-function to recipient cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) H1299-p53R273H cells were transfected with siRNAs targeting Rab35 (Rab35-sp or Rab35#1), 
Rab27a/Rab27b (Rab27) or a non-targeting control (NT) ± GFP-PODXL. EVs were purified by differential 
centrifugation. Nanoparticle tracking was used to characterise EVs. values are mean ± SEM, n = 6 movies from 
2 individual experiments. (B) H1299-p53R273H cells were transfected with siRab27, siRab35-sp, siRab35#1 or 
siNT. EVs collected from these cells were used to treat recipient H1299-p53−/− cells and the characteristics of 
their migration into scratch-wounds was determined. Values are mean ± SEM; n > 262 cells; for siRab35#1 n= 
100 cells; ***p < 0.001, Mann–Whitney.   
Figure 3-23- Production of phenotype-altering EVs by mutp53-expressing cells depends on Rab35. 
p53R273H + siRNA: 
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3.3 Discussion 
Mutp53 promotes metastasis by driving cancer aggressiveness in a cell autonomous fashion. 
This is, in part, through a GOF mechanism in which mutp53 binds to p63 and suppress its 
ability to transactivate Dicer, thus resulting in loss of Dicer expression and its related anti-
metastatic roles (Muller et al., 2014; Strano et al., 2002; Xu et al., 2011; Su et al., 2010). 
Accordingly, expression of mutp53s correlates with poor patient prognosis in a variety of 
cancer types, it drives metastasis in mouse models of PDAC (Hingorani et al., 2005; Morton 
et al., 2010; Schofield et al., 2018), and promotes invasiveness of cancer cells in 3D 
microenvironments (Coffill et al., 2012; Muller et al., 2014, 2013, 2009). Indeed, our 
observation that mutp53-expression in H1299 cells increases their ability to invade into 
organotypic plugs confirmed mutp53’s role in the acquisition of cell autonomous invasive 
traits (Figure 3-1) (Timpson et al., 2011a).  
Tumour progression can be also driven by non-cell autonomous mechanisms. Although 
some studies have shown that cancer cells can communicate with each other, through the 
release of diffusible factor(s), to drive cancer aggressiveness in vivo (Chapman et al., 2014; 
Inda et al., 2010; Zhang et al., 2015), the mechanisms by which specific oncogenic pathways 
promote this type of communication remain unclear.. Thus, we took advantage of an isogenic 
cell model to investigate whether mutp53s promote the release of pro-invasive factors. 
Strikingly, p53-/- and mutp53-expressing H1299 cells invaded to similar extents into plugs 
which were cultured in the same Petri dish (i.e. contacting the same culture media), strongly 
indicating that mup53 expression drives the release of factor(s) to promote invasive traits in 
other cancer cells (Figure 3-1) However, because the organotypic plugs contain fibroblasts 
whose role is to pre-condition the plug by re-modelling collagen, at this stage we are unable 
to determine whether the pro-invasive diffusible factor(s) exert their effects via the cancer 
cells or the fibroblasts.  In the following chapter, we show that EVs from mutp53-expressing 
cancer cells do, indeed, exert their pro-invasive influence by changing integrin trafficking 
and ECM re-modelling in the fibroblasts.  Therefore, to conclusively establish the 
contribution made by cancer cell-derived diffusible factor to the invasiveness of cancer cells 
themselves it would be necessary to evaluate the invasiveness of cancer cells in plugs 
depleted of fibroblasts by pre-incubation of contracted plugs with puromycin (Rath et al., 
2017). 
Expression of mutp53s drives fast and non-persistent migration of cancer cells on 2D 
substrates (Muller et al., 2009; Rainero et al., 2012). Conditioned media from donor mutp53-
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expressing H1299 cells induced this type of migration in isogenic recipient p53-/- cells, 
indicating that mutp53-driven migratory traits can be transferred to other cancer cells 
through diffusible factors (Figure 3-3). Importantly, the pre-incubation of recipient p53-/- 
cells with EVs released from donor cells expressing mutp53s (either of the two most 
commonly mutated forms in human cancers – p53R273H and p53R175H) was sufficient to 
invoke such migratory traits in them, suggesting that EVs mediate the transfer of mutp53s-
induced migratory characteristics (Figure 3-6). Mutations in the DNA-binding domain of 
p53, such as p53R273H and p53R175H, lead to loss of tumour-suppressive functions. 
Nonetheless, a number of studies in yeast and human cells have reported that mutp53s can 
still bind to certain p53wt responsive elements, indicating that mutp53s may maintain p53wt 
functions to a certain extent (Como and Prives, 1998; Jordan et al., 2008; Kato et al., 2003; 
Resnick and Inga, 2003). However, EVs released by donor H1299-p53wt cells did not affect 
the migratory traits of recipient H1299-p53-/-, reinforcing that the non-cell autonomous role 
of mutp53s on cancer cell migration and invasion is, indeed, a GOF (Figure 3-7). 
Furthermore, the fact that H1299 cells do not express p53wt provides evidence that this 
phenotype occurs through a GOF mechanism and not through dominant-negative effects of 
mutp53s over p53wt functions, as previously described for other cancer cell lines (Willis et 
al., 2004). 
Mutp53s drive RCP- and DGKa-mediated a5b1 integrin recycling in cancer cells.  This 
then promotes recycling of a number of RTKs, leads to downstream Akt signalling and 
subsequently, phosphorylation and activation of Rac1GAP (Jacquemet et al., 2013).  
Consequently, it leads to a switch from Rac1 to RhoA at the cell front, driving filipodia-
mediated invasion or fast and random migration in 3D or 2D substrates respectively 
(Jacquemet et al., 2013). We have found that mutp53-EVs potently promoted the recycling 
of a5b1 integrin and cMET in recipient p53-/- cells (Figure 3-8 B), and inhibition on DGKa 
in recipient cells abolished EV-mediated recycling (Figure 3-9). We also determined that 
inhibition of RCP or DGKa function in recipient cells impaired their ability to migrate 
differently when pre-incubated with mutp53-EVs (Figure 3-10B). Together, these 
observations indicate that mutp53s promote the release of EVs with the ability stimulate 
RCP- and DGKa-mediated integrin and RTK recycling in recipient cells, leading to RhoA-
dependent migratory and invasive phenotypes. Interestingly, however, we found that 
recycling of TfR, the receptor for transferrin which was thought not to be regulated by the 
mutp53-RCP-DGKα pathway, was stimulated along with the other receptors (Figure 3-8 B). 
Previous studies from our laboratory have measured recycling of a labelled ligand for the 
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TfnR – 125I-Tfn – and found this to be unaffected by expression of mutp53s (Muller et al., 
2009).  Thus, the present study suggests that mutp53 may influence the recycling of the 
receptor for Tfn, but not its ligand.  Indeed, it has been shown that internalised Tfn and its 
receptor (TfnR) do not necessarily return to the plasma membrane via the same route (Mayle 
et al., 2012), and further studies will be necessary to determine precisely which receptor 
recycling routes are and are not influenced by EVs derived from mutp53-expressing cancer 
cells.   
Activation of p53wt following DNA damage has previously been shown to promote EV 
release in cancer cells, via a mechanism mediated by the p53 target TSAP6 (Lespagnol et 
al., 2008; Yu et al., 2006). Mutp53s are inefficient in transactivating p53 target genes, 
including TSAP6, making this target unlikely to be controlling processes through which 
mutp53s influence EV composition. Moreover, our studies indicate that the abundance and 
size distribution of EVs released by H1299 cells (Figure 3-4), and their profile of EV markers 
is not altered by mutp53 expression (Figure 3-5).  Similar findings were reported for cells 
derived from mouse colorectal tumours with different p53 status (Cooks et al., 2018) and, 
together with our data, this is consistent with a situation in which mutp53s do not regulate 
EV biogenesis and/or release. Finally, titration of EVs determined that p53-/--EVs could not 
influence the migratory phenotype of recipient cells even when used at a 100-fold higher 
concentration than is required for p53R273H-EVs to evoke increased cell migration (Figure 3-
6 C), indicating the likelihood that mutp53’s influence over certain EV-cargoes, and not 
simply altered EV production, is responsible for intercellular transfer of invasive behaviour. 
SILAC-based proteomics allowed us to dissect the influence of mutp53 on the composition 
of EV-associated cargoes (Figure 3-11). Although previous studies reported that mutp53 
expression in cancer cells had a profound effect on the cellular proteome (Polotskaia et al., 
2015), we found that most of the identified proteins were indistinguishably expressed in p53-
/-- and p53R273H-EVs. However, we observed that p53R273H-EVs had reduced levels of 
podocalyxin, a sialomucin previously found in EVs collected from urine and cell cultures 
(Fernández et al., 2011; Hogan et al., 2014; Kwon et al., 2014). Accordingly, expression of 
mutp53 in cancer cells led to a reduction of podocalyxin at both mRNA and protein levels 
(Figure 3-13 A, B), and this was phenocopied by knock-down of p63 in p53-/- cells (Figure 
3-13 D). Thus, it is tempting to propose a mechanism by which mutp53s interfere with p63 
function to suppress podocalyxin levels in cancer cells and, as a consequence, in EVs 
released by these cells. A previous study demonstrated that treatment of mutp53-expressing 
kidney cancer cells with CP-31398, a small molecule which was shown to restore wild-type 
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function to mutp53s, led to reduced expression of podocalyxin (Stanhope-Baker et al., 2004). 
At first glance, this observation appears not to be consistent with a role for mutp53 in 
suppressing podocalyxin expression. A possible reason for this discrepancy may lie on CP-
31398’s ability to intercalate DNA and induce p53-independent cell death in a number of 
cancer cell lines (Rippin et al., 2002), which may imbue CP-31398 with p53-independent 
mechanisms of action. 
Rab GTPases are key for membrane trafficking and EV release has been shown to be 
regulated by members of this family, including Rab27 and Rab35 (Hsu et al., 2010; 
Ostrowski et al., 2010). Although Rab27’s role in EV release is well-characterised in a 
number of cell types and has been attributed to its role in the docking and fusion of vesicles 
with the plasma membrane (Ostrowski et al., 2010), the involvement of Rab35 in EV-release 
is less well-established, and has only been demonstrated in oligondrocytes (Hsu et al., 2010).  
However, Rab27-independent pathways for EV release have been described (Koles et al., 
2012) and we have found that neither Rab27 nor Rab35 influence the quantity or size of EVs 
released by H1299 cells (Figure 3-23 A).  Rather, we have shown that Rab35 (but not Rab27) 
is necessary for the intercellular transfer of mutp53’s gain-of-function because it associates 
with podocalyxin and controls its intracellular trafficking. Specifically, Rab35 traffics 
podocalyxin to the plasma membrane (Figure 3-19), thus limiting the amount of podocalyxin 
available in late endosomes to be sorted into EVs (Figure 3-20). 
Given that previous studies have highlighted transfer of certain miRNAs in EVs as the 
mechanism that cancer cells use to “educate” other cells into aggressive phenotypes (Tang 
et al., 2018), we initially proposed that podocalyxin-containing EVs might influence 
recipient cell phenotypes by altering gene expression. To test this, we conducted an extensive 
RNAseq analysis and have been completely unable to demonstrate any reproducibly altered 
levels of mRNAs following treatment of recipient cells with EVs from mutp53-expressing 
cancer cells.  This implies that mutp53-EVs influence recipient cell phenotype via post-
transcriptional mechanisms. Thus, it is interesting to speculate how EV-associated 
podocalyxin levels might influence receptor recycling in recipient cells. Podocalyxin is a 
glycocalyx component which, by virtue of negative charge imparted by sialylated N- and O- 
linked oligosaccharide residues, controls the separation of apposed lipid bilayers to promote 
the opening of lumens during morphogenesis, and to dictate the spacing of kidney podocytes 
(Doyonnas et al., 2001) Given that sialomucins would be expected to contribute to the 
surface charge of EVs, our data therefore suggest the possibility that EVs within a defined 
charge range can influence receptor trafficking by acting on membrane spacing within the 
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endosomal system. Thus, it would be interesting to determine whether post-translational 
modifications of podocalyxin, which would be expected to influence EV charge, contribute 
to the ability of EVs to interfere with endosomal processes. Alternatively, the level of 
podocalyxin in EVs might influence the levels of other cargoes. This possibility is consistent 
with a previous study that suggested that podocalyxin has affinity for sphingomyelin lipids 
and clustering of these in the plasma membrane is required for trafficking of podocalyxin to 
such sites (Ikenouchi et al., 2013).  
Many studies have provided evidence for podocalyxin roles in carcinogenesis. In particular, 
it has been recently suggested that the ratio of surface/cytoplasmatic podocalyxin levels 
correlate with worse prognosis in many cancer types, including pancreatic, colorectal or 
bladder cancers (Boman et al., 2017, 2013; Kaprio et al., 2014; Saukkonen et al., 2015). We 
show that the maintenance of EV podocalyxin levels within a certain range is important to 
dissemination of invasive phenotypes, so it is interesting to speculate whether podocalyxin, 
by accumulating at the cell surface in aggressive cancers, is within an adequate range in 
MVE and EVs to allow mutp53 to influence non-cell-autonomous aggressiveness. 
Furthermore, as we have found that the podocalyxin content of EVs depends, not only on its 
expression in cancer cells, but on Rab35’s capacity to dictate how much of this is sorted to 
EVs, it is now clear that we need to re-evaluate the role of podocalyxin in metastasis in 
human cancers to include analysis of how Rab35 levels and activity intersect with 
podocalyxin expression to dictate clinical outcomes.
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 The effect of mutp53-EVs on ECM 
deposition 
(This chapter features work relating to Novo et al. (2018) – Appendix II). 
4.1 Introduction 
Tumour progression is influenced by reciprocal interactions between tumour and stromal 
cells within the tumour microenvironment. Initial tumour growth is coupled with secretion 
of growth factors from tumour cells, some of which activate resident fibroblasts into CAFs, 
which feature aspects of the phenotype displayed by fibroblasts engaged in wound-healing 
(Augsten, 2014; Kalluri, 2016). Extracellular matrix (ECM) components, in particular 
fibronectin and fibrillar collagens, and ECM remodelling proteins, such as enzymes involved 
in collagen crosslinking (e.g. LOX) or turn-over (e.g. MMPs) are prominent amongst the 
CAF secretome (De Boeck et al., 2013; Tommelein et al., 2015). Through deposition and 
remodelling of the ECM, CAFs modulate linearisation of collagen fibres in the tumour 
stroma, which in turn increases stiffness to drive collective invasion of cancer cells away 
from the primary tumour (Levental et al., 2009). In addition to these local ECM remodelling 
events, primary tumours can also effect ECM deposition in distant organs through the release 
of factors into the circulation, and this is thought to prime PMNs for subsequent cancer cell 
colonisation and metastatic growth (Costa-Silva et al., 2015; Peinado et al., 2012). Although 
the mechanisms by which cancer cells promote ECM deposition and invasive behaviour in 
the stroma (via activation of fibroblasts) are well-understood, the mechanisms by which 
cancer cells influence the ECM in distant sites remain elusive.  
ECM deposition can be regulated by endocytic trafficking of receptors for ECM ligands, 
such as integrins. Internalisation and recycling of α5β1 and αvβ3 integrins are known to 
affect deposition of fibronectin - a key ECM ligand for these integrins (Jones et al., 2009; 
Shi and Sottile, 2008; Varadaraj et al., 2017). As fibrillogenesis of fibronectin influences 
deposition of other abundant matrix proteins such as fibrillar collagens, trafficking of α5β1 
integrin in fibroblasts is likely to have profound effects on ECM dynamics (Sottile and 
Hocking, 2002). In the previous chapter, we presented data showing that EVs released by 
mutp53-expressing cancer cells influence recycling of α5β1 integrin in other cancer cells. 
Thus, this raised the possibility that mutp53 GOF might also be transferred to non-cancer 
cells, such as fibroblasts and, if this were to occur, it would likely have implications for the 
nature of the ECM deposited by these cells.  
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In this chapter, we have characterised the effect of mutp53-EVs on the behaviour of 
fibroblasts, with particular focus on the way in which they recycle an integrin receptor for 
the ECM (α5β1) from endosomes to the plasma membrane, and how integrin recycling 
influences ECM deposition. Subsequently, we have explored in more detail the effect of EVs 
on the characteristics of ECM which these fibroblasts deposit/remodel, with particular regard 
to its organisation, physical properties and ability to support invasive migration of cancer 
cells. Finally, we have used autochthonous mouse models of cancer and transplantation 
approaches to evaluate whether expression of mutp53 in tumours affects ECM 
characteristics in the stroma, as well as in pre-metastatic target organs.  
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4.2 Results 
4.2.1 mutp53-EVs influence fibroblast migration 
To test whether mutp53-EVs can influence the behaviour of fibroblasts, we pre-incubated 
recipient telomerase-immortalised human fibroblasts (TIFs) with p53R273H- or p53R175H-EV, 
termed mutp53-EVs, or with p53-/--EV (Figure 4-1A).  
  
Figure 4-1- mutp53-EVs promote cell migration in fibroblasts. 
(A) Protocol followed for assessing the effect of EVs on fibroblast behaviour. (B) mutp53-H1299 cells, or cells 
generated by CRISPR from the latter (PODXL-CR; Rab35-CR), were transfected with GFP or PODXL-GFP 
or were left untransfected. EVs collected from H1299-p53−/− and the transfected and untransfected mutant p53-
expressing cells were used to treat TIFs and migration was analysed as for Figure 3-2. n = >52; ***red vs blue, 
***purple vs yellow, ***green vs black, ***light blue vs black: p < 0.001, Mann–Whitney. *** is p < 0.001, 
Mann–Whitney. (C) TIFs were treated for 72 hr with EVs collected H1299 cells. EV-TIFs were trypsinised 
and then re-plated at low density onto plastic surfaces and imaged using time-lapse video microscopy. Values 
are mean±SEM, n>80 cell per condition, ***p<0.001 Mann-Whitney. 
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Evaluation of the migration of TIFs in scratch wounds and of these cells seeded sparsely  
revealed that pre-incubation of recipient TIFs with p53R273H- or p53R175H-EV evoked the 
migratory characteristics that we have associated with mutp53 GOF in tumour cells (i.e 
suppression of FMI and directionality, and an increase in speed) (Figure 4-1B, C). In 
contrast, migration of recipient TIFs which had been pre-incubated with p53-/--EVs was 
indistinguishable from untreated TIFs (Figure 4-1B, C). Importantly, manipulation of levels 
of podocalyxin associated with p53R273H-EVs (by knocking-down podocalyxin, using RNAi 
or CRISPR, by over-expressing podocalyxin-GFP, or by knocking-down Rab35, in donor 
H1299-p53R273H cells) abrogated the ability of EVs collected from H1299-p53R273H cells to 
influence fibroblast migration (Figure 4-1B, C). Taken together, these data indicate that 
mutp53’s migratory gain-of-function can be transferred to fibroblasts through EVs, and that 
the levels of EV-associated podocalyxin are critical for this to occur. 
4.2.2 mutp53-EVs drive fibroblast DGKa-dependent receptor 
recycling  
We have previously demonstrated that mutp53-EVs influence cancer cell migration by 
driving RCP- and DGKa-mediated integrin recycling in p53-/- cancer cells (Figures 3-9 and 
3-10), via a mechanism that phenocopies mutp53 expression itself (Muller et al., 2009). To 
examine whether mutp53-EVs can promote receptor recycling in fibroblasts, we pre-
incubated recipient TIFs with p53R273H-, p53R175H- or p53-/--EVs and evaluated the recycling 
rates of a5b1 integrin and TfnR (Figure 4-2).  
 
Figure 4-2- mutp53-EVs promote RCP/DGKa-dependent receptor recycling in fibroblasts. 
(A) EVs were collected from mutp53-expressing R175H or R273H H1299 cells, or H1299-p53−/− were used 
to treat recipient TIFs for 72 hrs. Recipient cells were then trypsinised and re-plated. Seventy-two hours 
following re-plating, R59022 (10 μM) or DMSO was added to TIFs as indicated and recycling of integrin α5β1 
and TfnR was determined. Mean ± SEM, n = 6. In a ***red versus blue, and ***green versus black are p < 
0.001, ANOVA. 
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Pre-incubation of recipient TIFs with p53R273H- or p53R175H-EVs increased the recycling of 
these receptors by at least two-fold, while p53-/- EVs were ineffective in this regard. 
Furthermore, inhibition of DGKa in recipient cells opposed the ability of p53R273H-EV to 
promote receptor recycling (Figure 4-2). These data imply that mutp53-EVs stimulate 
RCP/DGKa-dependent receptor recycling in fibroblasts. 
4.2.3 mutp53-EVs influence the organisation of ECM deposited 
by fibroblasts in a DGKα-dependent manner 
To test whether altered RCP/DGKα-dependent integrin trafficking influences ECM 
deposition (Figure 4-3A), we allowed TIFs that had been pre-incubated with p53R273H-, 
p53R175H- or p53-/--EVs to deposit ECM for 8 days.  Cell monolayers were then de-
cellularised using a buffer containing non-ionic detergents, and the remaining cell-free ECM 
was then analysed by immunofluorescence against fibronectin.  
This showed that levels of fibronectin in the ECM were not affected by pre-incubation of 
TIFs with mutp53-EV. Furthermore, it showed that ECM deposited by TIFs is normally 
organised into bundles of largely parallel filaments, and pre-incubation of the TIFs with p53-
/--EVs did not alter this. By contrast, pre-incubation of TIFs with p53R273H-or p53R175H-EVs 
led to a more branched, orthogonal ECM network (Figure 4-3B). To quantify this, we used 
grey level co-occurrence matrix (GLCM) analysis (Mohanaiah et al., 2013). This method 
determines the probability (intensity correlation) that pixels at increasing distances 
(comparison distance) from a given point can be found to have similar intensities. Thus, if 
an image consists mainly of long straight fibres it is possible to travel some distance in a 
straight line away from a given point without much alteration to intensity, and this will be 
reflected by long comparison distances for a given intensity correlation - i.e. a long mean 
decay distance. However, if an image is comprised mainly of short, orthogonally arrayed 
filaments then the correlation will fall more quickly as one travels away from a given point 
- yielding a shorter mean decay distance.  
GLCM analysis showed that the intensity correlation of ECM deposited by fibroblasts 
treated with p53R273H-or p53R175H-EVs decreased more quickly with distance than it did in 
ECM from untreated fibroblasts or those incubated with p53-/--EVs. Furthermore, inhibition 
of DGKα (during the ECM deposition period) opposed deposition of orthogonal ECM with 
a short mean decay distance (Figure 4-3C). Together, these data indicate that mutp53-EVs 
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educate fibroblasts to deposit ECM with similar levels of fibronectin, but with increased 
orthogonality, and this depends on DGKα-dependent recycling in recipient cells.  
 
Figure 4-3- mutp53-EVs influence ECM deposition/remodelling. 
(A) Protocol for evaluating the effect of EVs on fibroblast-derived ECM. (B) TIFs were incubated with EVs 
from H1299 (p53−/−, p53R273H, p53R175H) cells or left untreated and allowed to deposit ECM in the presence and 
absence of R59022 (10 μM) or DMSO. ECM was then de-cellularised, stained with antibodies recognising 
fibronectin and image stacks were collected using confocal microscopy. Extended focus projections of these 
stacks are displayed, bar, 50 μm. (C) The organisation of the ECM fibres in these was determined using GLCM. 
The decay curves and the weighted means of the decay distances derived from these are presented in the centre 
and right panels of c respectively. Weighted mean ± SEM, n = 8, * is p < 0.05, Mann–Whitney. 
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4.2.4 Pre-incubation of fibroblasts with mutp53-EVs leads to 
deposition of ECM with reduced adhesiveness 
EV-driven alterations in ECM organisation might be expected to influence its mechanical 
properties. To test this hypothesis, we performed atomic force microscopy (AFM) on ECM 
deposited by TIFs which had been pre-incubated with p53R273H - or p53-/--EVs (Figure 4-
4A). This revealed that ECM deposited by fibroblasts which were pre-incubated with 
p53R273H-EVs had similar stiffness to that from untreated fibroblasts and, despite 
observations that pre-incubation with p53-/--EVs encouraged the deposition of a slightly 
stiffer ECM (increased Young’s modulus), this was not consistent with the ability of ECM 
deposited by p53R273H-EVs to support increased cell migration (see Figure 4-5; below).  We, 
therefore, continued to use AFM to determine the adhesive properties of the ECM. We 
attached a silica bead to the tip of the AFM cantilever, allowed this to interact with the ECM 
for a defined time, and then measured the energy required to remove the bead. The energy 
required to remove a silica bead from the ECM deposited by untreated TIFs was unchanged 
by pre-incubation of recipient TIFs with p53-/--EVs. However, pre-incubation of TIFs with 
p53R273H-EVs led to a three- to four-fold reduction in energy necessary to remove a bead 
from the ECM deposited by these fibroblasts (Figure 4-4A).  This suggests that EVs from 
mutant p53-expressing cancer cells induce fibroblasts to deposit an ECM with reduced 
stickiness.   
Because of this altered adhesiveness, we assessed the adhesions formed when cancer cells 
interacted with these matrices. To this end, we seeded MDA-MB-231 breast cancer cells into 
de-cellularised ECM and visualised paxillin-positive adhesions by immunofluorescence 
(Figure 4-4B). Quantitative analysis of adhesion distribution showed that MDA-MB-231 
cancer cells assembled significantly smaller cell-ECM adhesions when they were seeded 
into ECM deposited by recipient TIFs pre-incubated with p53R273H-EVs, in comparison to 
those deposited by untreated or p53-/--EV- TIFs. Together, these data strongly indicate that 
mutp53-EVs educate fibroblasts in depositing/remodelling ECM with reduced adhesiveness, 
which influences the type of adhesion formed by cancer cells interacting with these ECMs.   
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Figure 4-4- mutp53-EVs promote deposition of ECM with reduced stickiness. 
(A) TIFs were treated with EVs from H1299 (p53−/− or p53R273H) cells or were left untreated and allowed to 
deposit ECM. De-cellularised ECM was analysed using AFM. The left and right panels indicate ECM stiffness 
and stickiness/adhesiveness respectively. Mean ± SEM, n > 6 ECM preparations from two individual 
experiments *** is p < 0.001, Mann–Whitney. (B) MDAMB-231 cells were seeded onto de-cellularised ECM 
deposited by EV-treated TIFs as indicated. Cells were fixed and cell:ECM adhesions visualised by 
immunofluorescence suing an antibody recognising paxillin. Left panel shows representative images (bar, 20 
μm). Average area of paxillin-positive particles is plotted in the right panel left. Mean ± SEM, n > 16, * is p < 
0.05, Mann–Whitney 
4.2.5 Pre-incubation of fibroblasts with mutp53-EVs leads to 
DGKα-dependent deposition of pro-migratory ECM 
Changes in cancer cell-ECM adhesion strength is likely to affect migration of cancer cells 
in 3D microenvironments. To test this hypothesis, we used time-lapse microscopy to 
evaluate the speed in which MDA-MD-231 cells migrate through ECM deposited by EV-
treated TIFs (Figure 4-5). Cell tracking analysis revealed that cancer cells migrated 
significantly more quickly through ECM from TIFs that had previously been incubated with 
p53R273H-EVs than they did through ECM from untreated TIFs or those treated with p53-/--
EVs (Figure 4-5). Furthermore, the ability of TIFs that had been pre-incubated with 
p53R273H-EVs to deposit ECM which supported enhanced cancer cell migration was 
completely opposed by inhibition of DGKα (Figure 4-5). These data indicate that when 
incubated with mutp53-EVs, fibroblasts deposit an ECM that fosters increased cancer cell 
migration. 
Chapter 4 107 
 
 
Figure 4-5- mutp53-exosomes educate fibroblasts to generate pro-migratory ECM. 
TIFs were pre-treated with EVs from H1299-p53−/−, H1299-p53R273H or H1299-p53R175H cells and allowed to 
generate ECM in the presence and absence of R59022 as for Fig. 5C. ECM was then decellularized and MDA-
MB-231 breast cancer cells plated onto these. The migration of MDA-MB-231 cells through the de-cellularised 
ECM was recorded over a 16-hour period using time-lapse microscopy and cell tracking software. 
Representative tracks are indicated by the coloured lines in the top panels. Bar, 100 μm. The migration speed 
of the MDA-MB-231 cells was calculated and is presented in the plot. Values are mean ± SEM, n > 79 cells; 
**p <0.01, ***p < 0.001, Mann–Whitney.  
4.2.6 Pre-incubation of fibroblasts with mutp53-EVs modulate 
ECM organisation in organotypic plugs 
Through possessing multiple domains for interaction with other ECM components, 
fibronectin is known to modulates the deposition of other fibrillar proteins, such as collagen 
type I (Schwarzbauer and DeSimone, 2011; Sottile and Hocking, 2002). Given that the pre-
incubation of fibroblasts with mutp53-EVs led to altered organisation of fibronectin fibres 
in decellularized ECMs, we hypothesised that mutp53-EVs may affect deposition and/or 
remodelling of fibrillar collagens.  
To test this, we conditioned organotypic plugs with EV-treated fibroblasts and imaged 
fibrillar collagen in these matrices by SHG microscopy (Figure 4-6A). Pre-incubation of 
recipient TIFs with cancer cell-derived EVs led to an increased SHG signal in organotypic 
plugs (Figure 4-6C, D).  However, this increase was similar whether the EVs were generated 
by p53-/- or p53R273H-expressing cancer cells indicating that mutp53-expressing tumour cells 
do not specifically modulate the level of fibrillar collagen deposited by TIFs.  Instead, 
GLCM analysis showed that pre-incubation of TIFs with p53R273H-EV prior to seeding them 
into collagen plugs significantly reduced mean decay distance of fibrillar collagen within 
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these plugs, while p53-/--EVs did not alter this index of ECM organisation (Figure 4-6E). 
Thus, these data suggest that EVs released by mutp53-expressing cancer cells can induce 
fibroblasts to deposit fibrillar collagen with altered organisation.  
 
Figure 4-6- mutp53-exosomes encourage fibroblasts to produce altered ECM in “organotypic” plugs. 
(A) Schematic with protocol for assessing the effect of EVs in fibroblast conditioning of organotypic plugs. 
TIFs were incubated with EVs from H1299-p53−/− (p53−/−) or H1299-p53R273H (p53R273) cells for 72 hrs. EV-
treated TIFs were trypsinised, mixed with acid-extracted collagen and the resulting organotypic plugs allowed 
to polymerise and contract for 3 days. (B) Representative picture of contracted “organotypic” plugs according 
to the referred condition. (C) Second harmonic generation (SHG) microscopy was used to image fibrillar 
collagen in these matrices. Representative optical slices from these are displayed, bar, 4 μm. The coverage of 
the SHG signal (D) and organisation of the fibrillar collagen (E) were determined using GLCM as for Figure 
4-3. The decay curves from these are presented in the left panels of (E) and the weighted means of the decay 
distances derived from these curves are displayed in the graph on the right. Values in (D) are mean ± SEM, n 
= 22 fields of view across three separate experiments. Values in (E) are weighted mean ± SEM, n = 46 fields 
of view across three separate experiments; * is p < 0.05, Mann–Whitney 
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4.2.7 Pre-incubation of fibroblasts with mutp53-EVs promote 
deposition/remodelling of pro-invasive ECM 
ECM organisation is likely to affect their ability to support cancer cell invasion. To 
determine whether mutp53-EVs influence ECM deposition to modulate cancer cell 
migration in a 3D microenvironment, we pre-incubated TIFs with EVs and allowed them to 
pre-condition organotypic plugs, which were subsequently overlaid with H1299 cancer cells 
(Figure 4-7). This indicated that H1299 cells, irrespective of their p53 status, invaded 
efficiently into collagen plugs that had been conditioned by TIFs which were pre-incubated 
with p53R273H-EV. By contrast, pre-incubation of TIFs with p53-/--EVs did not confer 
increased invasion in organotypic collagen plugs. Thus, these data emphasise that mutp53-
EVs educate fibroblasts to deposit/remodel the ECM in a way which is highly supportive of 
cancer cell invasion.   
 
 
Figure 4-7- mutp53-EVs encourage fibroblasts to remodel pro-invasive ECM. 
Collagen plugs were conditioned for 48 hours with untreated TIFs or with TIFs that had been pre-treated for 
72 hours with EVs from H1299-p53−/− or H1299-p53R273H cells. Conditioned plugs were overlaid with H1299-
p53−/− (p53−/−) or H1299-p53R273H (p53R273H) cells and these were allowed to invade for 10 days. Plugs were 
then fixed, and tumour cells visualised using H&E. The distance between each tumour cell and the top of the 
plug was determined using ImageJ. Bars are mean ± SEM, n > 233 cells; *** p < 0.001 Mann–Whitney test. 
4.2.8 EVs from mutp53-expressing human PDAC promote 
deposition of pro-invasive ECM. 
We determined whether the p53 status of human PDAC dictates the capacity of EVs from 
these cells to influence ECM deposition. Human PDAC may be categorised into four main 
subtypes, and these are termed, progenitor, immunogenic, ADEX and squamous. As the 
squamous subtype has the worst prognosis, is enriched for mutp53 and is thought to be 
driven by interference of p63 function (Bailey et al., 2016), we focussed on three patient-
Chapter 4 110 
derived cell lines (PDCLs) from this category. Of these, two (SQ2 and SQ3) expressed 
mutations that led to ablation of p53 protein expression and were considered, therefore, to 
be p53 null, while another (SQ1) expressed mutp53 (p53M237I) with described GOF 
properties (Kang et al., 2013) (Figure 4-8A). 
 
Figure 4-8- EVs released by mutp53-expressing PDCL influence ECM architecture. 
(A) p53 expression in lysates from PDCLs expressing mutp53- SQ1- or null for p53 (SQ2 and SQ3) was 
assessed by western blot. (B) TIFs were left untreated or incubated with EVs collected from SQ1, SQ2, or SQ3 
cells. TIFs were re-plated for a further 48 hrs and migratory characteristics of these cells into scratch-wounds 
were determined as for Figure 3-2. Values are mean ± SEM. n > 60 cells, *** is p < 0.001, Mann–Whitney. 
(C) TIFs were left untreated or incubated with EVs for 72 hours as indicated. TIFs were then re-plated and 
cultured for 8 days to allow deposition of ECM. ECM was de-cellularised, stained with antibodies recognising 
fibronectin and images collected using confocal microscopy. Extended focus projections of these stacks are 
displayed in the left, Bar, 50 μm. ECM organisation was determined using GLCM as for Figure 4-3. Decay 
curves from this are presented in the top left panel of and the weighted means of the decay distances are 
displayed in the bar chart. Values are weighted mean ± SEM, n > 8, *** is p < 0.001, Mann–Whitney. 
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We then isolated EVs from medium conditioned by these PDCLs (termed SQ1-, SQ2- or 
SQ3-EV) and incubated them with TIFs. We assessed the migration of these EV-incubated 
TIFs into scratch-wounds and found that only SQ1-EVs was able to increase speed and 
supress persistence and FMI (Figure 4-8B), as we had previously found for H1299 cells 
expressing mutant p53s. Furthermore, ECM deposited by fibroblasts pre-incubated with 
SQ1-EVs had reduced mean decay distance (Figure 4-8C) and supported invasive migration 
of cancer cells (Figure 4-10), while SQ2- and SQ3-EVs were inefficient in this regard.  
Importantly, we found that knockdown of mutp53 in SQ1 cells, which did not significantly 
affect EV quantity or size (Figure 4-9B), led to increased podocalyxin levels (Figure 4-9A) 
and opposed the ability of EVs released by these cells to alter fibroblast migration (Figure 
4-9 C) and deposition of pro-invasive ECM (Figure 4-9D, Figure 4-10). Together, these data 
indicate that squamous PDCL expressing mutp53 release EVs that promote deposition of 
misaligned, pro-invasive ECM, likely through controlling podocalyxin expression, as for 
H1299 cells. 
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Figure 4-9- Loss of p53 in mutp53-expressing PDCL impairs their ability to produce EVs that effect 
fibroblast behaviour.   
(A) SQ1 were transfected with siRNAs targeting p53 (si-p53), or a nontargeting control (siNT) and levels of 
Podocalyxin and p53 in cell lysates were assessed by western blotting, with actin as a sample control. (B) EVs 
were collected from the above transfected cells by differential centrifugation. Nanoparticle tracking was used 
to determine EV number and size distribution). Values are mean ± SEM. n = 3. (C) TIFs were incubated for 
73 hrs with EVs collected from SQ1 transfected with a non-targeting siRNA (siNT) or a siRNA targeting p53 
(si-p53). Recipient TIFs were re-plated for a further 48 hours and migratory characteristics of these cells into 
scratch-wounds were determined as for Figure 3-2. Values are mean ± SEM. n > 60 cells and *** is p < 0.001, 
Mann–Whitney. (D) TIFs were left untreated or incubated with EVs for 72 hrs as indicated. TIFs were then 
trypsinised, re-plated, and cultured for 8 days to allow deposition and remodelling of ECM. ECM was then de-
cellularised, stained with antibodies recognising fibronectin and image stacks were collected using confocal 
microscopy. Extended focus projections of these stacks are displayed in the left, Bar, 50 μm. The ECM 
organisation was determined by GLCM as for Figure 4-3. Decay curves from this are presented in the plot on 
the left and the weighted means of the decay distances are displayed in the graph on the right. Values are 
weighted mean ± SEM, n > 8, *** is p < 0.001, Mann–Whitney. 
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Figure 4-10- mutp53-expressing PDCLs release EVs that encourage fibroblasts to produce pro-
migratory ECM. 
TIFs were left untreated or incubated with EVs collected from SQ1, SQ2, or SQ3 cells or SQ1 cells transfected 
with a non-targeting siRNA (siNT) or a siRNA targeting p53 (sip53) for 73 hrs. After replating, TIFs were 
allowed to deposit ECM for 7 days. De-cellularised ECMs were prepared and MDAMB-231 breast cancer cells 
were plated onto these. The migration of MDA-MB-231 cells through the de-cellularised ECMs was recorded 
over a 16-hour period using time-lapse video microscopy and cell tracking software. The migration speed of 
the MDA-MB-231 cells was calculated. Values are mean ± SEM, n > 53 cells; ***p < 0.001, Mann–Whitney 
4.2.9 mutp53-expressing pancreatic tumours affect ECM 
organisation in target organs 
Following our observation that mutp53-expressing human squamous PDAC release EVs to 
influence fibroblastic ECM deposition/remodelling, we used mouse models of PDAC to 
investigate whether the p53 status of mouse primary pancreatic tumours dictates their ability 
to influence ECM deposition in vivo. To this end, we took advantage of the KP172C and 
KPflC autochthonous mouse models of PDAC. In these, tumour initiation and growth is 
driven by expression of constitutively-active KRas (LSL-KRasG12D) in combination with 
either deletion of an allele of p53 (p53fl/+ generating KPflC mice) or expression of mutp53s 
(LSL-p53R172H generating the KP172C mouse) under control of pancreatic-specific Cre 
recombinase, Pdx-Cre (Hingorani et al., 2005). Importantly, KPC tumours have previously 
been shown to recapitulate characteristics of the human squamous subtype (Bailey et al., 
2016). We then used SHG/GLCM to visualise fibrillar collagen in primary tumours from 
these mice and found that the mean decay distance of collagen fibres in the stroma from 
KPC mice was significantly increased by comparison with the stromal regions of KPflC 
tumours (Figure 4-11). This indicated that the expression of mutant p53 in PDAC is 
associated with ECM cross-linking and assembly of parallel arrays of collagen fibres in the 
stroma, as it was previously reported (Miller et al., 2015; Vennin et al., 2019). Furthermore, 
it indicates that the influence of mutant p53-expressing tumour cells on the collagen cross-
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linking within the tumour itself differs markedly from the changes in the ECM organisation 
that we have found to be evoked by pre-treatment of fibroblasts with mut53-EVs.   
 
Figure 4-11- ECM of the stroma of mutp53-expressing and p53-/--PDAC. 
(A) KP172C (Pdx1-Cre;KrasG12D/+;p53R172H/+) or KPflC (Pdx1-Cre;KrasG12D/+;p53fl/+) mice were 
sacrificed by IP injection of pentobarbital, and the stromal regions of PDAC imaged by SHG microscopy. 
Representative SHG pictures of the tumour stroma are displayed on the left. Bar, 50 μm. Fibrillar collagen 
organisation was determined using GLCM. The decay curves from these are presented in the centre panel. 
Weighted means of the decay distances derived from decay curves are displayed in the right panel. Values are 
weighted mean ± SEM. N=4 animals per condition. * is p<0.05, Mann-Whitney. 
We, therefore, determined whether mutant p53-expressing tumours had any influence on the 
ECM organisation at sites that are distant from the primary tumour.  In particular, we were 
interested in the collagen structure in organs to which PDAC commonly metastasises, such 
as the lung and liver. Indeed, PDAC driven by mutant KRas in combination with mutp53 
(such as the ones in KP172C and KP270C mice, equivalent to the human R175H and R273H 
respectively) metastasise to the liver and lung. On the other hand, PDAC driven by KRas in 
combination with p53 loss (p53fl/+) appear with similar penetrance, but do not metastasise as 
efficiently (Hingorani et al., 2005; Morton et al., 2010). We thus sought to compare the ECM 
of the lung (parenchyma and perivascular regions) and liver capsule at an age (10-12 weeks) 
in which primary tumour growth was underway, but metastases were not detectable yet 
(Figure 4-12). As controls, we used KC mice, which only express LSL-KRasG12D under 
control of Pdx-Cre, but the resulting tumours do not readily progress past the pre-malignant 
PanIN (pancreatic intraepithelial neoplasm) stage.  
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Figure 4-12- Investigating ECM architecture in the liver and lung of PDAC-bearing mice. 
PDAC driven by mutant KRas in combination with mutp53 metastasise to the liver and lung. In contrast, PDAC 
driven by KRas in combination with p53 loss appear with similar penetrance but are poorly metastatic (Morton 
et al. 2010). Thus, we used SHG microscopy to visualise ECM of the lung and liver capsule at an age (10–12 
weeks) in which primary tumour growth was underway, but metastases were not detectable. As controls, we 
used KC mice, which only express LSL-KRasG12D under control of Pdx-Cre, but the resulting tumours do 
not readily progress past the pre-malignant PanIN (pancreatic intraepithelial neoplasm) stage. 
SHG/GLCM analysis of live precision-cut lung slices (PCLSs) and liver indicated that 
collagen filaments in these organs in KP172C and KP270C animals were shorter and 
misaligned, and the mean decay distance of these fibres, as assessed by GLCM analysis, was 
reduced by comparison with that of KC (Figures 4-13 and 4-14). By contrast, ECM 
organisation in the lung and liver of KPflC mice was indistinguishable from KC animals. 
These data highlight that alterations to ECM organisation, which we have established to be 
driven by the influence of p53R273H- or p53R175H-EVs on integrin trafficking in fibroblasts, 
may also be detected in target organs of animals bearing autochthonous PDAC expressing 
the equivalent p53 mutations, but not of animals with PDAC driven by p53 loss. 
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Figure 4-13- Mutant p53-expressing PDAC influences ECM architecture in the lung. 
(A, B) KP172C (Pdx1-Cre:KrasG12D/+: p53R172H/+) or KP270C (Pdx1 Cre:KrasG12D/+:p53R270H/+), KPflC 
(Pdx1-Cre:KrasG12D/+:p53fl/+) or KC (Pdx1-Cre:KrasG12D/+) mice were sacrificed by IP injection of 
pentobarbital, lungs were inflated with 2% low melting point agarose which was then allowed to solidify. 
Agarose-filled lungs were sliced using a vibratome and the perivascular (A) and parenchymal (B) regions of 
the lungs were imaged by SHG microscopy. Representative SHG pictures of lungs are displayed in the left. 
Bar in A, 25μm; bar in B, 100 μm. Fibrillar collagen organisation was determined using GLCM. The decay 
curves from these are presented in the centre panels. Weighted means of the decay distances derived from 
decay curves are displayed in the right panels. Values are weighted mean ± SEM. In A, n = 3 for KC, n =4 for 
KPflC and n = 5 animals for KPC. * is p < 0.05, Mann–Whitney. In B, n > 7 lung fields from three animals per 
condition (except for KC, where there were 6 animals); * is p < 0.05, Mann–Whitney.  
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Figure 4-14- Mutant p53-expressing PDAC influences ECM architecture in the liver capsule. 
(A) KP172C (Pdx1-Cre:KrasG12D/+: p53R172H/+), KPflC (Pdx1-Cre:KrasG12D/+:p53fl/+) or KC (Pdx1-
Cre:KrasG12D/+) mice were sacrificed by IP injection of pentobarbital, dissected and whole livers were 
collected in culture media and imaged by SHG microscopy. Representative pictures of liver capsule SHG are 
shown. (B) Fibrillar collagen organisation was determined using GLCM. The decay curves from these are 
presented. (C) Weighted means of the decay distances derived from decay curves. (D) Weighted Area-under-
curve calculated for the decay curves. Values are weighted mean ± SEM. N=2 animals for KC, N=3 for KPflC 
and N=4 for KP172C. * is p < 0.05, ANOVA. 
4.2.10  mutp53-driven subcutaneous tumours influence lung ECM 
organisation in a podocalyxin- and Rab35-dependent 
manner 
We used a xenograft approach to determine whether mutp53-expressing H1299 cancer cells 
could influence ECM deposition in vivo (Figure 4-15A). We injected p53-/- or mutp53-
expressing (p53R273H or p53R175H) H1299 cells subcutaneously in nude mice. We then let the 
tumours growth until they reached 8 mm in diameter (Figure 4-15 B) and, at this point, used 
SHG/GLCM to evaluate the organisation of collagen fibres in the lungs of these animals 
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(Figure 4-16). Xenografts of mutp53-expressing H1299 cells resulted in decreased decay 
distance of collagen fibres in the lung in comparison to animals injected with p53-/--H1299 
cells or non-injected animals (Figure 4-16), thus indicating that human cancer cells can be 
used as subcutaneous xenografts to explore the mechanism through which mutp53-
expression in tumours influence ECM deposition in distant organs. 
 
 
Figure 4-15- A xenograft approach for investigating the effect of mutp53 on lung ECM architecture. 
(A) Schematic of the xenograft model used for investigating the effect of mutp53 in lung ECM architecture. 
H1299-p53−/−, H1299-p53R273H or H1299-p53R175H cells were injected subcutaneously into CD1 nude mice. 
Mice were monitored for tumour growth and culled when tumours reached 0.8 cm diameter. At this time, 
fibrillar collagen in the lung was imaged by SHG microscopy. In (B), xenograft tumour growth curves are 
shown on the plot in the left, and tumour gain upon first detection is shown on the right. Values are mean ± 
SEM. 
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Figure 4-16- Tumour xenografts of mutp53-expressing H1299 cells influence lung ECM architecture. 
(A) H1299-p53−/−, H1299-p53R273H or H1299-p53R175H cells were injected subcutaneously into CD1 Nude 
mice. Mice were monitored for tumour growth and culled when tumours reached 0.8 cm diameter. Mice were 
sacrificed by IP injection of pentobarbital, and lungs were inflated with 2% low melting point agarose which 
was then allowed to solidify. Agarose-filled lungs were sliced using a vibratome, and parenchymal regions 
were imaged by SHG microscopy. Representative SHG pictures of lungs from CD1 nude mice transplanted 
with the respective cell line are displayed on the top. Bar, 100 µm. Fibrillar collagen organisation was 
determined using GLCM. The decay curves from these are presented in the bottom-left panel. Weighted means 
of the decay distances derived from decay curves are displayed in the bottom-right panel. Values are weighted 
mean ± SEM; n > 4 animals per condition (except for H1299-p53R175H, where n = 3); * is p < 0.05, *** is p 
< 0.001, Mann–Whitney test. 
We took advantage of this model to test whether regulation of the levels of podocalyxin in 
tumour cell-derived EVs dictate ECM organisation in the lung. We subcutaneously injected 
control H1299-p53R273H or H1299-p53R273H cells in which podocalyxin or Rab35 had 
been deleted by CRISPR into nude mice (Figure 4-17A, B). Loss of podocalyxin or Rab35 
in mutp53-expressing H1299 cells impaired the ability of xenografts to modulate ECM 
deposition in the lung, as determined by GLCM (Figure 4-17C). Thus, these data suggest 
that the ability of mutant p53-expressing tumours to influence ECM deposition in distant 
organs depends on the levels of podocalyxin associated with EVs released by these tumours.  
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Figure 4-17- mutp53-expressing xenografts influence lung ECM architecture in a podocalyxin- and 
Rab35-dependent manner.  
(A) Schematic of the xenograft models used for investigating whether mutp53 affects lung ECM architecture 
via podocalyxin and Rab35-dependent mechanisms. p53R273H-H1299 cells in which Rab35 or podocalyxin had 
been disrupted by CRISPR were injected subcutaneously into CD1 Nude mice. Mice were monitored for 
tumour growth and culled when tumours reached 0.8 cm diameter. Mice were sacrificed by IP injection of 
pentobarbital, and lungs were inflated with 2% low melting point agarose which was then allowed to solidify. 
Agarose-filled lungs were sliced using a vibratome, and parenchymal regions were imaged by SHG 
microscopy. (B) The loss of podocalyxin and Rab35 in H1299-p53R273H cells was confirmed by western 
blotting, using tubulin as a loading control. (C) GLCM was used to analyse SHG organisation in lung. 
Weighted means of the decay distances derived from decay curves are displayed in the right panel. Values are 
weighted mean ± SEM; n > 4 animals per condition; * is p < 0.05, Mann–Whitney. 
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4.3 Discussion 
In the previous chapter, we reported that mutp53-expressing H1299 cells release diffusible 
factors, which we subsequently demonstrated to be EVs with a defined podocalyxin level, 
to promote invasion of p53-/- cancer cells into organotypic plugs. However, fibroblasts were 
present within the plugs, raising the possibility that cancer cell invasion might be indirectly 
mediated by the effect of EVs on cells that are wild-type for p53. Thus, we tested whether 
fibroblasts respond to EVs. Pre-incubation of recipient TIFs with mutp53-EVs (from cancer 
H1299 cells, either p53R273H or p53R175H-EVs) imbues them with increased migratory speed 
and decreased migratory FMI/persistence when they move on 2D substrates, indicating that 
a migratory phenotype resembling mutp53’s pro-invasive gain-of-function can be 
transferred to fibroblasts. Furthermore, knock-down of Rab35 or podocalyxin, or 
overexpression of podocalyxin, in donor mutp53-expressing H1299 cells, impaired their 
ability to release EVs that influence migration of recipient TIFs, indicating that, as was the 
case for recipient cancer cells, transfer of mutp53’s gain-of-function to fibroblasts requires 
tight regulation of EV-associated podocalyxin levels in donor mutp53-expressing cancer 
cells.  
Previous studies have shown that directionally-erratic and rapid migration of fibroblasts on 
2D substrates is associated with rapid  recycling of α5β1 integrin through a pathway which 
depends on the Rab11 effector, RCP  (Caswell et al., 2008; White et al., 2007). Moreover, it 
is now clear that RCP function requires the lipid kinase, DGKα which generates a source of 
phosphatidic acid which is necessary for the tethering and exocytosis of RCP-positive 
recycling vesicles (Rainero et al., 2012).  Thus, the use of inhibitors of DGKα has been 
established as an effective pharmacological approach to opposing RCP-dependent receptor 
recycling. Here we show that pre-incubation of fibroblasts with mutp53-EVs activates 
recycling of α5β1 integrin, and inhibition of DGKα opposed this, indicating that mutp53-
EVs promote recycling through the Rab11/RCP pathway in fibroblasts in much the same 
way as they do in p53-/- cancer cells. α5β1 integrin is the major receptor for fibronectin and 
participates in its fibrillogenesis. With this in mind, we developed quantitative approaches 
(GLCM analysis) to characterise the organisation of ECM deposited by mutp53-EV-treated 
TIFs. Treatment of fibroblasts with mutp53-EVs led to deposition of a more misaligned and 
branched ECM; a phenotype that depended on DGKα activity in the fibroblasts. Thus, our 
data are consistent with a mechanism through which mutp53-EVs modulate ECM deposition 
by increasing RCP- and DGKα-dependent α5β1 recycling in fibroblasts. Previous studies 
have shown that alteration to the trafficking of another fibronectin receptor, αvβ3 integrin in 
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endothelial cells leads to increased fibronectin polymerisation and deposition (Jones et al., 
2009).  Moreover, inhibition of caveolin-dependent α5β1 endocytosis is known to 
compromise fibronectin turnover in the endothelium and lead to accumulation of fibronectin 
(Sottile and Chandler, 2005). However, the EV-driven changes to ECM organisation 
described in the present study are not associated with altered levels of fibronectin.   
It is interesting to consider the possible mechanisms through which increased α5β1 recycling 
may influence ECM organisation.  One possibility is that it is the way in which fibroblasts 
move during the assembly and re-modelling of the ECM that is key to its organisation.  
Indeed, we have characterised how mutp53-EVs, via altered integrin recycling, change 
fibroblast migration speed and persistence. To pursue this, we have conducted some 
preliminary long-term time-lapse experiments to observe fibroblast movement in the 
confluent monolayers that they form whilst depositing ECM.  This indicated that fibroblasts 
in a confluent monolayer normally migrate within a restricted area and this movement is 
directionally constrained – i.e. they tend to move backwards and forwards over an unaltering 
linear course.  By contrast, mp53-exosome-treated fibroblasts under go much longer range 
and directionally adventitious movements (not shown), and this behaviour may be what leads 
to the more branched and disorganised ECM that they deposit.  This hypothesis could be 
further investigated by studying in detail the relationship between ECM assembly (using 
fluorescently-labelled fibronectin and fibronectin-null-fluorescently-labelled TIFs, and 
time-lapse multiphoton microscopy), fibroblast movement and integrin trafficking in 
confluent monolayers and 3D organotypic plugs.   
A recent study reported that fibronectin fibrillogenesis was promoted by activation of TGFβ 
receptor-2 (TGFβRII) and that this was dependent on Rab11 and α5β1 integrin recycling 
(Varadaraj et al., 2017).  This is intriguing, considering first that RCP is an effector of Rab11 
and second that TGFβ signalling was previously shown to potentiate mutp53-gain-of-
functions (Adorno et al., 2009). However, this study relied on the use of dominant negative 
Rab11 (Varadaraj et al., 2017) which has a far more profound and generally disruptive 
influence on endosomal trafficking (and affects other processes, such as cytokinesis (Wilson 
et al., 2005; Yu et al., 2007)).  Because we have found that gross alterations in fibronectin 
fibrillogenesis do not underlie the influence of mutp53-EVs on ECM organisation, we feel 
that it is unlikely that TFGβ receptors signal through RCP-dependent recycling – as opposed 
to another Rab11-regulated pathway, but further work will be needed to establish the 
relationship between TGFβ signalling and the function of mutp53-EVs in pro-invasive niche 
priming.   
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Our studies indicate that mutp53-EVs influence not only the organisation of the ECM, but 
also reduce its stickiness and stiffness, and that this correlates with decreased focal adhesion 
assembly in cells plated into de-cellularised matrices. It is now generally accepted that it is 
increased (not reduced) ECM stiffness that generates a more pro-invasive microenvironment 
for cancer cells. Indeed, cancer cells plated into stiff microenvironments display increased 
focal adhesion assembly and enhanced signalling downstream of integrin – for instance to 
focal adhesion kinase – which drives invasiveness (Jansen et al., 2017; Yeh et al., 2017).  
The level of ECM adhesiveness is also accepted to influence invasion, but the relationship 
between this property and cell migration is more complex that it is with stiffness.  Indeed, 
when substrata are coated with fibronectin at moderate levels, this supports cell migration 
because it allows efficient assembly and disassembly of adhesions.  However, on substrates 
coated with high concentrations of fibronectin, adhesions assembly efficiently, but cannot 
disassemble, and this inhibits cell migration. It is probably, therefore, that the reduced 
stickiness of mutp53-EV-fostered ECM allows efficient adhesion and disassembly, thus 
favouring invasiveness. It is also possible that alterations to ECM organisation influence the 
spacing and orientation of integrin-binding sites in a way that affects its adhesive properties. 
Indeed, a previous study reported that the strength of cell-ECM adhesions in human breast 
myoepithelial cells embedded in soft polyacrylamide gels functionalised with RGD peptides 
(a canonical ECM ligand for α5β1 and αvβ3 integrins) depends on the spacing of the RGD 
ligands within the gel (Oria et al., 2017).  It is currently unclear why the adhesiveness of 
ECM is influenced by DGKα-dependent integrin trafficking in the fibroblasts that deposit it, 
and how this relates to its organisation.  Further investigation will be aimed at addressing 
the mechanistic connections between these properties.   
Here we show that in PDCLs derived from tumours corresponding to the squamous subtype 
of PDAC (Bailey et al., 2016), mutp53 influences the production of EVs capable of altering 
ECM deposition. We show that this is likely owing to the ability of mutp53 to suppress 
podocalyxin expression in these cells, in much the same way as we reported for H1299 cells 
in chapter 3. Moreover, the KPC mouse model used in the present study corresponds 
histologically to the squamous subtype of PDAC (Bailey et al., 2016).  However, we have 
collected EVs from PDCLs corresponding to other subtypes of PDAC and found that this 
mechanism may not be generally applicable.  Indeed, we found that EVs from the pancreatic 
progenitor subtype of PDAC produce EVs that profoundly influence ECM organisation 
irrespective of their p53 status (not shown).  Mutations in TP53 are prevalent in PDAC and 
they are thought to be key drivers of their progression. Of the molecular subtypes of PDAC 
recently identified, squamous PDAC express high levels of DNp63, a p63 isoform that is 
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characteristic of squamous epithelia (Lin et al., 2014), and it is likely that DNp63’s ability to 
interfere with TAp63 function accounts for the particularly poor prognosis of this category 
of PDAC (Bailey et al., 2016; Collisson et al., 2019). Another way in which TAp63 function 
may be compromised is via expression of mutp53s, which are also enriched for in squamous 
PDAC (Bailey et al., 2016; Collisson et al., 2019). However, in PDAC subtypes which do 
not express TA-p63 it is likely that mutp53 may not be able to influence podocalyxin 
expression. Thus, it is likely that oncogenes other than mutp53 have the potential to alter EV 
composition and the sorting of sialomucins into EVs so as to influence their ability to change 
endosomal trafficking and ECM deposition. Further work will be necessary to elucidate how 
the composition of EVs from PDAC subtypes other than squamous may drive the generation 
of pro-invasive microenvironments.   
The combined expression of mutant KRas and mutp53 in the pancreatic epithelium of KPC 
mice drives the formation of highly invasive metastatic tumours. The ECM in the stroma of 
PDAC is likely to contribute to metastasis as this will define the invasiveness of the primary 
tumour and thus the ability of cells to reach the circulation. Previous work showed that 
fibrillar collagen is more aligned in the stroma of KPC tumours by comparison with those 
from KPflC (p53 loss) mice, and we have confirmed this observation.  Miller et al., showed 
that the increased stiffness and collagen alignment in the PDAC stroma is owing to mutp53’s 
ability to drive increased expression of the collagen cross-linking enzyme lysyl oxidase 
(LOX) (Miller et al., 2015).  Broadly consistent with this, a recent study characterised the 
effect of mutp53 on the tumour stroma, by evaluating the behaviour of CAFs isolated from 
KPC or KPflC tumours in organotypic plugs. The authors reported that KPC-CAFs 
contracted the plugs more efficiently than did KPflC-CAFs, leading to higher levels of 
aligned fibrillar collagen and increased ECM stiffness which fostered cancer cell invasion 
and chemoresistance.  Moreover, these workers showed that this was driven by the local 
release of factors from mutp53-expressing tumour cells, which activated NFκB signalling in 
the fibroblasts (Vennin et al., 2019). Clearly, the mutp53-EV-mediated influence on ECM 
deposition in distant organs differs from that which occurs in the stroma of the primary 
tumour.  This is likely to be owing to the differences in the short range and long-range signals 
evoked by mutp53s.  Thus, signals which mediate mutp53s desmoplastic phenotype in the 
stroma are likely to be mediated by locally-acting fibroblast-activating growth factors which 
dominate over any influence that EVs may have on stromal fibroblasts.  By contrast, we 
propose that EVs can carry signals over longer distances through the circulation to foster 
deposition of less well-aligned tangled/orthogonal ECM that we observe to occur in the liver 
and lungs of animals bearing mutp53-expressing tumours. 
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 Final Discussion 
Mutp53 drives metastasis in humans and mice. Here, we show that expression of mutp53 in 
tumour cells drives release of EVs that influence migration and membrane trafficking in 
other tumour cells and in fibroblasts, inducing the latter to deposit and/or 
remodel the ECM, in a way that did not alter its stiffness but altered its orthogonality 
and stickiness and ability to support tumour cell invasiveness. We also identified 
key players in this novel GOF of mutp53, such as suppression of podocalyxin levels in EVs 
that results from the combined action of the mutp53-p63 axis and Rab35. Finally, we report 
that ECM orthogonality can be induced by EV produced by PDCLs of mutp53-expressing 
PDAC, and that increased ECM orthogonality may be observed in target organs of mice 
bearing mutp53-expressing subcutaneous tumours and PDAC.   
 
 
Figure 5-1- Proposed model for mutp53’s gain-of-function via EVs. 
mutp53-expressing cancer cells produce EVs that mediate intercellular transfer of mutp53’s invasive/migratory 
gain-of-function by increasing RCP/DGKα-dependent receptor recycling in other cancer cells. This process 
depends on mutp53’s ability to control expression of the sialomucin podocalyxin, and on the activity of the 
GTPase Rab35, a podocalyxin interactor that influences its sorting to EVs. mutp53-EVs also stimulate receptor 
recycling in normal fibroblasts, in turn promoting deposition of a pro-invasive ECM with characteristic 
orthogonal architecture. The ECM in the target organs (lung and liver) of mice possessing mutp53-expressing 
pancreatic tumours also displays increased orthogonal architecture which precedes metastasis, indicating that 
mutp53 can influence the microenvironment in distant organs in a way that may support metastatic outgrowth.  
Further work will be required to explore whether the “tangled” ECM in the liver and lungs 
of mice bearing mutp53-expressing PDAC contributes to metastasis formation. Despite 
multiple lines of pre-clinical and clinical evidence indicating that invasion in the TME 
mostly occurs through collective cell migration in the direction of ECM fibres (reviewed in 
(Clark and Vignjevic, 2015), the mechanism through which tumour cells colonise distant 
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organs remain unclear. Thus, our observation that mutp53-EV-mediated ECM is highly 
permissive for tumour cell invasion may suggest a role for this ECM in promoting 
colonisation of disseminated tumour cells in target sites, a process that is likely to affect 
metastatic outgrowth. Furthermore, as we have demonstrated that the ECM fostered 
by mutp53-EVs affects cell-ECM adhesions, processes other than cell migration which 
are regulated by adhesion signalling – such as cell growth and survival - might be influenced 
by this type of ECM. Indeed, although the ECM fostered by mutp53-EVs did not affect 
tumour cell proliferation in our culture conditions, ECM remodelling in microenvironments 
such as the perivascular space - where tumour cells reside following extravasation - have 
previously been found to contribute to integrin-dependent metastatic out-growth 
(Albrengues et al., 2018). Because we have detected more orthogonal/tangled ECM in the 
perivascular space of the lung PMN, there is a possibility that, by modulating cell-ECM 
adhesions in vivo, mutp53-EVs might influence this or other integrin-mediated processes, 
thereby affecting metastasis formation. Though, this remains to be further investigated.  
Another possible mechanism through which “tangled” ECM in the metastatic target 
organs might contribute to metastasis is through influencing recruitment of immune cell 
types (Amanda McFarlane, unpublished, personal communication). Notably, extensive 
immuno-phenotyping and time-lapse microscopy revealed that neutrophils accumulate in 
higher numbers and are more migratory in the lungs of KPC mice than observed in their 
counterparts bearing p53 null PDAC. Neutrophils in target organs are thought to promote 
metastasis formation by stimulating suppression of tumour-reactive lymphocytes (Leach et 
al., 2019). Additionally, the release of neutrophil-extracellular traps (NETs) from 
neutrophils has been shown to influence different aspects of metastatic outgrowth and to 
awaken dormant disseminated tumour cells residing in the lung. It is thought that stickiness 
of DNA in NETs may allow capture of tumour cells along the endothelium, promoting 
tumour cell extravasation (Chen, 2016) . Moreover, the proteolytic capacity of NETs may 
contribute to remodelling of the ECM, stimulating tumour cell invasion and growth (Park et 
al., 2016). Finally, a recent study has demonstrated that, during chronic 
inflammation, the NET components elastase and MMP9 led to remodelling of the 
BM, thus stimulating integrin-dependent outgrowth of dormant disseminated tumour cells 
(Albrengues et al., 2018). Therefore, accumulation of neutrophils in the lung is likely to 
contribute to the metastatic nature of the KPC model of PDAC.   
Although a causal relationship between “tangled” ECM and neutrophil recruitment/function 
in mutp53-tumour-bearing mice remains to be demonstrated, the 
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ECM has previously been shown to modulate neutrophil recruitment, transmigration 
through the endothelium and activation. In particular, neutrophils are potently chemotactic 
toward the tripeptide PGP, a collagen-derived matrikine with a key role in inflammation 
(Akthar et al., 2015) and which is deregulated in processes such as chronic inflammation 
and fibrosis (O’Reilly et al., 2017). Thus, an attractive hypothesis is that the ECM fostered 
by mutant p53-extracellular vesicles may be more amenable 
to liberating chemotactic matrikines which promote neutrophil recruitment and migration. 
The ECM composition has also previously been shown to affect neutrophil behaviour (such 
as chemotaxis) and the formation of TEMs, and so there is a possibility that 
mutp53 expressing primary tumours might influence these processes by modulating ECM 
composition in metastatic target organs to prime PMNs. Some recent evidence suggests that 
the ECM components of the metastatic site undergo dramatical changes during metastatic 
outgrowth (Pearce et al., 2018). Nonetheless, the characteristics of the ECM in the PMN (i.e. 
prior to colonisation) are still largely unexplored. We plan to employ approaches 
for enrichment of ECM components from tissues, coupled with LCMS, to investigate the 
composition of the matrisome in PDAC-bearing mice, and to test whether expression 
of mutp53 in the primary tumour is able to influence this.   
We have demonstrated that mutp53-EVs promote receptor recycling and migration of p53-
/- cells. PDAC are highly heterogenous and in some cases, within the same tumour, 
polyclonal populations with different p53 status may co-exist (Grant et al., 2016). 
Furthermore, the inherent instability of mutp53 may result in heterogenous levels of mutp53 
expression, a phenomenon that is described in both human and mouse tumours (Koga et al., 
2001; Olive et al., 2004) Thus, our data suggest that in a tumour context, indolent tumour 
cells lacking mutp53 expression might acquire migratory characteristics by being ‘educated’ 
with mutp53-EVs. Speculatively, it would imply that cells lacking mutp53 might be able to 
invade and escape the primary tumour, and eventually reach metastatic target organs. 
Although it is known that metastases from mutp53-expressing tumours often display high 
levels of mutp53 expression, a recent study suggested that environmental cues, such as 
stiffness, interfere with mutp53 levels, by activating RhoA- and HSP90-mediated mutp53 
stabilisation (Ingallina et al., 2018). Therefore, the expression of mutp53 is likely dynamic 
throughout tumour progression, rendering this hypothesis difficult to address in vivo.   
PDAC is often characterised by acquisition of both mutant KRas and mutp53, and mouse 
models have demonstrated that these events drive PDAC initiation and invasion respectively 
(Morton et al., 2010). A recent study suggested that the combinatory expression of 
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mutant KRas and mutp53 stimulates Arf6-dependent receptor recycling in KPC cells. These 
workers showed that while KRas functioned in mediating translation of transcripts encoding 
for Arf6 and AMAP1, mutp53 activated Arf6 by upregulation PDGFR and the MVP, 
consequently leading to Arf6-dependent invasion and immune evasion (Hashimoto et al., 
2019). Our observations that inhibition of RCP or DGKα in recipient cells completely 
abolished their response to mutp53-EVs is strong indication for the recycling events that 
drive migration and ECM remodelling occurring through Rab11, but not Arf6. Nonetheless, 
the interaction of mutp53 with its myriad partners, in particular those that influence mutp53-
p63 inhibition, might influence the non-cell autonomous GOF for mutp53 that we have 
described here. Importantly, TGFβ is often present within the PDAC TME (Principe et al., 
2016), and has previously been reported to drive metastasis in the KPC model(Zhong et al., 
2017), which is reason for future investigation of the role of mutp53-p63-SMAD axis in the 
production of phenotype-altering EVs.   
The deletion of podocalyxin or Rab35 in mutp53-expressing tumours impaired their ability 
to influence ECM deposition in distant organs. This indicates that regulation of EV-
associated podocalyxin is the mechanism by which mutp53-expressing tumours mediate 
ECM deposition and/or remodelling in the PMN. Consistent with the fact that a large 
fraction of the negative charge of podocalyxin results from sialic acid residues, a recent study 
suggested that the amount of this sugar on EVs dictates their ability to accumulate in organs 
and travel through the lymphatics. These researchers injected radiolabelled EVs into mice 
and used PET scanning to find that at 5 minutes following injection, EVs accumulated in the 
liver and lung. At 72 hours, they still found EVs present in both the liver and the lung, though 
neuraminidase incubation (i.e. sialic acid removal) of EVs increased their accumulation in 
the lung and led them to travel through the lymphatics more efficiently (Royo et al., 2019). 
This indicates that EV charge, in particular negative charge, dictates biological function, 
and we believe that modulation of EV charge by podocalyxin may be important because it 
might act within the endosomal system of recipient cells, thereby allowing mutp53 to 
influence receptor recycling in a paracrine fashion and induce ECM remodelling in the 
PMN.   
Together, the data discussed throughout this thesis highlights a non-cell autonomous 
mechanism that might contribute to the metastatic phenotype characteristic of many mutp53-
expressing cancers. There is, indeed, a pressing need to identify mechanisms and 
biomarkers for metastatic disease, and our data highlights an intercellular communication 
pathway comprising a number of well-characterised components (including Rab35, 
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Podocalyxin, RCP, DGKα, collagen organisation), which may represent a panel of 
druggable targets and may also act as novel biomarkers to indicate the presence of metastatic 
tumours.   
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Appendices 
Appendix I - EV-associated proteome Dataset 
Protein name Gene symbol 
Mol. 
weight 
[kDa] 
SILAC 
ratio3-/-) 
(log2) 
Sig. Unique peptides 
Podocalyxin PODXL 58.64 -0.70 + 4 
Ras GTPase-activating-like protein 
IQGAP3 IQGAP3 184.70 -0.60   2 
Charged multivesicular body protein 5 CHMP5 24.57 -0.59   2 
Cofilin-2 CFL2 18.74 -0.58   4 
26S proteasome non-ATPase regulatory 
subunit 2 PSMD2 100.20 -0.56   2 
Twinfilin-1 TWF1 40.28 -0.49   2 
Frizzled-2;Frizzled-7 FZD2;FZD7 63.55 -0.45   2 
DnaJ homolog subfamily A member 4 DNAJA4 44.80 -0.44   1 
Matrilin-2 MATN2 106.84 -0.43   10 
Integrin-linked protein kinase ILK 51.42 -0.41   3 
EH domain-containing protein 4 EHD4 61.17 -0.40   11 
Matrix metalloproteinase-14 MMP14 65.89 -0.38   2 
Charged multivesicular body protein 1b CHMP1B 22.11 -0.37   4 
Tight junction protein ZO-1 TJP1 195.46 -0.36   3 
MIT domain-containing protein 1 MITD1 23.03 -0.36   2 
Coronin-1C;Coronin CORO1C 53.25 -0.36   5 
Charged multivesicular body protein 1a CHMP1A 21.70 -0.33   2 
Lethal(2) giant larvae protein homolog 1 LLGL1 115.42 -0.32   2 
Pituitary tumor-transforming gene 1 
protein-interacting protein PTTG1IP 20.32 -0.31   3 
Connective tissue growth factor CTGF 38.09 -0.31   4 
Talin-1 TLN1 269.76 -0.31   11 
BRO1 domain-containing protein 
BROX 
BROX;C1orf
58 46.48 -0.31   4 
Flotillin-1 FLOT1 47.36 -0.30   4 
Cofilin-1 CFL1 18.50 -0.30   8 
Heat shock protein beta-1 HSPB1 22.78 -0.30   4 
Centrosomal protein of 55 kDa CEP55 54.18 -0.30   8 
Elongation factor 1-beta EEF1B2 24.76 -0.29   2 
IST1 homolog IST1 39.75 -0.28   6 
Tetraspanin-4 TSPAN4 15.20 -0.28   4 
Sodium-coupled neutral amino acid 
transporter 2 SLC38A2 56.03 -0.27   4 
Neuroblast differentiation-associated 
protein AHNAK AHNAK 629.09 -0.27   13 
Septin-2 Sep-02 41.49 -0.27   3 
40S ribosomal protein S11 RPS11 18.43 -0.27   2 
Protein S100-A13 S100A13 11.47 -0.27   3 
Septin-11 Sep-11 49.40 -0.26   3 
Charged multivesicular body protein 4b CHMP4B 24.95 -0.26   7 
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Neutral amino acid transporter A SLC1A4 55.72 -0.25   3 
Nuclear migration protein nudC NUDC 38.24 -0.25   2 
Tumor susceptibility gene 101 protein TSG101 43.94 -0.24   6 
CD63 antigen CD63 25.64 -0.24   2 
Phosphatidylinositol 4-phosphate 5-
kinase type-1 alpha PIP5K1A 62.63 -0.23   3 
Tropomyosin alpha-4 chain TPM4 28.52 -0.22   4 
Platelet-activating factor acetylhydrolase 
IB subunit alpha PAFAH1B1 46.64 -0.22   2 
Fascin FSCN1 54.53 -0.22   5 
Ubiquitin carboxyl-terminal hydrolase 
14; Ubiquitin carboxyl-terminal 
hydrolase 
USP14 56.07 -0.21   2 
Serine incorporator 1 SERINC1 50.49 -0.21   2 
DnaJ homolog subfamily A member 1 DNAJA1 44.87 -0.20   7 
Ras-related protein Rab-1A RAB1A 22.68 -0.20   2 
Transgelin-2 TAGLN2 22.39 -0.20   10 
A-kinase anchor protein 12 AKAP12 191.48 -0.20   7 
Programmed cell death protein 6 PDCD6 21.87 -0.19   4 
Vimentin VIM 53.65 -0.19   13 
Vacuolar protein sorting-associated 
protein VTA1 homolog VTA1 33.88 -0.19   3 
Protein kinase C and casein kinase 
substrate in neurons protein 3 PACSIN3 48.49 -0.18   4 
Adenylyl cyclase-associated protein 1 CAP1 51.90 -0.18   8 
Proliferating cell nuclear antigen PCNA 28.77 -0.18   3 
EH domain-containing protein 1 EHD1 60.63 -0.18   8 
DnaJ homolog subfamily A member 2 DNAJA2 45.75 -0.17   8 
Peptidyl-prolyl cis-trans isomerase 
FKBP4 FKBP4 51.80 -0.17   6 
Ras-related protein Rab-6A RAB6A 23.59 -0.17   2 
Serine incorporator 3 SERINC3 52.58 -0.17   3 
ADP-ribosylation factor 6 ARF6 20.08 -0.16   4 
Vacuolar protein sorting-associated 
protein 4B VPS4B 49.30 -0.16   4 
Destrin DSTN 18.51 -0.16   4 
40S ribosomal protein S4, X isoform RPS4X 29.60 -0.15   3 
Microtubule-associated protein RP/EB 
family member 1 MAPRE1 30.00 -0.15   2 
Syntenin-1 SDCBP 32.44 -0.15   2 
Protein HEG homolog 1 HEG1 147.46 -0.15   2 
LIM and SH3 domain protein 1 LASP1 29.72 -0.15   4 
Cyclin-dependent kinase 1 CDK1 34.10 -0.15   2 
Methylenetetrahydrofolate 
dehydrogenase MTHFD1 101.56 -0.15   6 
Reticulon-4 RTN4 129.93 -0.14   2 
Eukaryotic initiation factor 4A-
I;Eukaryotic initiation factor 4A-II 
EIF4A1;EIF
4A2 46.15 -0.14   7 
Heat shock 70 kDa protein 1A/1B HSPA1A 70.05 -0.13   6 
T-complex protein 1 subunit zeta CCT6A 58.02 -0.13   5 
CD151 antigen CD151 28.30 -0.13   4 
 132 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 GNB2L1 35.08 -0.13   3 
Transaldolase TALDO1 37.54 -0.13   2 
Programmed cell death 6-interacting 
protein PDCD6IP 96.02 -0.12   34 
40S ribosomal protein S23 RPS23 15.81 -0.12   2 
CD44 antigen CD44 81.54 -0.12   8 
Elongation factor 1-gamma EEF1G 50.12 -0.12   3 
Retinoic acid-induced protein 3 GPRC5A 40.25 -0.12   2 
Protein S100-A11 S100A11 11.74 -0.12   2 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 GNB2 37.33 -0.12   3 
Endophilin-A2 SH3GL1 41.49 -0.12   4 
Vinculin VCL 123.80 -0.12   16 
Vacuolar protein sorting-associated 
protein 35 VPS35 91.71 -0.12   4 
Complement decay-accelerating factor CD55 41.40 -0.12   3 
60S acidic ribosomal protein P2 RPLP2 11.67 -0.12   2 
Synaptosomal-associated protein 23; 
Synaptosomal-associated protein SNAP23 23.35 -0.11   8 
Sodium-dependent multivitamin 
transporter SLC5A6 68.64 -0.11   5 
Sulfate transporter SLC26A2 81.66 -0.11   2 
Tyrosine-protein kinase Yes YES1 60.80 -0.11   5 
E3 ubiquitin-protein ligase NEDD4-like; 
E3 ubiquitin-protein ligase NEDD4L 111.93 -0.11   8 
Integrin alpha-3;Integrin alpha-3 heavy 
chain; Integrin alpha-3 light chain ITGA3 116.61 -0.10   20 
Myelin protein zero-like protein 1 MPZL1 29.08 -0.10   6 
Syntaxin-binding protein 1 STXBP1 67.57 -0.10   2 
Ras-related protein Rab-8A RAB8A 23.67 -0.10   5 
5-nucleotidase NT5E 63.37 -0.10   15 
Ras-related protein Ral-A RALA 23.57 -0.10   2 
MAGUK p55 subfamily member 6 MPP6 61.12 -0.10   10 
Sodium-coupled neutral amino acid 
transporter 1 SLC38A1 54.05 -0.09   4 
Phosphatidylethanolamine-binding 
protein 1; Hippocampal cholinergic 
neurostimulating peptide 
PEBP1 21.06 -0.09   4 
Fermitin family homolog 2 FERMT2 77.86 -0.09   11 
WD repeat-containing protein 1 WDR1 66.19 -0.09   10 
Disintegrin and metalloproteinase 
domain-containing protein 9 ADAM9 90.56 -0.09   3 
Nuclease-sensitive element-binding 
protein 1 YBX1 35.92 -0.09   2 
Translationally-controlled tumor protein TPT1 19.60 -0.09   4 
L-lactate dehydrogenase B chain;L-
lactate dehydrogenase LDHB 36.64 -0.09   11 
SLIT-ROBO Rho GTPase-activating 
protein 2 SRGAP2 120.88 -0.08   2 
Programmed cell death protein 10 PDCD10 24.70 -0.08   4 
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Thioredoxin domain-containing protein 
17 TXNDC17 13.94 -0.08   2 
CD59 glycoprotein CD59 14.18 -0.08   4 
Alpha-soluble NSF attachment protein NAPA 33.23 -0.08   2 
Beta-2-microglobulin;Beta-2-
microglobulin form pI 5.3 B2M 13.71 -0.08   3 
Programmed cell death protein 5 PDCD5 14.29 -0.08   4 
Ras-related protein Rab-13 RAB13 22.77 -0.08   4 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-5 GNG5 7.32 -0.07   3 
CD9 antigen CD9 25.42 -0.07   5 
Ras-related protein Rap-1b;Ras-related 
protein Rap-1b-like protein RAP1B 20.83 -0.07   2 
40S ribosomal protein S28 RPS28 7.84 -0.07   2 
Endothelin-converting enzyme 1 ECE1 87.16 -0.06   4 
Heat shock cognate 71 kDa protein HSPA8 70.90 -0.06   19 
Ras-related protein Rab-10 RAB10 22.54 -0.06   5 
Phosphoglycerate kinase 
1;Phosphoglycerate kinase PGK1 44.61 -0.06   14 
Nascent polypeptide-associated complex 
subunit alpha NACA 205.42 -0.06   2 
Choline transporter-like protein 1 SLC44A1 73.30 -0.06   4 
Myoferlin MYOF 234.71 -0.06   28 
Copine-8 CPNE8 63.11 -0.06   29 
Ras-related protein Rab-11B;Ras-related 
protein Rab-11A 
RAB11B;RA
B11A 24.49 -0.06   7 
14-3-3 protein gamma;14-3-3 protein 
gamma, N-terminally processed YWHAG 28.30 -0.06   3 
Epidermal growth factor receptor EGFR 134.28 -0.05   15 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 UCHL1 24.82 -0.05   6 
Stress-induced-phosphoprotein 1 STIP1 62.64 -0.05   6 
Catenin alpha-1 CTNNA1 100.07 -0.05   19 
Poly(rC)-binding protein 1 PCBP1 37.50 -0.05   3 
Ras-related protein Rab-7a RAB7A 23.49 -0.04   11 
T-complex protein 1 subunit theta CCT8 59.62 -0.04   3 
60S ribosomal protein L13a RPL13A 23.58 -0.04   4 
Axin interactor, dorsalization-associated 
protein AIDA 35.02 -0.04   2 
Profilin-1 PFN1 15.05 -0.04   8 
Unconventional myosin-Ib MYO1B 131.98 -0.04   16 
Plastin-3 PLS3 70.81 -0.04   6 
Nucleoside diphosphate kinase 
B;Nucleoside diphosphate kinase 
NME2;NME
1-
NME2;NME
1 
30.14 -0.04   3 
Transmembrane 4 L6 family member 1 TM4SF1 10.99 -0.03   1 
Lactadherin;Lactadherin short 
form;Medin MFGE8 43.12 -0.03   22 
Membrane cofactor protein CD46 41.36 -0.03   4 
ADP-ribosylation factor 3;ADP-
ribosylation factor 1 ARF3;ARF1 20.60 -0.03   2 
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Tyrosine-protein kinase receptor UFO AXL 98.34 -0.03   11 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 DDAH2 29.64 -0.03   3 
Myosin light polypeptide 6 MYL6 16.93 -0.03   3 
Elongation factor 1-alpha 1;Putative 
elongation factor 1-alpha-like 3 
EEF1A1;EE
F1A1P5 50.14 -0.03   13 
Peroxiredoxin-6 PRDX6 25.04 -0.03   3 
Ras-related protein Rab-22A RAB22A 21.86 -0.03   2 
Anoctamin-6 ANO6 106.16 -0.03   3 
Septin-7 Sep-07 50.68 -0.03   8 
Pyruvate kinase PKM;Pyruvate kinase PKM;PKM2 57.94 -0.02   21 
Phosphoribosylaminoimidazole 
carboxylase PAICS 47.08 -0.02   3 
Calmodulin 
CALM1;CA
LM2;CALM
3 
16.84 -0.02   7 
Importin subunit alpha-1 KPNA2 57.86 -0.02   5 
Ras-related protein Rap-2b RAP2B 20.50 -0.02   3 
Myosin-9 MYH9 226.53 -0.02   21 
Caldesmon CALD1 93.23 -0.02   2 
Peptidyl-prolyl cis-trans isomerase A PPIA 18.01 -0.02   6 
Sodium bicarbonate cotransporter 3 SLC4A7 123.41 -0.02   9 
Galectin-1 LGALS1 14.72 -0.02   4 
Actin, alpha skeletal muscle; Actin, 
alpha cardiac muscle 1;Actin, gamma-
enteric smooth muscle; Actin, aortic 
smooth muscle 
ACTA1;AC
TC1;ACTG2
;ACTA2 
42.05 -0.01   1 
Protein eva-1 homolog B EVA1B 18.37 -0.01   2 
CD82 antigen CD82 29.63 -0.01   3 
Utrophin UTRN 394.46 -0.01   10 
Cell division cycle-associated protein 3 CDCA3 29.00 -0.01   3 
Palmitoyltransferase ZDHHC5 ZDHHC5 77.54 -0.01   5 
Clathrin heavy chain 1 CLTC 191.61 -0.01   12 
Catenin beta-1 CTNNB1 85.50 -0.01   11 
Zinc finger CCCH-type antiviral protein 
1 ZC3HAV1 101.43 -0.01   3 
Nucleosome assembly protein 1-like 1 NAP1L1 45.37 -0.01   2 
40S ribosomal protein S3a RPS3A 29.95 -0.01   3 
Drebrin DBN1 71.43 -0.01   5 
Alpha-actinin-1 ACTN1 103.06 -0.01   10 
T-complex protein 1 subunit eta CCT7 59.37 -0.01   4 
6-phosphogluconate dehydrogenase, 
decarboxylating PGD 53.14 0.00   5 
Syntaxin-binding protein 3 STXBP3 67.76 0.00   16 
MARCKS-related protein MARCKSL1 19.53 0.00   2 
Alpha-actinin-4 ACTN4 104.85 0.00   21 
Transcription factor COE2 EBF2 62.65 0.00   1 
Ras GTPase-activating-like protein 
IQGAP1 IQGAP1 189.25 0.00   23 
5-AMP-activated protein kinase 
catalytic subunit alpha-1 PRKAA1 64.01 0.00   2 
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14-3-3 protein zeta/delta YWHAZ 27.75 0.00   10 
Raftlin RFTN1 63.15 0.00   9 
Kinesin-like protein KIF23 KIF23 110.06 0.00   18 
GTP-binding nuclear protein Ran RAN 24.42 0.01   5 
Protein CYR61 CYR61 42.03 0.01   14 
Syndecan-4;Syndecan SDC4 21.64 0.01   3 
Integrin beta-1 ITGB1 88.41 0.01   17 
Eukaryotic translation initiation factor 
5A-1; Eukaryotic translation initiation 
factor 5A-2; Eukaryotic translation 
initiation factor 5A-1-like 
EIF5A;EIF5
A2;EIF5AL1 16.83 0.01   3 
Tubulin alpha-1B chain;Tubulin alpha-
1A chain;Tubulin alpha-4A 
chain;Tubulin alpha-3C/D chain;Tubulin 
alpha-3E chain 
TUBA1B;T
UBA1A;TU
BA4A;TUB
A3C;TUBA3
E 
50.15 0.01   3 
Actin-binding protein anillin ANLN 124.20 0.01   11 
CD81 antigen CD81 25.81 0.02   2 
Butyrophilin subfamily 2 member 
A1;Butyrophilin subfamily 2 member 
A2 
BTN2A1;BT
N2A2 59.63 0.02   5 
Protein XRP2 RP2 39.64 0.02   7 
Tumor necrosis factor receptor 
superfamily member 6 FAS 37.73 0.02   2 
Prostaglandin E synthase 3 PTGES3 18.70 0.02   3 
Peripheral plasma membrane protein 
CASK CASK 105.12 0.02   11 
T-complex protein 1 subunit delta CCT4 57.92 0.02   5 
Guanine nucleotide-binding protein 
subunit alpha-11 GNA11 42.12 0.02   7 
Glyceraldehyde-3-phosphate 
dehydrogenase GAPDH 36.05 0.02   12 
Tumor necrosis factor receptor 
superfamily member 10A TNFRSF10A 50.09 0.02   2 
Protein DJ-1 PARK7 19.89 0.02   3 
Guanine nucleotide-binding protein G(i) 
subunit alpha-2 GNAI2 40.45 0.02   8 
Rab GDP dissociation inhibitor beta GDI2 50.66 0.03   13 
Coactosin-like protein COTL1 15.95 0.03   5 
Leukocyte surface antigen CD47 CD47 35.21 0.03   3 
Fatty acid-binding protein, epidermal FABP5 15.16 0.03   6 
Heat shock protein 105 kDa HSPH1 96.86 0.03   6 
Disintegrin and metalloproteinase 
domain-containing protein 10 ADAM10 84.14 0.03   8 
Ras-related protein R-Ras2 RRAS2 23.40 0.03   3 
Nucleophosmin NPM1 32.58 0.03   4 
Receptor-type tyrosine-protein 
phosphatase F PTPRF 212.88 0.03   10 
60S ribosomal protein L24 RPL24 17.78 0.03   2 
Dynein light chain 2, 
cytoplasmic;Dynein light chain 1, 
cytoplasmic 
DYNLL2;D
YNLL1 10.35 0.03   2 
Tyrosine-protein kinase JAK1 JAK1 133.28 0.03   3 
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Polyubiquitin-B;Ubiquitin;Ubiquitin-
40S ribosomal protein 
S27a;Ubiquitin;40S ribosomal protein 
S27a;Ubiquitin-60S ribosomal protein 
L40;Ubiquitin;60S ribosomal protein 
L40;Polyubiquitin-C;Ubiquitin 
UBB;RPS27
A;UBC;UBA
52;UBBP4 
25.76 0.04   4 
Monocarboxylate transporter 8 SLC16A2 59.51 0.04   2 
60S ribosomal protein L15;Ribosomal 
protein L15 RPL15 24.15 0.04   2 
Elongation factor 2 EEF2 95.34 0.04   23 
Alpha-enolase ENO1 47.17 0.04   17 
78 kDa glucose-regulated protein HSPA5 72.33 0.05   4 
Triosephosphate isomerase TPI1 30.79 0.05   11 
Borealin CDCA8 31.32 0.05   2 
Protein Niban FAM129A 103.13 0.05   6 
14-3-3 protein beta/alpha;14-3-3 protein 
beta/alpha, N-terminally processed YWHAB 28.08 0.05   6 
Long-chain-fatty-acid--CoA ligase 4 ACSL4 79.19 0.05   7 
60S ribosomal protein L4 RPL4 47.70 0.05   2 
Filamin-C FLNC 291.02 0.05   26 
CD166 antigen ALCAM 65.10 0.05   2 
GTP-binding protein Rheb RHEB 20.50 0.05   4 
L-lactate dehydrogenase A chain LDHA 36.69 0.05   10 
Myristoylated alanine-rich C-kinase 
substrate MARCKS 31.55 0.05   8 
Annexin;Annexin A6 ANXA6 75.28 0.05   16 
Cell division control protein 42 homolog CDC42 21.26 0.05   3 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 GNB1 37.38 0.06   7 
Transitional endoplasmic reticulum 
ATPase VCP 89.32 0.06   8 
Adenosylhomocysteinase AHCY 47.72 0.06   3 
60S ribosomal protein L3 RPL3 46.11 0.06   4 
Disintegrin and metalloproteinase 
domain-containing protein 17 ADAM17 93.02 0.06   2 
Ras-related protein Rab-5B RAB5B 23.71 0.06   2 
Annexin A11;Annexin ANXA11 54.39 0.06   5 
Copine-1 CPNE1 59.06 0.06   5 
Disco-interacting protein 2 homolog B DIP2B 171.49 0.06   2 
Rho-related GTP-binding protein RhoG RHOG 21.31 0.06   2 
Tubulin beta chain;Tubulin beta-2B 
chain 
TUBB;TUB
B2B 49.67 0.06   2 
Heat shock protein HSP 90-beta HSP90AB1 83.26 0.06   11 
RELT-like protein 1 RELL1 29.34 0.06   3 
Inorganic pyrophosphatase PPA1 32.66 0.06   4 
Peroxiredoxin-1 PRDX1 22.11 0.06   8 
T-complex protein 1 subunit epsilon CCT5 59.67 0.06   8 
Macrophage migration inhibitory factor MIF 12.48 0.07   2 
Ras-related protein Rab-14 RAB14 23.90 0.07   2 
Catenin delta-1 CTNND1 108.17 0.07   12 
Calcium-binding protein 39 CAB39 39.87 0.07   2 
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Hsc70-interacting protein;Putative 
protein FAM10A4;Putative protein 
FAM10A5 
ST13;ST13P
4;ST13P5 41.33 0.07   3 
Rho GDP-dissociation inhibitor 1 ARHGDIA 23.21 0.07   4 
Neutral amino acid transporter B(0) SLC1A5 56.60 0.07   8 
Rac GTPase-activating protein 1 RACGAP1 71.03 0.07   8 
T-complex protein 1 subunit gamma CCT3 60.53 0.07   6 
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms short;Guanine 
nucleotide-binding protein G(s) subunit 
alpha isoforms XLas 
GNAS 45.66 0.07   8 
Sodium-dependent phosphate 
transporter 1 SLC20A1 73.70 0.07   2 
Transferrin receptor protein 
1;Transferrin receptor protein 1, serum 
form 
TFRC 84.87 0.08   14 
T-complex protein 1 subunit beta CCT2 57.49 0.08   6 
Heat shock protein HSP 90-alpha HSP90AA1 84.66 0.08   14 
Sorcin SRI 21.68 0.08   5 
Copine-3 CPNE3 60.13 0.08   10 
Ras-related protein Rab-18 RAB18 22.98 0.08   5 
Protein lin-7 homolog C;Protein lin-7 
homolog A 
LIN7C;LIN7
A 21.83 0.08   5 
GTPase NRas NRAS 21.23 0.08   2 
40S ribosomal protein S2 RPS2 31.32 0.08   3 
Zinc transporter ZIP10 SLC39A10 94.13 0.08   7 
60S ribosomal protein L13 RPL13 24.26 0.08   6 
Annexin A5;Annexin ANXA5 35.94 0.09   10 
TLD domain-containing protein 1 TLDC1 50.99 0.09   6 
Poliovirus receptor-related protein 2 PVRL2 51.36 0.09   4 
Transforming protein RhoA RHOA 21.77 0.09   5 
Equilibrative nucleoside transporter 1 SLC29A1 50.22 0.09   3 
Endoplasmin HSP90B1 92.47 0.09   5 
Plasma membrane calcium-transporting 
ATPase 1 ATP2B1 138.75 0.09   6 
DnaJ homolog subfamily C member 5 DNAJC5 22.15 0.09   3 
Disks large homolog 1 DLG1 100.45 0.09   8 
Cysteine-rich and transmembrane 
domain-containing protein 1 CYSTM1 10.63 0.09   2 
Guanine nucleotide-binding protein 
subunit alpha-13 GNA13 44.05 0.09   5 
Guanine nucleotide-binding protein 
subunit beta-4 GNB4 37.57 0.09   3 
Annexin A1 ANXA1 38.71 0.10   15 
Folate transporter 1 SLC19A1 64.87 0.10   3 
Neurogenic locus notch homolog protein 
2;Notch 2 extracellular truncation;Notch 
2 intracellular domain 
NOTCH2 265.40 0.10   3 
Vacuolar protein sorting-associated 
protein 28 homolog VPS28 25.43 0.10   2 
Fructose-bisphosphate aldolase 
A;Fructose-bisphosphate aldolase ALDOA 39.42 0.10   12 
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14-3-3 protein epsilon YWHAE 29.17 0.10   10 
ADP-ribosylation factor 4 ARF4 20.51 0.11   2 
Protein scribble homolog SCRIB 174.88 0.11   17 
Cytoplasmic FMR1-interacting protein 
1;Cytoplasmic FMR1-interacting protein 
2 
CYFIP1;CY
FIP2 145.18 0.11   3 
Ras-related protein R-Ras RRAS 23.48 0.11   5 
Glucose-6-phosphate isomerase GPI 63.15 0.11   6 
Calreticulin CALR 48.14 0.11   5 
Plexin-B2 PLXNB2 205.12 0.11   24 
Niban-like protein 1 FAM129B 84.14 0.11   12 
Tyrosine-protein kinase Lyn LYN 58.57 0.11   7 
Phosphoglycerate mutase 1 PGAM1 28.80 0.11   4 
Solute carrier family 2, facilitated 
glucose transporter member 1 SLC2A1 54.08 0.12   6 
Serine/threonine-protein phosphatase 
PP1-gamma catalytic 
subunit;Serine/threonine-protein 
phosphatase 
PPP1CC 36.98 0.12   2 
Ras-related protein Rab-35 RAB35 23.03 0.12   7 
Vasodilator-stimulated phosphoprotein VASP 39.83 0.12   2 
Integrin alpha-4 ITGA4 114.90 0.12   16 
Guanine nucleotide-binding protein 
G(k) subunit alpha GNAI3 40.53 0.12   3 
F-actin-capping protein subunit alpha-1 CAPZA1 32.92 0.12   2 
2,3-cyclic-nucleotide 3-
phosphodiesterase CNP 47.58 0.12   13 
Annexin A4;Annexin ANXA4 35.88 0.12   5 
Radixin RDX 68.56 0.12   8 
Desmoglein-2 DSG2 122.29 0.13   5 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-12 GNG12 8.01 0.13   5 
Sodium/potassium-transporting ATPase 
subunit beta-1 ATP1B1 35.06 0.13   6 
Vacuolar protein sorting-associated 
protein 4A VPS4A 48.90 0.13   2 
Plakophilin-2 PKP2 97.41 0.13   6 
Ephrin type-B receptor 4 EPHB4 108.27 0.13   2 
Phospholipid scramblase 1 PLSCR1 35.05 0.13   3 
FERM, RhoGEF and pleckstrin domain-
containing protein 1 FARP1 118.63 0.13   5 
Zinc transporter ZIP6 SLC39A6 85.05 0.13   3 
Golgin subfamily A member 7 GOLGA7 15.82 0.13   6 
Plasminogen activator inhibitor 1 SERPINE1 45.06 0.13   2 
Myosin regulatory light chain 12B; 
Myosin regulatory light chain 12A; 
Myosin regulatory light polypeptide 9; 
MYL12B;M
YL12A;MY
L9 
19.78 0.13   4 
T-complex protein 1 subunit alpha TCP1 60.34 0.13   7 
Hypoxanthine-guanine 
phosphoribosyltransferase HPRT1 24.58 0.13   2 
Stathmin STMN1 17.30 0.14   4 
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Sodium/potassium-transporting ATPase 
subunit beta-3 ATP1B3 31.51 0.14   7 
Ribonuclease inhibitor RNH1 49.97 0.14   2 
Erythrocyte band 7 integral membrane 
protein STOM 31.73 0.14   9 
ADP-ribosylation factor-like protein 6-
interacting protein 1 ARL6IP1 27.17 0.14   2 
Ephrin type-A receptor 2 EPHA2 108.27 0.15   21 
Multivesicular body subunit 12A MVB12A 28.78 0.15   2 
High affinity cationic amino acid 
transporter 1 SLC7A1 67.64 0.15   4 
60S ribosomal protein L8 RPL8 28.02 0.15   2 
Ras-related protein Ral-B RALB 23.41 0.15   4 
UDP-N-acetylhexosamine 
pyrophosphorylase UAP1 58.77 0.16   9 
Nicastrin NCSTN 78.41 0.16   6 
Glutathione S-transferase P GSTP1 23.36 0.16   2 
Large neutral amino acids transporter 
small subunit 1 SLC7A5 55.01 0.17   5 
40S ribosomal protein S9 RPS9 22.59 0.17   4 
MOB kinase activator 1B;MOB kinase 
activator 1A 
MOB1B;MO
B1A 25.09 0.17   3 
Ras-related protein Rab-23 RAB23 26.66 0.17   4 
Brain-specific angiogenesis inhibitor 1-
associated protein 2-like protein 1 BAIAP2L1 56.88 0.17   3 
Zinc transporter ZIP14 SLC39A14 54.21 0.17   3 
Guanine nucleotide-binding protein G(i) 
subunit alpha-1 GNAI1 40.36 0.18   3 
Urokinase-type plasminogen activator PLAU 48.51 0.18   3 
Syntaxin-4 STX4 34.18 0.18   4 
14-3-3 protein eta YWHAH 28.22 0.18   3 
G protein-regulated inducer of neurite 
outgrowth 1 GPRIN1 102.40 0.18   2 
Integrin alpha-V;Integrin alpha-V heavy 
chain;Integrin alpha-V light chain ITGAV 116.04 0.18   24 
Moesin MSN 67.82 0.19   23 
Sodium/potassium-transporting ATPase 
subunit alpha-1 ATP1A1 112.89 0.19   34 
Poliovirus receptor PVR 45.30 0.19   6 
Protein FAM49B FAM49B 36.75 0.19   5 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1 SLC9A3R1 38.87 0.19   2 
Guanine nucleotide-binding protein 
G(q) subunit alpha GNAQ 42.14 0.19   2 
Formin-like protein 2 FMNL2 123.32 0.19   5 
Intercellular adhesion molecule 1 ICAM1 57.83 0.20   4 
Chromosome-associated kinesin KIF4A KIF4A 139.88 0.20   6 
1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase beta-4 PLCB4 136.10 0.20   17 
Ras-related C3 botulinum toxin 
substrate 1;Ras-related C3 botulinum 
toxin substrate 3 
RAC1;RAC3 21.45 0.21   4 
60S ribosomal protein L18 RPL18 21.63 0.21   3 
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Ezrin EZR 69.41 0.21   14 
Importin subunit beta-1 KPNB1 97.17 0.22   5 
Inosine-5-monophosphate 
dehydrogenase 2 IMPDH2 55.80 0.22   2 
Scavenger receptor class B member 1 SCARB1 56.97 0.22   3 
Protein LAP2 ERBB2IP 158.30 0.22   11 
Fatty acid synthase FASN 273.42 0.23   11 
Calnexin CANX 67.57 0.23   3 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A;Peptidyl-prolyl cis-trans 
isomerase 
FKBP1A;FK
BP12-Exip2 11.95 0.24   2 
Monocarboxylate transporter 1 SLC16A1 53.94 0.24   6 
Ubiquitin-conjugating enzyme E2 
variant 1;Ubiquitin-conjugating enzyme 
E2 variant 2 
UBE2V1;T
MEM189;U
BE2V2 
11.77 0.25   3 
Heterogeneous nuclear 
ribonucleoprotein H 
HNRNPH1;
HNRNPH2 49.23 0.25   3 
Regulator of G-protein signaling 20 RGS20 27.06 0.25   4 
Chloride intracellular channel protein 4 CLIC4 28.77 0.25   7 
Mitogen-activated protein kinase kinase 
kinase kinase 4;TRAF2 and NCK-
interacting protein kinase 
MAP4K4;T
NIK 142.10 0.25   5 
Integrin beta-5 ITGB5 88.05 0.25   5 
Inactive tyrosine-protein kinase 7 PTK7 118.39 0.27   2 
40S ribosomal protein S6 RPS6 28.68 0.27   4 
GTPase KRas;GTPase KRas, N-
terminally processed KRAS 21.42 0.27   3 
CUB domain-containing protein 1 CDCP1 92.93 0.28   15 
Voltage-dependent calcium channel 
subunit alpha-2/delta-1 CACNA2D1 124.57 0.28   5 
Collagen alpha-1(XVIII) 
chain;Endostatin COL18A1 178.19 0.28   6 
Exportin-2 CSE1L 110.42 0.28   2 
26S protease regulatory subunit 4 PSMC1 49.18 0.28   3 
Integrin alpha-6;Integrin alpha-6 heavy 
chain;Integrin alpha-6 light chain ITGA6 119.47 0.29   2 
Protein tweety homolog 3 TTYH3 57.54 0.29   3 
Polyadenylate-binding protein 
1;Polyadenylate-binding protein 3 
PABPC1;PA
BPC3 70.67 0.30   2 
Protein EFR3 homolog A EFR3A 92.92 0.30   3 
Chloride intracellular channel protein 1 CLIC1 26.92 0.31   9 
Ras-related protein Rab-2A;Ras-related 
protein Rab-2B 
RAB2A;RA
B2B 23.55 0.31   6 
Rho-related GTP-binding protein RhoC RHOC 22.01 0.31   5 
Plasma membrane calcium-transporting 
ATPase 4 ATP2B4 137.92 0.32   4 
Neprilysin MME 85.51 0.32   10 
CD276 antigen CD276 57.24 0.33   3 
MAP/microtubule affinity-regulating 
kinase 3;Serine/threonine-protein kinase 
MARK1 
MARK3;MA
RK1 84.49 0.33   2 
S-adenosylmethionine synthase isoform 
type-2 MAT2A 43.66 0.33   3 
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Septin-9 Sep-09 65.40 0.33   3 
MHC class I polypeptide-related 
sequence B MICA;MICB 22.24 0.34   2 
Heat shock 70 kDa protein 4 HSPA4 94.33 0.34   2 
Plexin-A1 PLXNA1 211.06 0.34   5 
CD97 antigen;CD97 antigen subunit 
alpha;CD97 antigen subunit beta CD97 91.87 0.35   6 
Basigin BSG 42.20 0.36   5 
Integrin alpha-5;Integrin alpha-5 heavy 
chain;Integrin alpha-5 light chain ITGA5 114.54 0.37   9 
Claudin domain-containing protein 1 CLDND1 28.60 0.37   2 
Zinc transporter 1 SLC30A1 55.30 0.38   2 
Multidrug resistance-associated protein 
1 ABCC1 171.59 0.40   3 
Protein-glutamine gamma-
glutamyltransferase 2 TGM2 77.33 0.41   6 
14-3-3 protein theta YWHAQ 27.76 0.41   2 
Lactoylglutathione lyase GLO1 20.78 0.41   3 
Histone H3.2;Histone H3.1;Histone 
H3.3;Histone H3.1t;Histone H3;Histone 
H3.3C 
HIST2H3A;
HIST1H3A;
H3F3A;HIS
T3H3;H3F3
B;H3F3C 
15.39 0.42   4 
ATP synthase subunit alpha, 
mitochondrial;ATP synthase subunit 
alpha 
ATP5A1 59.75 0.43   2 
Urokinase plasminogen activator surface 
receptor PLAUR 36.98 0.45   4 
Histone H4 HIST1H4A 11.37 0.47   6 
Major vault protein MVP 99.33 0.47   19 
60 kDa heat shock protein, 
mitochondrial HSPD1 61.05 0.51   5 
Malate dehydrogenase, 
mitochondrial;Malate dehydrogenase MDH2 35.50 0.59   2 
Phosphatidylinositol 4-kinase alpha PI4KA 231.32 0.60   3 
Carboxypeptidase M CPM 50.51 0.64 + 4 
Basement membrane-specific heparan 
sulfate proteoglycan core 
protein;Endorepellin;LG3 peptide 
HSPG2 468.83 0.76 + 32 
Afadin MLLT4 206.80 0.96 + 2 
Appendix I - SILAC-based proteomic comparison of H1299-p53-/- and H1299-p53R273H EVs. 
H1299-p53-/- and H1299-p53R273H cells were SILAC-labelled with heavy (H) and light (L) amino acids 
respectively. Conditioned media were collected from labelled cells, exosomes purified from these using 
differential centrifugation, and their proteome analysed by mass spectrometry. Column F indicates the SILAC 
ratio of p53R273H/H1299-p53-/- EV which is calculated from reciprocal of the ratio of H/L peptides. Sig. 
means significant. Significance B statistic test, False discovery rate of 5%, Perseus software.  
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Appendix II – Novo et al., 2018 
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Appendix III – Novo et al., 2018 
Novo, D., Heath, N., Mitchell, L., Caligiuri, G., MacFarlane, A., Reijmer, D., Charlton, L., Knight, J., Calka, 
M., McGhee, E., Dornier, E., Sumpton, D., Mason, S., Echard, A., Klinkert, K., Secklehner, J., Kruiswijk, F., 
Vousden, K., Macpherson, I.R., Blyth, K., Bailey, P., Yin, H., Carlin, L.M., Morton, J., Zanivan, S., Norman, 
J.C., 2018. Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature 
Communications. 9. 
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